THE SPECTRUM OF HIV RELATED NEPHROPATHY IN KWAZULU-NATAL: A PATHOGENETIC APPRAISAL AND IMPACT OF HAART

By

DURAN RAMSURAN

Submitted in partial fulfilment of the requirements for the degree of

DOCTOR OF PHILOSOPHY

in the

Optics and Imaging Centre,
Doris Duke Medical Research Institute,
College of Health Sciences
University of KwaZulu-Natal
Durban
2012
PREFACE

This study represents original work by the author and has not been submitted in any other form to another University. Where use was made of the work of others, it has been duly acknowledged in the text.

The research described in this thesis was carried out in the Optics & Imaging Centre, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa under the supervision of Professors T. Naicker and R. Bhimma.

___________________________
Duran Ramsuran
(Candidate)

___________________________
Professor Thajasvarie Naicker
(Supervisor)

___________________________
Professor Rajendra Bhimma
(Co-supervisor)
DECLARATION

I, Duran Ramsuran declare that:

(i) The research reported in this dissertation, except where otherwise indicated is my original work.

(ii) This dissertation has not been submitted for any degree or examination at any other university.

(iii) This dissertation does not contain other person’s data, pictures, graphs or other information, unless specifically acknowledged as being sourced from other persons.

(iv) This dissertation does not contain other persons writing, unless specifically acknowledged as being sourced from other researchers. Where other sources have been quoted, then:

a) Their words have been rewritten but the general information attributed them has been referenced.

b) Where their exact words have been used their writing had been placed inside quotation marks and referenced.

(v) Where I have reproduced a publication of which I am an author, co-author, I have indicated in detail which part of the publication was actually written by myself alone and have fully referenced such publications.

(vi) This dissertation does not contain text, graphics, or tables copied and pasted from the internet, unless specifically acknowledged and the source being detailed in the dissertation and the reference sections.

Signed: ___________________________ Date: ___________________________
DEDICATION

To

My Parents

(Mr and Mrs Ramsuran)
PEER REVIEW PUBLICATIONS AND CONFERENCES PRESENTATIONS

PEER REVIEW JOURNAL ARTICLES:


JOURNAL ARTICLE HAVE BEEN SUBMITTED: (AWAITING RESPONSE)


PEER-REVIEWED CONFERENCE PRESENTATIONS:


INTERNATIONAL CONFERENCE PRESENTATIONS:


**NATIONAL CONFERENCE PRESENTATIONS:**


ACKNOWLEDGEMENTS

I wish to express my sincere thanks and gratitude to:

Prof T Naicker, for her excellent supervision, support, encouragement and her invaluable help with microscopy; as well as to fuel my passion for science and helped me on a personal level and to groom me to become a better scientist;

Prof R Bhimma, for all the hard work that he has put into this project and for making this achievement possible, it was a real pleasure to have worked with you;

Prof M Adhikari, for your words of encouragements and for always keeping me on track. For always having my best interest at heart, no words can express my gratitude;

Prof PK Ramdial, for expert and meticulous assistance with the histology and spectrum analysis and for your endless support;

Prof T Ndung’u for all your help with the molecular aspect of my project;

To all the members in the Department of Anatomical Pathology, thank you for all the support and help throughout my degree, with a special thanks to Mrs. M. Moodley and Mr. Clive Sydney;

To all the members of the HPP, thank you for all the help and support I am grateful to all of you guys with a special thank you to Mrs Keshni Hiramen, Mr Ravesh Singh, Mrs Kavidha Reddy and Dr Kamini Gounder;
Optics and Imaging Centre, DDMRI, Nelson R Mandela School of Medicine, where the work was carried out;

My parents for always being there for me, your love, encouragement and understanding are immensely appreciated, thank you for believing in me, and for all the sacrifices that you have made over the years so I could get to this point in my life;

My family members, especially my brothers Nedon and Veron for helping me reach this point; I could not have done it without your support, with a special thank you to my sister-in-laws. To my nephew Sarvesh, and niece Nāradi, may this be your inspiration;

I would like to thank the Medical Research Council (SA), National Research Foundation (SA), K-Rith (SA) and the David Hepburn Foundation (SA), for funding this project;

Finally, to Shree Krishna for making this possible.

“No child should be born with HIV; no child should be an orphan because of HIV; no child should die due to lack of access to treatment”

Ebube Sylvia Taylor, 2010 United Nations Millennium Development Goals Summit
TABLE OF CONTENTS

PREFACE ......................................................................................................................... ii
DECLARATION ................................................................................................................... iii
DEDICATION ................................................................................................................... iv
PEER REVIEW PUBLICATIONS AND CONFERENCES PRESENTATIONS ....... v
Peer review journal articles: ............................................................................................ v
Journal article have been submitted: (awaiting response)............................................... v
Peer-reviewed conference presentations: ........................................................................ v
International conference presentations: ........................................................................ v
National conference presentations: ................................................................................ vi
ACKNOWLEDGEMENTS .............................................................................................. vii
TABLE OF CONTENTS ............................................................................................. ix
LIST OF ABBREVIATIONS ......................................................................................... xiii
LIST OF FIGURES ......................................................................................................... xv
LIST OF TABLES ............................................................................................................. xix
ABSTRACT .................................................................................................................... xx
CHAPTER 1 ...................................................................................................................... 1
INTRODUCTION ............................................................................................................. 2
  1.1 HIV ..................................................................................................................... 2
    1.1.1 Epidemiology .............................................................................................. 2
    1.1.2 HIV morphology ....................................................................................... 4
    1.1.3 HIV Replication ....................................................................................... 5
    1.1.4 Effect on host immune response ............................................................... 8
  1.2 NORMAL KIDNEY ............................................................................................ 10
    1.2.1 Function .................................................................................................. 10
    1.2.2 Normal morphology ............................................................................. 10
    1.2.3 Nephron .................................................................................................. 10
      1.2.3.1 Renal tubule .................................................................................... 11
      1.2.3.2 Renal corpuscle .......................................................... 12
        1.2.3.2.1 The Bowman’s capsule ........................................ 12
        1.2.3.2.2 The glomerulus ......................................................... 12
        1.2.3.2.3 Podocytes .............................................................. 13
          1.2.3.2.3.1 Synaptopodin ................................................ 16
      1.2.3.2 Podocytes ..................................................................................... 13
    1.3 PODOCYTE CELL CYCLE ........................................................................ 18
      1.3.1 Podocyte proliferation ..................................................................... 19
2.4.5.3 Sequencing ................................................................. 48
2.4.5.4 Sequence Analysis .................................................... 49
2.5 KIDNEY BIOPSY ................................................................. 50
2.5.1 Histopathology ............................................................... 51
2.5.1.1 Fixation and tissue processing .................................... 51
2.5.1.2 Microtomy ................................................................. 52
2.5.1.3 Haematoxylin & Eosin (H&E); Periodic acid Schiff reaction (PAS), Masson’s trichrome, Miller’s Elastic and Silver Methenamine staining .......... 52
2.5.1.2 Immunofluorescent staining .......................................... 57
2.5.2 Transmission electron microscopy .................................... 57
2.5.2.1 Fixation and tissue processing .................................... 57
2.5.2.2 Ultramicrotomy .......................................................... 58
2.5.2.3 Transmission electron microscopy evaluation ................ 59
2.5.3 Immunohistochemistry ....................................................... 59
2.5.3.1 Rabbit Anti-Human Syno Antibody .............................. 59
2.5.3.2 Mouse Anti-Human Immunodeficiency Virus Antibody .......... 60
2.5.3.3 Mouse anti human Ki67 antibody ................................. 60
2.5.4 Laser Microdissection ....................................................... 62
2.5.5 Tissue DNA extraction ..................................................... 62
2.6 STATISTICAL ANALYSIS ..................................................... 63

CHAPTER 3 ................................................................................. 64

RESULTS .................................................................................. 65
3.1 PATIENT POPULATION ....................................................... 65
3.1.1 Pre-HAART Group ......................................................... 65
3.1.2 Post-HAART Group ......................................................... 65
3.1.3 Clinical data of Pre-HAART Group ................................. 66
3.1.4 Histopathological spectrum of HIVRN in Pre-HAART .......... 68
3.1.5 Treatment ....................................................................... 68
3.1.6 Clinical data of Post-HAART Group ................................. 76
3.1.7 Comparison of children Pre-HAART vs. Post-HAART ....... 79
3.1.8 Histopathological spectrum of HIVRN in Post-HAART biopsy group .......... 82
3.1.9 Comparison of matched Pre-HAART Biopsy vs. Post-HAART Biopsy ...... 82
3.2 SYNAPTOPODIN, Ki67 AND p24 IMMUNOREACTIVITY ............ 83
3.2.1 Pre-HAART Synaptopodin .............................................. 83
3.2.2 Post-HAART Synaptopodin .............................................. 83
3.2.3 Morphometric image analysis of synaptopodin Pre vs. Post-HAART .......... 83
3.2.4 Pre- HAART Ki67 ......................................................... 85
LIST OF ABBREVIATIONS

HIV : Human Immunodeficiency Virus
HIVRN : Human Immunodeficiency Virus Related Nephropathy
HIVAN : Human Immunodeficiency Virus Associated Nephropathy
AIDS : Acquired Immuno Deficiency Syndrome
HAART : Highly Active Antiretroviral Therapy
ESRD : End Stage Renal Disease
FSGS : Focal Segmental Glomerular Sclerosis
PBMC : Peripheral Blood Mononuclear Cell
ACE-I : Angiotensin Converting Enzyme Inhibitor
DNA : Deoxyribonucleic Acid
RNA : Ribonucleic Acid
PCR : Polymerase Chain Reaction
CG : Collapsing Glomerulopathies
WHO : World Health Organization
G : Grams
ml : Millilitre
ng : Nanograms
mg : Milligram
Kg : Kilogram
µl : Microlitre
µm : Micron
Kb : Kilo basepair
h : Hour
Min : Minute
CD : Cluster of differentiation
°C : Degrees Celsius
% : Percentage
bp : basepair
IALCH : Inkosi Albert Luthuli Central Hospital
EM : Electron microscopy
IMF : Immunofluorescence
LMD : Laser Micro-dissection
NIH : National Institutes of Health
TBS : Tris-buffered saline
PBS : Phosphate buffer saline
GBM : Glomerular basement membrane
Sec : Second
CDK : cyclin-dependent kinase
CKIs : cyclin-dependent kinase inhibitors
HIVICK : HIV Immune complex disease
TEMP : Temperature
Viz : Namely
Init : Initial
Mag : Magnification
IgG : Immunoglobulin G
L : Litres
USA : United States of America
RT-PCR : Real Time Polymerase Chain Reaction
ER : endoplasmic reticulum
FP : Foot processes
env : Envelope
H₂O : Water
dH₂O : Distilled water
H&E : Haematoxylin & Eosin
Pas : Periodic acid-Schiff
gp : glycoproteins
MCD : Minimal change disease
FITC : Fluorescein isothiocyanate
APOL1 : Apolipoprotein L1
DARC : Duffy antigen chemokine receptor
eGFR : Estimated Glomerular Filtration Rate
LIST OF FIGURES

Figure 1.1: World map illustrating intensity of HIV infection ........................................ 3
Figure 1.2: Histogram showing estimated HIV prevalence among South Africans .......... 4
Figure 1.3: (A) Anatomy of the HIV; (B) Electronmicrograph of HIV .......................... 5
Figure 1.4: The replication cycle of a HIV ................................................................. 7
Figure 1.5: Different stages, CD4⁺ T cell and viral load over time ................................ 9
Figure 1.6: Cross section of kidney linking structure to function .................................. 11
Figure 1.7: (A). Cross section of glomerulus. (B). H&E depicting normal nephron .... 13
Figure 1.8: (A). Podocyte and the glomerular filtering apparatus. (B). GBM ................. 14
Figure 1.9: Molecular anatomy of the podocyte foot process cytoskeleton .................. 15
Figure 1.10: Comparison of Synpo-long and Synpo-short isoform expression ............ 17
Figure 1.11: Podocyte phenotype dysregulation ........................................................... 18
Figure 1.12: A typical functioning glomeruli versus a diseased glomeruli ................. 21
Figure 1.13: EM graph of fused/effaced foot processes as observed in MCD .............. 22
Figure 1.14: Cross-section of A & B: normal glomeruli; C & D glomeruli with FSGS.. 23
Figure 1.15: Light micrographs indicating thickened capillary walls .......................... 24
Figure 1.16: Micrograph showing immune complex deposition ................................ 25
Figure 1.17: (A). A glomerulus shows global collapse; (B). Tubulointerstitial damage... 26
Figure 1.18: HIVICK (A) showing mesangial prominence. (B) Glomerular capillary .... 27
Figure 1.19: Comparing HIVRN adults (A) with children (B) in South Africa. HIVICK 29
Figure 2.1: An overview for DNA extraction from buffy coat sample ......................... 43
Figure 2.2: Schematic diagram showing the three biopsy coresand their division ....... 50
Figure 3.1: Histopathological spectrum of pre-HAART children ............................ 68
Figure 3.2: H&E stained section showing an increase in mesangial cells .................. 69
Figure 3.3: Periodic acid-Schiff stain showing segmental mesangial hypercellularity. 69
Figure 3.4: Masson’s trichrome illustrating mesangium increase ............................. 70
Figure 3.5: H&E stained section depicting mesangial hypercellularity of glomeruli. .... 70
Figure 3.6: Periodic acid-Schiff depicting segmental mesangial hypercellularity ....... 71
Figure 3.7: Masson’s trichrome illustrating focal mesangial hypercellularity .......... 71
Figure 3.8: Methenamine stained illustrating extensive glomerular tuft collapse ....... 72
Figure 3.9: H&E stained section showing collapse of glomerular capillaries .......... 72
Figure 3.10: Masson’s trichrome stained showing the collapsing glomerulopathy .... 73
Figure 3.11: H&E stain showing dilated tubular lumina with eosinophilic casts ....... 73
Figure 3.12: H&E stained depicting polymorphonuclear lymphocytes...........................74
Figure 3.13: H&E stain normal appearing glomeruli..............................................74
Figure 3.14: Periodic acid-Schiff stained section glomeruli with MCD.........................75
Figure 3.15: Ultrasound image of the right kidney with HIV infection pre-HAART......81
Figure 3.16: Ultrasound image of the same kidney one year later i.e., post-HAART......81
Figure 3.17: Histopathological spectrum of post-HAART children with HIVRN........82
Figure 3.18: Positive control - telencephalic dendrites...........................................84
Figure 3.19: Negative control - telencephalic dendrites........................................84
Figure 3.20: Pre-HAART - segmental glomerular immunoreactivity of synaptopodin...84
Figure 3.21: Pre-HAART - Mild to absent immunoreactivity of synaptopodin.............84
Figure 3.22: Post-HAART – globally diffuse immunoreactivity of synaptopodin.........84
Figure 3.23: Post-HAART - globally diffuse immunoreactivity of synaptopodin.......84
Figure 3.24: Histogram glomerular mean field area of synaptopodin.......................85
Figure 3.25: U87 glioblastoma cell line - positive control.......................................86
Figure 3.26: Hind gut carcinoma - positive control................................................86
Figure 3.27: U87 human glioblastomacell line -Negative control..............................86
Figure 3.28: Pre-HAART - Ki67 antibody staining the specific tubular epithelial cells..86
Figure 3.29: Pre-HAART - Ki67 immuno-precipitation within parietal.......................86
Figure 3.30: Ki67 immunoprecipitation within distal tubular epithelial cells ..........86
Figure 3.31: Post-HAART - Absence of Ki67 immunoreactivity................................87
Figure 3.32: Post-HAART - Absence of Ki67 immunoreactivity.................................87
Figure 3.33: Histogram illustrating glomerular mean field area of Ki67.......................87
Figure 3.34: Lymph node negative control.............................................................89
Figure 3.35: Lymph node negative control.............................................................89
Figure 3.36: Pre-HAART - p24 immunoreactivity within the glomeruli.....................89
Figure 3.37: Pre-HAART - p24 immunoreactivity within the epithelials cells..........89
Figure 3.38: Post-HAART - absence of p24 immunoreactivity within renal biopsy.....89
Figure 3.39: Post-HAART - weak p24 immunoreactivity within renal biopsy..........89
Figure 3.40: Histogram illustrating glomerular mean field area of p24......................90
Figure 3.41: EM illustrating the glomerular filter....................................................93
Figure 3.42: EM depicting contouring or frilling of the lamina rara interna of the GBM93
Figure 3.43: EM depicting two opposing GBM interfaced with electron dense deposits.94
Figure 3.44: EM illustrating GBM with fibrin within the lamina rara densa..............94
Figure 3.45: EM graph illustrating focal effacement of foot processes.....................95
Figure 3.46: EM graph showing sub endothelial immune deposits.
Figure 3.47: EM graph illustrating GBM with focal effacement of the foot process.
Figure 3.48: EM graph illustrating GBM with segmental podocytes effacement.
Figure 3.49: EM graph illustrating cisternal pools of dilated endoplasmic reticulum.
Figure 3.50: EM graph showing dilated golgi stacks with centrioles.
Figure 3.51: EM graph showing lipid distention within podocyte cytoplasm.
Figure 3.52: EM graph demonstrating podocyte nucleo lemmal crenation.
Figure 3.53: EM graph illustrating vacuolation within a podocyte cell body.
Figure 3.54: EM graph showing “ball and cup” appearance of immune deposits.
Figure 3.55: EM graph showing an undifferentiated podocyte cytoplasm.
Figure 3.56: EM graph demonstrating podocyte microvillous profusion.
Figure 3.57: EM graph illustrating endothelial cell body and fenestration.
Figure 3.58: EM graph depicting tubular reticular structure within an endothelial cell.
Figure 3.59: EM graph showing mesangial matrix extension.
Figure 3.60: EM graph showing focal mesangial cell proliferation.
Figure 3.61: EM graph showing crescent formation and occlusion of BC.
Figure 3.62: EM graph illustrating visceral and parietal epithelial cell adhesion.
Figure 3.63: EM graph illustrating BC denuded of parietal epithelial lining.
Figure 3.64: EM graph showing incomplete glomerular sclerosis.
Figure 3.65: EM graph illustrating diffuse glomerular sclerosis.
Figure 3.66: EM graph showing normal appearance of proximal tubular cells.
Figure 3.67: EM graph of distal tubular cells with mild cast inclusion within lumen.
Figure 3.68: EM graph depicting interstitial inflammatory infiltrate between tubules.
Figure 3.69: EM graph illustrating focal frilling of the GBM.
Figure 3.70: EM graph showing normal appearance of podocytes.
Figure 3.71: EM graph depicting focal effacement of foot processes.
Figure 3.72: EM graph showing undilated endoplasmic reticulum.
Figure 3.73: EM graph showing mesangial matrix and focal mesangial cell increase.
Figure 3.74: EM graph illustrating mesangial cell proliferation.
Figure 3.75: EM graph illustrating mesangial matrix and adhesion.
Figure 3.76: EM graph depicting occlusion of Bowman’s space.
Figure 3.77: EM graph illustrating podocyte adherent to parietal cell.
Figure 3.78: EM graph showing part of a sclerosed glomeruli.
Figure 3.79: EM graph showing proximal tubular cells.
Figure 3.80: EM graph depicting HIV-like particles.................................................... 114
Figure 3.81: Higher power electron micrograph of 3.80. ........................................114
Figure 3.82: The standard curve for albumin............................................................ 115
Figure 3.83: Albumin amplification (A). Melting curves (B). The melting peaks....... 116
Figure 3.84: The standard curve for gag .................................................................. 117
Figure 3.85: gag amplification (A). Melting curves. (B). The melting peaks........... 118
Figure 3.86: Validation of PCR specificity on a 1% agarose gel................................ 119
Figure 3.87: Scatterplot of proviral DNA of the pre-HAART group ....................... 121
Figure 3.88: Scatterplot of proviral DNA in the biopsy vs. blood............................ 121
Figure 3.89: Proviral DNA post-HAART matched with their pre-HAART.............. 122
Figure 3.90: Proviral DNA of biopsy and blood compared between groups.......... 122
Figure 3.91: (A). Comparing CD4 pre vs. post-HAART. (B). Comparing proviral DNA between the pre vs. post-HAART. (C). Scatterplot of viral load pre and post-HAART. (D). A correlation graph showing the relationship between A, B and C. ...................... 123
Figure 3.92: Agarose gel illustrating amplification of the env gene........................ 124
Figure 3.93: (A). Graphic representation of PCR insert within the Topo2.1 vector. ..... 125
Figure 3.94: Highlighter plot depicting mutations found in env region ............... 126
Figure 3.95: Phylogenetic analysis of HIV-1 env sequences comparing bld vs. bio...... 127
Figure 3.96: Highlighter plot of nucleotide polymorphism across the env region....... 128
Figure 3.97: Highlighter plot depicting silent and non-silent mutations within the env. 129
Figure 3.98: Phylogenetic analysis of sequences comparing pre vs. post-HAART bld.. 130
LIST OF TABLES

Table 2.1: Procedure for gel purification. ................................................................. 46
Table 2.2: Procedure for cloning PCR products into a PCR 2.1-Topo vector. .......... 47
Table 2.3: Procedure for plasmid isolation............................................................... 48
Table 2.4: Procedure for fluorescence-based sequencing reaction....................... 49
Table 2.5: Fixation, dehydration and embedding schedule for light microscopy........ 51
Table 2.6: Procedure for H&E staining................................................................. 52
Table 2.7: Procedure for PAS staining................................................................. 53
Table 2.8: Procedure for Masson’s Trichome staining......................................... 54
Table 2.9: Procedure for Miller’s Elastic staining.................................................. 55
Table 2.10: Procedure for Silver methenamine staining....................................... 56
Table 2.11: Processing schedule for electron microscopy .................................... 58
Table 2.12: Procedure for immunohistochemical staining.................................... 61
Table 3.1: Demographics of Referral Source of children with HIVRN................. 66
Table 3.2: Comparison of children Pre and Post-HAART with HIVRN............. 78
ABSTRACT

Sub-Saharan Africa bears 70% of the global HIV burden with KwaZulu-Natal (KZN) identified as the epicenter of this pandemic. HIV related nephropathy (HIVRN) exceeds any other causes of kidney diseases responsible for end stage renal disease, and has been increasingly recognized as a significant cause of morbidity and mortality. There is nonetheless a general lack of surveillance and reporting for HIVRN exists in this geographical region. Consequently, the aim of this study was to outline the histopathological spectrum of HIVRN within KZN. Moreover, from a pathology standpoint, it is important to address whether HIVRN was a direct consequence of viral infection of the renal parenchyma or is it a secondary consequence of systemic infection. Additionally, an evaluation of the efficacy of Highly Active Anti-Retroviral Therapy (HAART) in combination with angiotensin converting enzyme inhibitors (ACE-I) was performed via a genetic appraisal of localized replication of HIV-1 in the kidney, ultrastructural review and immunocytochemical expression of a podocyte maturity and proliferation marker pre and post-HAART.

Blood and renal biopsies were obtained from 30 children with HIV related nephropathy pre-HAART, followed-up clinically for a period of 1 year. This cohort formed the post-HAART group. Clinical and demographic data were collated and histopathology, RT-PCR, sequencing, immunocytochemistry and transmission electron microscopy was performed.

The commonest histopathological form of HIVRN in children (n = 30) in KZN was classical focal segmental glomerular sclerosis (FSGS) presented in 13(43.33%); mesangial hypercellularity 10(30%); mesangial, HIV associated nephropathy 3(11%) and minimal change disease 2(6.67%). Post-HAART (n = 9) the predominant pathology was mesangial hypercellularity 5(55.56%); FSGS 3(33.33%) and sclerosing glomerulopathy 1(11.11%). This study also provides data on the efficacy of HAART combined with ACE-I. The immunostaining pattern of synaptopodin, Ki67 and p24 within the glomerulus expressed as a mean field area percentage was significantly down-regulated in the pre-HAART compared to the post-HAART group respectively (1.14 vs. 4.47%, p
= 0.0068; 1.01 vs 4.68, p < 0.001; 4.5% vs 1.4%, p = 0.0035). The ultrastructural assessment of all biopsies conformed to their pathological appraisal however, features consistent with viral insult were observed. Latent HIV reservoirs were observed within the podocyte cytoplasm but was absent in mesangial or endothelial cells. Real-Time polymerase chain reaction assays provided evidence of HIV-1 within the kidney. Sequence analysis of the C2-C5 region of HIV-1 env revealed viral diversity between renal tissue to blood.

In contrast to a collapsing type of FSGS that occurs in adults, the spectrum of paediatric nephropathy in treatment-naive children within KwaZulu-Natal was FSGS with mesangial hypercellularity. Additionally, our study demonstrates podocyte phenotype dysregulation pre-HAART and reconstitution post therapy. Evidence of ultrastructural viral reservoirs within epithelial cells is supported by a genetic appraisal confirming the ubiquitous presence of HIV DNA in renal tissue. Moreover, sequence analysis showed viral evolution and compartmentalization between renal viral reservoirs to blood. Finally, the interplay of viral genes and host response, influenced by genetic background, may contribute to the variable manifestations of HIV-1 infection in the kidney in our paediatric population.
CHAPTER 1
INTRODUCTION

1.1 HIV

The global spread of human immunodeficiency virus (HIV) over the past four decades represents one of the most catastrophic paradigms of the emergence, transmission, and dissemination of a viral genome (Fassin and Schneider, 2003). HIV is a Retrovirus that leads to acquired immunodeficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections (Duesburg, 1988). HIV is transmissible via almost all body fluid including blood, semen, pre-ejaculate, vaginal fluid, or breast milk and can occur as a free virus and/or cell-associated virus (Bhimma, 2007; Osho and Olayinka, 1999).

1.1.1 Epidemiology

The World Health Organization (WHO) estimates that AIDS has killed more than 25 million people since it was first recognized on December 1, 1981 (Kharsany and Karim, 2011). By the end of 2010, globally an estimated 34.0 million (range: 31.6 million–35.2 million) people were living with HIV, with 2.6 million (range: 2.3 million–2.8 million) new HIV infections and 1.8 million (range: 1.6 million–2.1 million) deaths.

Sub-Saharan Africa is home to approximately 10% of the world’s population, yet bears a disproportionate burden of the disease, accounting for 70% of the global HIV infections (Figure 1.1); (UNAIDS, 2011). While there has been a decline in the number of new HIV infections, HIV incidence and mortality rates remain unacceptably high, with more than 75% of global AIDS related deaths occurring in this region. Provincial HIV estimates show geographic variations of the epidemic in South Africa whilst highlighting the fact that KwaZulu-Natal represents the highest burden of this infection (UNAIDS, 2011).
According to current estimates, HIV is set to infect 90 million people in Africa, resulting in a minimum estimate of 18 million orphans (UNAIDS, 2011). Antiretroviral treatment reduces both the mortality and morbidity of HIV infection, but routine access to antiretroviral medication is not available in many countries within Africa (Okera et al., 2003).

At the end of 2010, a global estimate of 3.4 million [3 000 000–3 800 000] children less than 15 years were living with HIV of which 390 000 [340 000–450 000] represented new infections. AIDS-related causes claimed an estimated 250 000 lives of children under 15 years in the same year (Figure 1.2); (UNAIDS, 2011).

Figure 1.1: World map illustrating intensity of HIV infection. Key indicates severity/percentage of burden (UNAIDS, 2010).
1.1.2 HIV morphology

AIDS was first recognized by Montagnier and Gallo in the early 1980’s. AIDS is caused by the human immunodeficiency virus (Kumar et al., 2001). This is an enveloped virus (Sun and Wirtz, 2006); the envelope being derived from the host cell membrane as the virus leaves the cell. Inserted into this surface membrane are two glycoproteins - gp120 and gp41. The viral core is composed of a capsid protein (p24) and a matrix protein (p17) that helps maintain viral structure (Chrystie and Almeida, 1988). Within the core are two identical copies of single stranded RNA viral genome and three enzymes, reverse transcriptase, protease and integrase (Figure 1.3); (Gelderblom, 1991).
1.1.3 HIV Replication

To establish infection, HIV must first attach to its host cell (Figure 1.4 - Step 1). Attachment occurs by interaction between gp120 on the surface of the virus and the cluster of differentiation (CD)4 antigen receptor on the surface of the host cell (Grimwood et al., 1996; Lapham et al., 1996). In addition to the CD4+ T cell receptor, there must also be a co-receptor on the host cell (Steffens and Hope, 2004). The co-receptor differs for different host cell types (Doms and Moore, 2000). After attachment, the viral envelope and host cell membrane fuse, resulting in entry of the virus into the cell (Figure 1.4 - Step 2); (Simm et al., 1996). Once the RNA is released into the cytoplasm of the host cell, reverse transcriptase makes a DNA copy of the viral RNA genome (Figure 1.4 - Step 3); (Bushman, 2004). As the DNA is being formed, reverse transcriptase degrades the RNA strand (Ichiyama and Yamamoto, 2002). A complementary DNA strand is then added by the reverse transcriptase and the end of the resulting double-stranded DNA segment are joined non-covalently (Pandit and Li, 2004; Trkola et al., 1996). Treatment with
nucleoside analogs or reverse transcriptase inhibitors interferes with these steps (Chan et al., 1998). The resulting circular DNA is then transferred to the nucleus and inserted into the host cell chromosome by the viral integrase enzyme (Figure 1.4 – Step 4); (Heuer and Brown, 1997). The integrated viral DNA is now referred to as proviral DNA (Huang et al., 2006; Stebbing et al., 2004). Following integration, the proviral DNA may remain dormant or, with host cell activation, RNA may be synthesized from the DNA, yielding messenger RNA and viral genome RNA (Figure 1.4 – Step 5); (Appel, 2007; Gallo et al., 2003). Viral messenger RNA is translated, yielding viral enzymes and structural proteins (Nelson et al., 2001). Some of the functional proteins are formed by cleavage of a long poly-protein by the enzyme, protease (Liu et al., 1999). Protease inhibitors interfere with this step (Barisoni et al., 1999; Reeves et al., 2002). Gp41 and gp120 are inserted into the host cell membrane and the structural proteins surround the viral RNA to form the core (Figure 1.4 – Step 6); (Melikyan et al., 2000). Finally, the virion is released by budding (Figure 1.4 - Step7).
Figure 1.4: The replication cycle of a human immunodeficiency virus (NIAID, 2010). Steps 1-7 indicate viral entry, replication and budding.
1.1.4 Effect on host immune response

HIV primarily infects vital cells in the human immune system such as helper T cells, macrophage and dendritic cells (Varbanov et al., 2006). HIV infection leads to low levels of CD4+ T cells through three main mechanisms: firstly, direct viral killing of infected cells; secondly, increased rates of apoptosis in infected cells; and thirdly, killing of infected CD4+ T cell by CD8 cytotoxic lymphocytes that recognize infected cells (Brest et al., 2004; Eggers and Kimmel, 2004; Izzedine et al., 1999; Paranjape, 2005).

Two types of blood tests are routinely used to monitor HIV-infected people. One of these tests, which counts the number of CD4+ T cells, assesses the status of the immune system (Connolly et al., 1995; Peraldi et al., 1999) whilst the other determines the viral load, by directly measuring the amount of virus in the system (Varbanov et al., 2006).

In individuals not infected with HIV, the CD4+ T cell count in the blood is normally above 500 cells per cubic milliliter (mm^3) of blood (Mannucci et al., 1994). HIV-infected people generally not at risk for complications unless their CD4+ T cell count is < 200 cells/mm^3 (Mannucci et al., 1994). A declining CD4+ T cell count indicates that the HIV disease is advancing. In addition, CD4+ T cell counts aid in determining the appropriate treatment according to the stage of the disease (Goldsmith et al., 1991). The viral load predicts whether or not the CD4+ T cell count will decline in the coming months (Fagard et al., 2005).

When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections as shown in Figure 1.5. The viral load increases over time, as the HIV virus is replicating, therefore
making the virus more abundant, and further infecting helper T cells, consequently decreasing the CD4$^+$ T cell count (Mackewicz et al., 2000). If untreated, eventually most HIV-infected individuals develop AIDS and die of opportunistic infection (Lal and Sengupta, 1994).

Figure 1.5: Graph illustrating the different stages, CD4$^+$ T cell and viral load over time from primary infection to death (Sigve, 2008).
1.2 NORMAL KIDNEY

1.2.1 Function
The primary role of the kidney is to maintain water and electrolyte homeostasis in the body (Kurokawa, 1993). This is achieved by filtration of blood plasma and excretion of toxic metabolic waste products in the urine (Verkman et al., 1995). The kidneys regulates the osmotic concentration of the blood plasma thereby ensuring the osmotic regulation of all other body fluids (Dorup, 1990).

1.2.2 Normal morphology
The urinary system consists of two kidneys, two ureters, the urinary bladder, and a urethra. The total blood volume of the body is filtered through the kidneys about 300 times/day (Rebouche, 2004). The urine produced is conducted via the ureters to the bladder where it is temporally stored prior to being voided to the outside via the urethra (Trump, 1970).

1.2.3 Nephron
The nephron, the functional unit of the kidney selectively filters molecules from blood plasma to form a filtrate (Figure 1.6); (Zuo et al., 2006). It is also involved in the selective re-absorption of water and other essential molecules from the filtrate, thereby leaving behind excess and waste material to be excreted as urine (Hayashi, 1998; Verkman et al., 1995). The nephron is composed of two important components, renal tubule and renal corpuscle, each with very specific functions (Burkitt et al., 1993).
1.2.3.1 Renal tubule

The primary function of the renal tubule is ultrafiltration and selective re-absorption of water and inorganic ions from the glomerular filtrate (Berglund and Lotspeich, 1956; Verkman et al., 1995). The renal tubule has a convoluted shape divided into four distinct histo-physiological regions (Morel, 1999) viz.,

a. proximal convoluted tubule - is lined by tall cuboidal epithelial cells with a brush border that is compliant with it role of re-absorption of approximately 75% of sugar, sodium and chloride ions, and water from the glomerular filtrate (Baum and Quigley, 1998; Matsuo et al., 1986).

b. loop of Henle - is a hairpin bend lined by stratified squamous epithelium whose main purpose is re-absorption of water and ions achieved by the counter current multiplier system (Hogg and Kokko, 1979; Wareing and Green, 1994).

c. distal convoluted tubule - is lined with simple cuboidal cells and is responsible for the active regulation of potassium, sodium, calcium, and pH (Maurer et al., 2004; Urreizti et al., 2007).
d. Collecting tubules - exit into the pelvicalyceal system and serve to concentrate urine by passive re-absorption of water into the medullary interstitium following the osmotic gradient created by the loops of Henle (Imai et al., 1987; Sands, 2003; Tenstad et al., 2001).

1.2.3.2 Renal corpuscle
The renal corpuscle functions as the initial filtering component for the plasma (Lacy et al., 1987). It is formed by the combination of two structures, the Bowman’s capsule and the glomerulus (Ojeda et al., 2003).

1.2.3.2.1 The Bowman’s capsule
The Bowman’s capsule is a cup-shaped structure surrounding a tuft of capillaries, the glomerulus (Boucher et al., 1987). It is lined by simple squamous epithelial cells referred to as the parietal layer whilst each capillary is lined by a layer of visceral epithelial cells (Khedun et al., 1997).

1.2.3.2.2 The glomerulus
Blood enters the glomerulus via the afferent arteriole, passes through the tuft of capillaries and then drains out via the efferent arteriole (Kosaka and Kosaka, 2005). The latter maintains a pressure gradient (Bruggeman et al., 2000; Nochy et al., 1993b) in the glomerulus, thereby contributing to the process of ultrafiltration where fluids and soluble materials in the blood are forced out of the capillaries and into the Bowman's space (Figure 1.7); (Honda, 1984). The rate at which blood is filtered through all of the glomeruli, and thus the measure of the overall renal function, is the glomerular filtration rate (GFR)
Blood is filtered via the filtration barrier which consists of three components viz:

a. Fenestrated endothelium with 50-100nm fenestrations. This luminal surface is negatively charged (Khedun et al., 1997).

b. Glomerular basement membrane (340nm) is made up of three zones, lamina densa, rara interna, and externa (Vogler et al., 1999). The structural meshwork of collagen and other matrix proteins of the lamina densa separates molecules on their basis of size and shape whilst the lamina rara externa and interna repels negatively charged molecules (Bertolatus, 1990; Brenner et al., 1978).

c. Podocyte layer – discussed in 3.2.1.

1.2.3.2.3 Podocytes

Podocytes also known as visceral epithelial cells (Hamano et al., 2002; Levidiotis and Power, 2005) are highly specialized cells essential to the ultrafiltration of blood, with the subsequent extraction of urine, the retention of protein, as well as in maintaining a massive filtration surface (Khedun et al., 1997; Pitts and Van Thiel, 1986; Sladen and Landry, 2000). The large cell body sends out major primary processes that further ramify into
secondary processes (foot processes/pedicels) (Figure 1.8); (Somlo and Mundel, 2000). Adjacent foot processes interdigitate with each other forming a direct contact with the urinary aspect of the glomerular basement membrane (GBM) (Nochy et al., 1993a). The uniform gaps (25nm) between adjacent foot processes are referred to as the filtration slit (Caulfield and Farquhar, 1974). Adjacent foot processes are linked by a diaphragm (4nm) (Caulfield and Farquhar, 1974). Large macromolecules such as serum albumin and gamma globulin remain in the bloodstream. Small molecules such as water, glucose and ionic salts are able to pass through the slit diaphragms and form an ultrafiltrate (Kawachi et al., 2006; Moeller and Holzman, 2006).

![Figure 1.8: (A). Low-power electron micrograph illustrating podocyte and the glomerular filtering apparatus. (B). High-power electron micrograph depicting glomerular basement membrane layers viz., lamina rara densa (LRD) opposed by lamina rara interna (LRI) and externa (LRE). Note foot processes (FP), slit diaphragm (arrow) and fenestrated endothelial cells (open arrow) lining the capillary loop (L).](image-url)
Figure 1.9: Molecular anatomy of the podocyte foot process cytoskeleton consisting of actin, myosin-II, α-actinin-4, talin, vinculin and synaptopodin that is connected to the GBM via α3β1 integrins. The actin cytoskeleton is linked to the slit diaphragm components, nephrin and P-cadherin, via CD2AP, Z complex and α-, β-, γ-catenin. Note nephrin (N); P-cadherin (P-C); α-catenin(α); β-catenin (β); γ-catenin (γ); ZO-1 (Z); 3-integrin (3); 1–integrin (1); vinculin (V); talin (T); paxillin (P); α-actinin-4 (α-act-4); synaptopodin (synpo) (Somlo and Mundel, 2000).

The function of podocytes is primarily based on its cytoarchitecture (Smoyer et al., 1997). The cytoskeleton of foot processes contain a dynamic highly ordered parallel contractile system comprised of actin, myosin-II, α-actinin-4, and synaptopodin that is connected to the GBM via α3β1 integrins (Figure 1.9); (Somlo and Mundel, 2000). This actin filament organization of the cytoskeleton is integrated with different signal-transduction pathways from the cytosolic matrix, GBM interface, the slit diaphragm and the cell surface (Ichimura et al., 2003; Lahdenkari et al., 2005; Patrakka et al., 2002).

Foot processes are defined by three membrane domains:

i) apical membrane domain-links the actin cytoskeleton, making it the common denominator in podocyte function and dysfunction (Kerjaschki, 2001)

ii) slit diaphragm protein complex, and

iii) basal membrane domain or sole plate (Kerjaschki, 2001).
The actin bundles are linked to the slit diaphragm complex through several scaffolding proteins such as actinin (Arias et al., 2009), CD2AP (Yuan et al., 2002), densin (Oh et al., 2004), nephrin (Arias et al., 2009), Nck (Yanagida-Asanuma et al., 2007) and ZO-1 (Mundel et al., 1997b; Schnabel et al., 1990). Disruption with any of the three foot process domains would lead to a reorganization of the parallel actin contractile bundles into an irregular network, hence a collapse of the cytoskeleton with the resultant foot process effacement and subsequent proteinuria (Faul et al., 2007; Yanagida-Asanuma et al., 2007).

Mutations affecting several podocyte proteins cause disruption of the filtration barrier by rearrangement of the highly dynamic podocyte actin cytoskeleton (Ramsuran et al., 2011b; Tryggvason et al., 2006) (Addendum II). Proteins regulating the plasticity of the podocyte actin cytoskeleton are therefore of critical importance for sustained kidney barrier function (Ramsuran et al., 2011b; Tryggvason et al., 2004) (Addendum II).

### 1.2.3.2.3.1 Synaptopodin

Synaptopodin is the founding member of a novel class of proline-rich actin-associated proteins highly expressed in telencephalic dendrites and renal podocytes (Mundel et al., 1991). It regulates the actin-binding activity of α-actinin in the highly dynamic cell compartments of podocytes (Mundel et al., 1997a). At the protein level, two isomers exist with synpo-long been expressed in the kidney, whereas synpo-short is expressed in the brain (Figure 1.10); (Asanuma et al., 2005).
Synaptopodin is found on chromosome 5 location 5q33.1. It has two isoforms, viz:

1. Isoform A- This variant represents the longer transcript consisting of 903 amino acids.
2. Isoform B- This variant uses an alternate splice site in the coding region which results in an early stop codon, compared to isoform A. The resulting protein (isoform B) has a shorter, distinct C-terminus and consists of 685 amino acids (Mundel and Reiser, 1997).

**Figure 1.10:** Comparison of Synpo-long and Synpo-short isoform expression. The blue box shows the first 670 AA that are shared between both isoforms; the purple box shows amino acid 671–903 corresponding to the Synpo-alt fragment of Synpo-long. Synpo-alt contains a LPPPP motif (yellow) for ENA/VASP binding and a PPRPF motif (red) for homer binding (Asanuma et al., 2005).

Synaptopodin is essential for the maintenance of the integrity of the actin cytoskeleton and for the regulation of podocyte cell migration (Asanuma et al., 2006). Cell behaviour, is mediated by the Rho family of small GTPases (RhoA, Rac1 and Cdc42). Synaptopodin, is a novel regulator of RhoA signalling and cell migration in podocytes via induction of stress fibres by competitive blocking of Smurf1-mediated ubiquitination of RhoA, thereby preventing the targeting of RhoA for proteasomal degradation (Denamur et al., 2000). Furthermore, gene silencing of synaptopodin in podocytes causes the loss of stress fibres and the formation of aberrant non-polarized filopodia and impairment of cell migration (Yanagida-Asanuma et al., 2007). Consequently, this impairment is correlated with loss of synaptopodin and ensued severity of proteinuria. Reduced expression of synaptopodin is associated with poor response to steroid therapy in glomerulosclerosis (Hirakawa et al., 2006).
1.3 PODOCYTE CELL CYCLE

The cell-division cycle is a series of events that takes place in a eukaryotic cell leading to its replication (Boye and Nordstrom, 2003; Nurse, 1991). It consists of four different phases \(\text{viz., } G_1, S, G_2\) and \(M\) phase (Figure 1.11); (Dewey and Humphrey, 1963). Activation of each phase is dependent on the proper progression and completion of the previous phase. Cells that have temporarily stopped dividing are said to have entered a state of quiescence called \(G_0\) phase (Barisoni et al., 2000b).

![Cell division cycle diagram](image)

**Figure 1.11:** Podocyte phenotype dysregulation-a complete series of events from one cell division to the next. It is usually divided into the phase when DNA is replicated (S phase), the phase when the cell actually divides into two cells (M phase), the two intervening gap phases (G1 and G2), and a quiescence phase (G0). adapted from (David, 1999).

The cell cycle progression is regulated by cyclin and cyclin-dependent kinase (CDK) complexes (Measday et al., 1994) (Figure 1.11). CDK activity is controlled by cyclin-
dependent kinase inhibitors (CKIs) (Baghdassarian and Ffrench, 1996). Each step in the cell cycle is initiated and controlled by a specific set of cyclins, CDKs, and CKIs. However, p27 and p57, can inhibit cyclin-CDK complexes (Pines, 1997). Entry into the cell cycle can have three consequences viz., cell proliferation, cellular hypertrophy, and cellular apoptosis (George et al., 2003).

Systematic analysis of the cell cycle regulatory molecules in podocytes have revealed a tight control of cell cycle quiescence, in sharp contrast to the proliferative capacity of the neighbouring mesangial cells (Marshall and Shankland, 2006; Ng et al., 1998). Podocytes enters the cell cycle at the G$_1$ phase (Figure 1.11) – however their growth at this phase of the cycle is mainly due to the presences of cyclin D and E (Wang et al., 2005). Mature non-proliferative podocytes enter the quiescent G$_0$ state from G$_1$ and may remain quiescent/growth-arrested expressing cyclin-dependent kinase inhibitors. These cells are terminally differentiated and express maturity markers such as synaptopodin and Wilm’s tumour (Conaldi et al., 2002; Saleem et al., 2002).

1.3.1 Podocyte proliferation

Cell proliferation is defined as the rapid multiplication of a cell (Truong et al., 1996). The Ki-67 protein located on chromosome 10q26.2 is a cellular marker for proliferation expressed in all active phases of the cell cycle (G$_1$, S, G$_2$ phase and mitosis) (Figure 1.11), but is absent from the quiescent cells (G$_0$) (Winking et al., 2004). During interphase, the Ki-67 antigen can be exclusively detected within the cell nucleus, whereas in mitosis most of the protein is relocated to the surface of the chromosomes (Noel et al., 2006; Winking et al., 2004).
The ability of podocytes to proliferate depends on their state of differentiation (Barisoni et al., 2000b). During glomerulogenesis, the immature podocyte precursor cells originate from the metanephric mesenchyme which undergoes marked proliferation. However, as podocytes mature they exit the cell cycle stop proliferating and becomes terminally differentiated thereby acquiring a phenotype that is quiescent (Barisoni et al., 2000b; Saleem et al., 2002). Normal terminally differentiated podocytes express regulatory proteins (CKI p27, p57 and Cyclin D1), indicating that they have entered the cell cycle, completed the DNA synthesis in S phase, and are ready for G2 phase in the cell cycle.

1.4 GLOMERULAR DISORDERS

Glomerular disorders is termed “Nephropathy” which originates form the Greek word “nephros” meaning kidney and “patho” meaning disease (Takata et al., 2000). Therefore, the name nephropathy refers to any damage or disease of the kidney (Hiura et al., 2006).

Histological evidence supports genetic data indicating podocyte dysfunction in glomerular disease (Naicker et al., 2006). An early event is the loss of integrity of foot processes and the slit diaphragm, leading to foot-process fusion, altering the filtration barrier with resultant protein in the urine (proteinuria) and blood in the urine (haematuria) (Figure 1.12; Bhimma et al., 2008; Lai et al., 2007; Tapia et al., 2008). Alternatively, foot process effacement may be a result of dysfunction of one of the molecular players in the signal-transduction pathway (Kawachi et al., 2006). If these early structural changes are not reversed it, ultimately leads to the development of glomerulosclerosis and to end stage renal disease (ESRD) (Jarad et al., 2006).
1.4.1 Spectrum of glomerular disorders

The histopathological spectrum of glomerular disorders that can cause nephrotic syndrome are highlighted below:

1.4.1.1 Minimal Change

Minimal change disease (MCD) is characterised by foot process effacement (Figure 1.13) and loss of the normal charge barrier such that albumin leaks out and proteinuria ensues (Han et al., 2006b). The glomerulus appears normal under the light microscope (Moeller and Holzman, 2006). Most cases of MCD are idiopathic, whilst secondary sources of aetiology may be drugs, cancer, viral and allergens (Lahdenkari et al., 2004).
1.4.1.2 Focal segmental glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) indicates that some (focal) segments (segmental) of the kidney filters (glomeruli) are scarred (sclerosis) (Figure 1.14); (Kriz, 2003). It is the direct common form of nephrotic syndrome in children and adolescents, leads to end stage kidney disease (Smeets et al., 2006). In contrast to MCD, patients with FSGS are more likely to have a form of non-selective proteinuria, hematuria, progression to chronic renal failure, and poor response to corticosteroid therapy (Bolton and Abdel-Rahman, 2001).
The pathogenesis of FSGS may be idiopathic, or it can be associated with several aetiological agents including HIV (Dijkman et al., 2006; Tucker, 2002). Clinical presentation of HIVAN include moderate to nephrotic range proteinuria (loss of large amount of protein in the urine), oedema (retention of water - weight gain), hypoalbuminemia (albumin in blood serum are abnormally low), hypertension (blood pressure is chronically elevated) and ultrasound findings of large, highly echogenic kidneys.(Schrier et al., 1981; Wyatt et al., 2008).

**Figure 1.14:** Schematic and light micrograph of cross-section of A & B: normal glomeruli; C & D glomeruli with focal segmental glomerulosclerosis. (Falk, 2008).

### 1.4.1.3 Membranous glomerulopathy

In membranous glomerulopathy, the GBM is thickened (Figure 1.15) due to the accumulation of immune complexes in the walls of glomerular capillaries between the basement membrane and the podocyte (O'Regan, 1979; Sheerin et al., 2006). Antibodies
bind to target molecules (antigens) (Figure 1.15); (Abrahamson, 1987; Caulfield and Farquhar, 1974) with the resultant immune complex formation that disturbs glomerular filtration hence proteins leak into the urine (proteinuria) (Brasile et al., 1997). In most patients, the source of the antigens in the immune complexes is idiopathic, however, in some patients, it comes from an infectious micro-organism. Occasionally, the antigen is an auto-antigen, for e.g., in patients with membranous glomerulopathy secondary to an auto-immune disease such as systemic lupus erythematosus (Jennette and Falk, 1997).

Figure 1.15: Schematic illustration of the process of normal accumulation of immune complexes (antibodies that are attached to antigens) within glomerular capillary walls of membranous glomerulopathy and light micrographs indicating thickened (arrows) capillary walls (Falk, 2008).

1.4.1.4 IgA nephropathy

IgA nephropathy (also known as IgA nephritis, IgAN, Berger's disease and synpharyngitic glomerulonephritis) is the commonest type of glomerulonephritis in the world (D'Amico, 1987). It is characterized by diffuse deposition of the IgA antibody in the mesangium (Hernandez et al., 1997; Suzuki et al., 2003; Yoshikawa et al., 1994). Henoch-Schönlein purpura is the most common disease associated with glomerular IgA deposits, considered by many to be a systemic form of IgA nephropathy (Figure 1.16); (Vogler et al., 1999).
1.4.1.5 Diabetic Glomerulosclerosis

Diabetic nephropathy is characterised by diffuse or nodular glomerulosclerosis, afferent and efferent hyaline arteriolosclerosis, and tubule-interstitial fibrosis and atrophy (Alsaad and Herzenberg, 2007). It is a major cause of ESRD (Markowitz et al., 2002).

1.4.1.6 HIV related nephropathy

Renal disease associated with AIDS was first reported in 1984 (Gardenswartz et al., 1984). Today HIV related renal diseases is considered the third leading cause of ESRD (Szczech, 2001). The etiological role of the virus in these pathologies is unknown (Symeonidou et al., 2008). It has been show that renal disease is more common in HIV infected patients with a CD4 T cell < 200 cells/µL (Gerntholz et al., 2006; Symeonidou et al., 2008). Majority of HIV-1 seropositive patients at some point during their illness, develop renal impairment ranging from minor transient electrolyte imbalance to ESRD (Symeonidou et al., 2008). HIV-1 seropositive patients progress rapidly (6-8 wks) to ESRD with a mortality-rate approaching 100% within 6 months of diagnosis (Moro et al., 2007).
The most common histologic lesion occurring in these patients is HIV associated nephropathy (HIVAN) (Kimmel et al., 2003). This lesion demonstrates collapsing type FSGS with proliferation of tubulo-epithelial cells (Gerntholz et al., 2006). Studies by Han et al (2006a), demonstrate that in South Africa, HIVAN is the commonest biopsy finding occurring in adult patients with HIV infection and is characterized by mesangial hyperplasia, variants of FSGS and with microcystic transformation of renal tubules (Figure 1.17).

Another variant, the histologic pattern of HIV Immune complex disease (HIVICK) involves immune deposition within the mesangial and paramesangial regions with concomitant (Figure 1.18), overlap of the tubulo-interstitial changes that occur in classic ‘HIVAN’ (Gerntholz et al., 2006).

Figure 1.17: Human HIV-associated nephropathy: (A). A glomerulus shows global collapse of capillary lumina. The glomerular basement membranes are wrinkled and folded, and the urinary space is occupied by proliferating podocytes forming pseudocrescents. Numerous protein reabsorption droplets are present in the podocyte cytoplasm; (B). Tubulointerstitial damage includes interstitial fibrosis with inflammation, tubular atrophy, and microcysts. Eosinophilic casts are present in the dilated tubular lumina (Kimmel et al., 2003).
Other variants, such as HIV associated thrombotic microangiopathies (TMA) resulting from hemolytic uremic syndrome (HUS) is believed to be triggered by endothelial cell dysfunction as a consequence of viral proteins (Kimmel et al., 2003).

HIV related nephropathy can also result from the adverse effects of HIV treatment regiments (Prins et al., 2005). An example of HAART-related renal disease was reported by Symeonidou and co-workers in 2008 due to the use of a protease inhibitor (indinavir) implicated in forming renal calculi. Additionally, a direct renal tubular toxicity is associated with antiretroviral agents, such as the nucleotide analog tenofovir (Symeonidou et al., 2008). Furthermore, patients with HIV disease are at risk for developing pre-renal azotemia due to volume depletion as a result of salt wasting, poor nutrition, nausea and/or vomiting (Moro et al., 2007).

HIV related nephropathy primarily occurs in Black patients, suggesting a genetic predisposition to the disease (Choi et al., 2007b; Moore and Doms, 2000). A recent study (Kopp et al., 2008) using mapping by admixture linkage disequilibrium identified MYH9 as a genetic variant that pre-disposes to HIV associated FSGS and additionally showed
strong association of African chromosomal ancestry with FSGS in African Americans. This racial discrepancy in susceptibility to HIV-related nephropathy (HIVRN) has been reported in studies from the USA, France and Brazil (Kopp and Winkler, 2003). Although the vast majority of infected patients reside in sub-Saharan Africa (approximately 75%), there is paucity of data from this continent (Gerntholz et al., 2006). In the USA, African Americans represent approximately 65% of all children with HIV-1 infection or AIDS of which 40% experience an increased prevalence of renal complications (Klotman, 1999; Ray et al., 2004; Winston et al., 1999).

Ray et al., (2004) suggested that HIV-1 infection per se was capable of inducing HIVAN in children and that HIVAN in children progressed at a slower rate when compared with adults with HIVAN. HIVAN occurs more frequently in males than in females, with a male-to-female ratio of 10:1 (Moro et al., 2007).

Over the past 28 years despite a substantial advancement in understanding the aetiology, natural history and drug therapy for the spectrum of HIVRN, renal biopsy remains the gold standard for the identifying the disease pattern (Gerntholz et al., 2006).

1.4.1.6.1 Spectrum of HIVRN in South Africa

Despite the large burden of HIV-1 disease in Africa, there have been no substantial reports of HIV-related kidney disease. Africa represents a true opportunity for refining our understanding of the epidemiology of HIV-related renal diseases (Cohen and Kimmel, 2007). If the US data for HIVAN was extrapolated to Africa, between 0.9 and 3.1 million people would be predicted to have HIV related diseases (Naicker et al., 2006). These figures predict an unprecedented and possibly underestimated burden of chronic kidney
disease in Africa. Naicker et al., (2006) suggest that the low socioeconomic conditions in South Africa contributes to the low prevalence of reported HIV related diseases as many patients demise before reaching ESRD.

A study by Gerntholtz et al., (2006) looks at the spectrum of 99 adult patients with HIVRN from South Africa (Fig 1.19 A). Ramsuran et al., (2011a) outlines the spectrum of HIV-1 related kidney diseases of children in South Africa (Fig 1.19 B); (Addendum I). Although collapsing glomerulopathy is thought to be the most common form of chronic kidney disease in adults of African descent who are HIV positive, it accounts for only about a quarter of the histological spectrum of disease seen in HIV positive children in our region. This conforms to reports from other regions in South Africa where HIVAN accounted for less than a third of all adult patients and 11.5% of all children with HIV-related nephropathy (Gerntholz et al., 2006; Kala U et al., 2007). Additionally a study by Cachat (1998) showed that in children of African American descent focal and segmental glomerulosclerosis occur in contrast to those of European ancestry (Caucasian) were mesangial hyperplasia, rarely with IgA nephropathy predominate.

![Piechart comparing HIVRN adults (A) with children (B) in South Africa. HIVICK: immune complex deposition disease; other GN's: other glomerulonephritides; HIVAN: collapsing nephropathy; IgAN: IgA nephropathy; PIGN: post-infectious glomerulonephritis; other: other (non-glomerulonephritic) renal disease; MP: mesangial proliferative glomerulonephritis; FSGS: focal glomerulosclerosis; and min change: minimal change (MCD), and MH: mesangial hypercellularity.](image-url)
1.4.1.6.2 Pediatric HIVRN

At the beginning of the HIV epidemic, childhood HIVAN was first reported in African American children from the United States of America (Barre-Sinoussi et al., 1983; Fauci, 1999; Pardo et al., 1987). The finding of HIVAN in children provided evidence that HIV-1 virions per se was capable of inducing renal disease independently of other confounding variables that are present in HIV-infected adults such as heroin abuse (Ray et al., 2004). However, unlike adults, many children with HIV and kidney disease did not develop collapsing glomerulopathy. In children, the unique microscopic feature of HIVAN is defined as the presence of classical FSGS with or without mesangial hyperplasia in combination with microcystic tubular dilatation and interstitial inflammation (Fauci, 1999; Mitsuya et al., 1985). However, mesangial proliferative lesions secondary to immune complex deposits have also been identified in some HIV-infected children with HIVAN (Fauci, 1999; Mitsuya et al., 1985; Ray, 2009). Thus the clinicopathological spectrum of childhood HIVAN has been revised (Ray, 2009).

Although Sub-Saharan Africa is the epicentre of HIV there have been no substantial reports of HIVRN in children. It has been estimated that of the 2.1 million HIV-infected children under 15 years of age living in sub-Saharan Africa, approximately 300,000 children without access to antiretroviral therapy could develop HIVAN (McCulloch and Ray, 2008). These figures predict an unprecedented and possibly underestimated burden of HIV renal disease in children in Africa (Gerntholz et al., 2006; Naicker et al., 2006).
1.4.1.6.3 Podocytes in HIVRN

An escape of the podocyte from the cell cycle blockade results in a disruption of glomerular architecture followed by a rapid decline of renal function. This is demonstrated by the deleterious course of collapsing focal glomerulosclerosis pathology and persistent proteinuria of HIV nephropathy (Kiryluk et al., 2007; Klotman, 1999).

HIV-1 protein expression, *Tat*, *Nef* and *Vpr* have been implicated in podocyte dysfunction and phenotypical change (Lu et al., 2007). More specifically, the regulatory protein *Tat* and the 2 accessory proteins *Vpr* and *Nef* have been linked to the pathogenesis of HIVAN. *Vpr* transports cytoplasmic viral DNA into Nucleus and *Tat* is essential for HIV infection and replication whilst *Nef* protects cell from dying. *Tat* and/or *Vpr* have also been reported to alter differentiation genes, whereas *Nef* induces proliferation (Figure 1.20); (Sunamoto et al., 2003).

**Figure 1.20:** Organization of the HIV-1 genome, the function of each protein is outlined. Vpr, tat nef have been linked to HIVRN (Sunamoto et al., 2003).

Podocytes are injured in many forms of glomerular disease, including disease that are immune mediated (membrane glomerulopathy), toxin associated (puromycin aminonucleoside model of minimal change nephropathy), metabolic (diabetes), and
hemodynamic (glomerular hyper-filtration) (Barisoni et al., 2000a; Ichikawa and Fogo, 1996; Remuzzi et al., 1997; Wharram et al., 2005).

However, under pathological conditions, podocytes de-differentiate, re-entering the cell cycle and proliferating, therefore detecting the Ki-67 antigen (Barisoni et al., 2000b; Ferrara, 2004). Ki67 is a constituent of compact chromatin hence is vital for cell proliferation. Exceptions to this rule are conditions of collapsing glomerulopathies, including HIVAN, where podocytes undergo a dysregulation of their differentiated phenotype and proliferate (Barisoni et al., 2000a; Mundel and Shankland, 1999; Shankland, 1999).

In most glomerular diseases, podocytes may undergo DNA synthesis and mitosis, but not in cytokinesis (Marshall and Shankland, 2006; Nagata et al., 2003; Shankland, 1999). Failure to replicate leads to an inappropriate response of podocytes to injury resulting in progressive glomerulosclerosis (Barisoni et al., 2000b; Ihalmo et al., 2007).

1.5 HIV MOLECULAR EXPRESSION IN HIVRN

As eluded to in 1.1.3 viral RNA enters the infected cell via receptors where reverse transcription occurs to synthesize complementary circular DNA. This is then inserted into the host cell chromosome by the viral integrase enzyme; the integrated viral DNA is now referred to as proviral DNA (Gibellini et al., 2004). HIV-1 RNA is considered to be an effective marker to predict the level of HIV expression (Gibellini et al., 2004; Katzenstein, 2003; Vitone et al., 2005).
HIV-1 proviral DNA represents viral reservoirs whereas HIV-1 RNA represents viral replication (Desire et al., 2001; Gibellini et al., 2004). Proviral HIV-1 DNA has been measured in Peripheral blood mononuclear cells (PBMC) as well as within lymphoid tissue biopsy specimens (Desire et al., 2001).

A study using transgenic murine models by Salifu (2010), presented one of the most persuasive evidence to show a direct role of HIV-1 in the development of HIV renal disease. It demonstrated latent viral reservoirs within renal glomerular and tubular epithelial cells, supporting the theory that epithelial cells like podocytes may transcytose viral particles despite their lack of HIV-1 receptors (Sagar et al., 2004; Salifu, M, 2010). Further research should be attributed to monitoring the interplay between proviral load and treatment which offers substantial therapeutic information, as the surrogate marker HIV RNA can drop below the detectable limits (Desire et al., 2001; McCutchan et al., 2000; Nora et al., 2008).

Envelope protein is essential for virus entry as it seeks out specific receptors for entry into CD4+ T cell. To be successful against the immune system the env protein mutates frequently (Zhang et al., 1993), causing nucleotide substitutions in HIV-1 envelope gene as characterized by a high non-synonymous/synonymous substitution ratio compared with other regions of the viral genome (Sagar et al., 2004). The most striking changes in diversity occur in the envelope glycoproteins by modest increases in nucleotide sequence diversity (Nora et al., 2008). HIV-1 can result in infection of the new host with multiple viruses expressing genetically diverse env sequences (McCutchan et al., 2000; Nora et al., 2008).
1.6 TREATMENT OF HIVRN

1.6.1 Highly Active Antiretroviral Therapy

The development of a multi-drug combination therapy (Highly Active Antiretroviral Therapy - HAART) for treatment of HIV in 2006 transformed this catastrophic illness of AIDS to a more manageable chronic illness (Delaney M, 2006). The WHO guidelines considers HIVAN as stage four (severe symptoms; Addendum IV), for disease progression, which is an immediate initiation of HAART, regardless of CD4\(^+\) T cell count (Kaufman \textit{et al.}, 2010). No standard therapy for HIVAN has been developed but HAART has been shown to retard the progression of renal disease in persons with HIVAN (Herman and Klotman, 2003; Moro \textit{et al.}, 2007). South Africa’s HIV epidemic remains the largest in the world with an increasing number of HIV infected patients accessing HAART. With an increasing total number of people living with HIV in South Africa; it reached an estimated 5.6 million [5 400 000 – 5 800 000] in 2010, of which only 1 389 865 people were receiving HAART, by the end of 2010 (UNAIDS, 2011).

However, the long term effects of HAART may be complicated by direct nephrotoxicity or by metabolic disorders that are associated with the development of kidney disease, such as hypertension and diabetes (Wyatt and Klotman, 2007).

1.6.2 Angiotensin-converting enzyme inhibitor

It has been suggested that renal recovery and histological improvement may be possible following the initiation of HAART with an adjunctive therapy of ACE inhibitors (Wyatt and Klotman, 2007). The exact pharmacology of this salubrious drug is unknown. In HIVAN there is an up regulation of circulating transforming growth factor-\(\beta\) which is
thought to contribute to the pathology (Bhimma, 2007). ACE-I has been shown to reduce the production of transforming growth factor-β (Choi et al., 2007a).

1.6.3 Corticosteroids
Studies have shown steroids have a beneficial effect when treating HIVAN, by improving renal function and proteinuria. Steroids are considered second line therapy, with ACE-I being the first line of therapy for HIVAN patients, as it has only short term benefits (Choi et al., 2007a).

1.6.4 Dialysis
In the pre-HAART era, HIVAN patients with ESRD demised soon after initiating dialysis, (Bhimma, 2007; Choi et al., 2007a).

1.6.5 Kidney transplantation
Transplantation is not standard of care for HIVAN patients within South Africa. The immunosuppression of HIVAN may increase the risk of opportunistic infections, factors contributing to increased morbidity and/or mortality (Bhimma, 2007; Choi et al., 2007a).
1.7 AIMS OF THE STUDY

1.7.1 The primary aims of this study were:

1. Compare the immunoexpression of podocyte cytoskeleton proteins (synaptopodin) as well as the proliferation marker (Ki67) pre and post-HAART treatment.
2. To provide evidence for localized replication of HIV-1 in the kidney and the existence of a renal viral reservoirs using polymerase chain reaction assays.
3. To provide ultrastructural architectural differences between pre and post treatment whilst at the same time identifying renal viral reservoirs.

1.7.2 Secondary Objectives and Secondary Endpoints:

1. Determine the efficacy of HAART combined with ACE-I in patients with HIV and nephropathy.
2. Outline the spectrum of HIV-related nephropathies in KwaZulu-Natal.

1.7.3 The hypothesis tested:

a. The loss of synaptopodin and the proliferation of podocytes are reversible events following HAART therapy.

b. Glomerular and tubular epithelial cells are a source of latent viral reservoirs in HIV positive patients.
CHAPTER 2
MATERIALS AND METHODS

2.1 ETHICAL APPROVAL AND PATIENT CONSENT

This prospective study was conducted at the Optics & Imaging Centre, Doris Duke Medical Research Institute (PG Reference Number PG030/07; Addendum V), Inkosi Albert Luthuli Central Hospital (IALCH) and King Edward VIII Hospital (KEH) in Durban, South Africa. For this study, ethical approval was obtained from the Biomedical Research Ethics Committee, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal (Reference Number BF149/07; Addendum VI). Permission to conduct research was granted by the Hospital Managers at IALCH (Addendum VII) and KEH (Addendum VIII). Informed consent was obtained from all parents/guardians of children participating in the study (example of Doc used; Addendum IX). Familial consent was sort for control brain tissue obtained at post mortem (Addendum X).

2.2 STUDY POPULATION

Patients were managed in accordance with the institutional guidelines for their kidney disease and HIV was managed according to the standard of care used by the Department of Health, KwaZulu-Natal. Demographics findings were recorded in all patients. Clinical examination, patient care and follow-up of patients were performed by a trained senior paediatric nephrologist at the Renal Units in IALCH and KEH.

The targeted study population included children with HIVRN (N = 30 patients) \(\text{viz.}\),

(i) Pre-Highly Active Anti-Retroviral Therapy (HAART) (N = 30 samples).

(ii) Post-HAART (N = 30 samples).

All patients within the pre-HAART group were followed-up clinically for a period of 12 months. This cohort formed the post-HAART group.
2.2.1 Inclusion Criteria for Study Group

(i) all patients with HIV infection (all stages of HIV infection) and evidence of nephropathy as evident by persistent proteinuria*;

(ii) informed written consent from the parent/guardian together with informed assent from children >8 years;

(iii) patients eligible for ARV therapy according to standard of care utilised by the Department of Health in KwaZulu-Natal.

* Persistent proteinuria is defined as urinary dipstick finding of 1+ or more proteinuria on two or more occasions in the absence of fever and a protein-to-creatinine ratio, (each measured in mg/dL using a random, early morning urine sample) of $\geq 0.2$ with or without the presence of haematuria on urine microscopy.

2.2.2 Exclusion Criteria for Pre-HAART Group

(i) patients with transient proteinuria and HIV infection.

(ii) failure to obtain informed written informed consent and/or assent in a child >8 years of age.

(iii) patients with congenital abnormalities of the renal tract with HIV infection.

(iv) patients with bleeding diatheses who cannot undergo renal biopsy.

(v) non South African patients.

2.3 RENAL BIOPSY

A complete aseptic technique was used to obtain biopsy material, viz., gowns, masks, gloves, etc. The skin was disinfected using chlorhexidine and povidone iodine. Land marks used were the lumbar vertebral spinous processes, the iliac crest, twelfth rib, the quadratus lumborum and the spinal extensor muscles. An in-house ultrasound scan was
performed by a qualified radiologist to obtain the size of the kidney, position of the lower pole and the depth of the lower pole of the kidney from skin surface. The patient was sedated with pethidine (1mg/kg; maximum dose 100mg) and midazolam (0.3-0.6mg/kg; maximum dose 15mg). If this was not sufficient to obtain adequate sedation, ketamine 1mg/kg diluted was added to the sedation. A 16 guage needle was used to explore the kidney depth after infiltration with 10cc (cubic centimetres) of 2% lignocaine used as a local anaesthetic. The needle was advanced until resistance of the renal capsule was encountered and the depth and position confirmed under ultrasound guidance. The scout needle was confirmed to be in kidney parenchyma when the needle oscillated with respiration. Once the site, path and depth of the scout needle was confirmed to be in the lower pole, it was removed. A 16-18 gauge tru-cut needle (QuickCore; Wilson-Cook Medical, NC) was used to biopsy the kidney under ultrasound guidance. The biopsy material was removed with a sterile forceps and placed on a microscope slide. A drop of saline was used to prevent the kidney biopsy material from drying. Three cores of tissue were obtained and part of the core was placed in a sterile tube snap frozen in liquid nitrogen for laser micro-dissection, polymerase chain reaction (PCR) and sequencing. The remaining 3 cores were stored in 4% glutaraldehyde, 5% formal saline and Mitchel’s medium respectively and transported to the Department of Anatomical Pathology Laboratory (IALCH) for routine light microscopy, immunofluorescence and electron microscopy. Finally the biopsy area was cleaned and sterilized, OpSite spray (Zhejiang Top-Medical, Medical Dressing Co., Ltd. China) was used as an aqua film dressing, and a pressure dressing was applied to prevent further bleeding. A post-biopsy ultrasound was done to detect the presence of a haematoma. During the biopsy the patient’s oxygen saturation was monitored. Pulse, blood pressure and electrocardiograph monitoring was carried out using an automated Welch Alan monitoring machine.
Post-biopsy monitoring was continued for 24 hours in the ward and if there was any evidence of frank haematuria or pallor the patient was subjected to a repeat ultrasound to check for evidence of an expanding hematoma. If bleeding did not stop within 48 hours or the patient became severely anaemic or haemodynamically unstable, an embolisation of the bleeding vessel was done by the radiologist using angiography.

Hypertension was controlled in patients using angiotensin converting enzyme (enalapril 0.3-0.5mg/kg). Diuretic therapy (hydrochlorothiazide and spironolactone) was used initially for control of oedema in patients with nephrotic syndrome and for control of hypertension in combination with angiotensin converting enzyme.

2.4 BLOOD ANALYSIS

Prior to biopsy, peripheral venous blood samples were obtained by venipuncture and collected in commercially available tubes containing a strong anti-coagulant viz., ethylene diamine tetra-acetic acid (EDTA; Becton Dickinson).

The samples were then analysed and subjected to the tests below:

2.4.1 CD4+ T cell count and Viral Load
2.4.2 Blood DNA extraction
2.4.3 HIV Proviral DNA Quantification
2.4.4 Sequence Diversity Analyses

2.4.1 Measurement of plasma viral load and CD4+ T cell counts:

PBMC and plasma were isolated by density gradient centrifugation at 1000 rpm (Heraeus Megafuge 1.0R) for 10 min at room temperature.
i) **Viral load** - Quantification of plasma HIV-1 RNA was made by using the automated ultrasensitive (lower detection limit 50 copies/ml) COBAS Amplicor/Ampli Prep HIV-1 Monitor Test V1.5 (Roche Molecular Systems Inc., New Jersey, USA) as per manufacturer’s instructions.

ii) **CD4⁺ T cell** - A cluster of differentiation (CD) cells from PBMCs were enumerated by using the Multi-test kit (CD4/CD3/CD8/CD45) on a four parameter FACS Calibre flow cytometer (Becton Dickinson, New Jersey, USA).

### 2.4.2 Blood DNA extraction

DNA was extracted from buffy coats using the QIAamp DNA Mini kit (Qiagen, Santa Clarita, CA, USA) according to the manufacturer’s instructions (Figure 2.1). DNA was quantified on the spectrophotometer NanoDrop 2000 (Thermo Scientific, Fermentas Canada Inc., Burlington, Ontario) to determine the quantity and quality of extracted DNA.
**Figure 2.1:** An overview of the QIAGEN QIAamp DNA Blood Mini Spin kit procedure for DNA extraction from buffy coat samples (Adapted from QIAGEN, 2003).

**Sample**

- **Lyse:** 200µl of the lysed sample was loaded on the column membrane.

**Bind**

- **Wash (Buffer AW1):** The column was then washed which allowed the DNA to bind in during centrifugation.

**Wash (Buffer AW2):** Protein and other contaminants will not bind to the membrane, due to the salt and pH conditions of the lysate buffer, and will therefore prevent downstream inhibition of PCR.

**Elute:** Finally purified DNA was eluted.
2.4.3 HIV Proviral DNA Quantification

A modified method of Desire et al., (2001) involving real time PCR technology was used for proviral load quantification. The LightCycler® 480 (Roche Molecular Systems, New Jersey, USA) was used for PCR amplification, acquisition and data analysis.

The PCR primers were selected to optimize HIV-1 subtype C gag sequence amplification, following earlier studies that suggest that this genetic subtype is the predominant virus in Southern Africa (Novitsky et al., 2001). The sequence of the forward and reverse primers were p24-F1 (5’-CAAGCAGCCATGCAAATGTT-3’) and 330L (5’-GGTACTAGTAGTTCCTGC TAT-3’) respectively. The primers ALB-S (5’-GCTGTCATCTCTCTTGGGCTGT-3’) and ALB-AS (5’-AAACTCATGGGAGCTGCTGGTT-3’) were used to quantify the human albumin gene. All samples, controls and standards were run in duplicate and the average value was used to compute HIV and albumin copy number. A standard curve for HIV and albumin was accepted with slopes ranging between -4.52 and -3.91 and when the coefficient of correlation ($r^2$) was >0.986.

Albumin DNA was quantified to determine the level of DNA input, to normalize for variation in buffy coat cell differences and for differences in DNA extraction. The normalized value of HIV proviral load was calculated as HIV DNA copy number/albumin DNA copy number multiplied by 2X10^6 cells. The 8E5 cell line (American Type Culture Collection., Manassas, USA), was cultured by incubation horizontally at 37°C in a 5% CO$_2$ in air atmosphere using RPMI-1640 medium (Sigma-Aldrich Corporation, MO) with 10% fetal bovine serum. The 8E5 cell line, a T lymphoblastoid cell line that contained a single
defective genome copy of HIV-LAV (lymphadenopathy-associated virus) per cell, was used as a positive control for each run and for the generation of a standard curve.

### 2.4.4 Sequence Diversity Analyses

Genomic DNA was extracted directly from PBMCs and kidney biopsy cells using the QIAamp Blood kit (Qiagen, Chatsworth, CA). Thereafter, the Expand High Fidelity PCR kit (Roche Molecular Systems, New Jersey, USA) was used to amplify a 957 base pair (bp) C2-C5 fragment of the *env* gene by using a nested PCR reaction protocol. In the first round reaction the forward primers was vpu232 (TGCTCCTTGGGATATTGATGA) while the reverse primers was p131 (AGCCAGGACTCTTGCCTGGAGCT). Five µL of the first round reaction product was subjected to a second round of amplification, with primers Bstq2+ (CCATAGTGCTTCCTCTTGCTGGCTCCTAAAGAACCCCA) and 1556 (CCATAGTGCTTCCTCTTGCTGGCTCCTAAAGAACCCCA). Ten picomoles of each primer were used per PCR reaction. The cycling conditions for both amplifications consisted of initial activation at 95°C for 10 mins, followed by 39 cycles of 95°C for 15 sec, 58°C for 30 sec and 72°C for 1 min with a final extension at 72°C for 7 mins. To minimize re-sampling bias and to gain an understanding of the extent of diversity within the samples, three independent PCR reactions were performed for each sample at each time point (pre and post-HAART in PBMCs and kidney tissue) using identical PCR conditions. These PCR products were run on a 1% agarose gel at 100 Volts for 2 h to confirm the amplification of the 957 bp C2-C5 fragment by electrophoresis on an Enduro-power supplier (Labnet International Inc, New Jersey, USA). The desired band was then cut from the gel to ensure a greater probability that no other products were carried onto sequencing. The gel purification was performed utilizing the GE Healthcare kit (Table 2.1; GE Healthcare Life Sciences, Buckinghamshire, UK).
Table 2.1: Procedure for gel purification.

<table>
<thead>
<tr>
<th>STEPS</th>
<th>METHOD</th>
<th>TEMP</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PCR products run on a 1% gel at 100 Volts</td>
<td>24°C</td>
<td>2 h</td>
</tr>
<tr>
<td>2</td>
<td>Excise band of interest</td>
<td>24°C</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>500µl Capture buffer type 3</td>
<td>60°C</td>
<td>5 mins</td>
</tr>
<tr>
<td>4</td>
<td>Add sample mix to GFX MicroSpin™ column and collection tube</td>
<td>24°C</td>
<td>1 min</td>
</tr>
<tr>
<td>5</td>
<td>Centrifuge @ 10000rpm (discarded flow through)</td>
<td>24°C</td>
<td>30 sec</td>
</tr>
<tr>
<td>6</td>
<td>500 µl wash buffer type 1</td>
<td>24°C</td>
<td>30 sec</td>
</tr>
<tr>
<td>7</td>
<td>Centrifuge @ 10000rpm (discarded flow collection tube)</td>
<td>24°C</td>
<td>30 sec</td>
</tr>
<tr>
<td>8</td>
<td>20µl elution buffer type 4</td>
<td>24°C</td>
<td>1 min</td>
</tr>
<tr>
<td>9</td>
<td>Centrifuge @ 12000rpm (retain flow through)</td>
<td>24°C</td>
<td>1 min</td>
</tr>
<tr>
<td>10</td>
<td>Run on a gel with a low DNA mass ladder (Invitrogen Corporation,</td>
<td>24°C</td>
<td>2 h</td>
</tr>
<tr>
<td></td>
<td>Carlsbad, California, USA) and Molecular Weight Marker (1kb O’gene</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ruler, Thermo Scientific, Fermentas Canada Inc. Canada, Ontario)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.4.5 Sequencing and Sequence Analysis

2.4.5.1 Cloning

The gel purified PCR products of specific segments of DNA with a single deoxyadenosine (A) to the 3’ end complemented to the 3’ deoxythymidine (T) of the PCR 2.1-Topo vector (Invitrogen Corporation, Carlsbad, California, USA), was then transformed into competent cells by the protocol outlined in Table 2.2.
Table 2.2: Procedure for cloning PCR products into a PCR 2.1-Topo vector.

<table>
<thead>
<tr>
<th>STEPS</th>
<th>METHOD</th>
<th>TEMP</th>
<th>TIME</th>
</tr>
</thead>
</table>
| 1     | Ligation: \( \text{H}_2\text{O} = 1\mu l \)  
\( \text{Vector} = 1\mu l \)  
\( \text{Salt} = 1\mu l \)  
\( \text{DNA (10ng/\mu l)} = 3\mu l \) | 24°C | 30 min |
| 2     | Transform: 3µl ligation to competent \( \text{E. coli One Shot® Mach1™} \) | On ice | 30 min |
| 3     | Heat shock | 42°C | 30 sec |
|       |         | On ice | 2 min |
| 4     | 250µl Super Optimal broth with Catabolite (S.O.C ) medium | 37°C | 5 h |
| 5     | 100µl cell mixture plated on X-gal, ampicillin | 37°C | overnight |
| 6     | TBE (growth medium) was inoculated with white colonies | 37°C | overnight |
| 7     | Cultures were pelleted @ 12000 rpm | 24°C | 2 min |

### 2.4.5.2 Plasmid isolation

This procedure was used to extract plasmid DNA, GeneJET™ (Thermo scientific, Fermentas Canada Inc. Canada, Ontario) from bacterial cell suspensions, as per manufacturer’s protocol. It is based on a silica membrane technology that utilises a spin column to selectively bind DNA molecules using high salt concentration and then washed to remove contaminants. Purified plasmid DNA was then eluted using the plasmid mini preparation as outlined in Table 2.3.
Table 2.3: Procedure for plasmid isolation.

<table>
<thead>
<tr>
<th>STEPS</th>
<th>METHOD</th>
<th>TEMP</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>To pelleted cells, 250µl of resuspension solution- vortex</td>
<td>24°C</td>
<td>15 sec</td>
</tr>
<tr>
<td>2</td>
<td>250µl lysis solution, invert tube 4-6 times</td>
<td>24°C</td>
<td>15 sec</td>
</tr>
<tr>
<td>3</td>
<td>350µl of neutralization solution, invert tube 4-6 times</td>
<td>24°C</td>
<td>15 sec</td>
</tr>
<tr>
<td>4</td>
<td>Centrifuge @ 12000rpm</td>
<td>24°C</td>
<td>5 min</td>
</tr>
<tr>
<td>5</td>
<td>Transfer supernatant to GeneJET™ spin column, Centrifuge @ 12000rpm</td>
<td>24°C</td>
<td>1 min</td>
</tr>
<tr>
<td>6</td>
<td>Wash column: 500µl wash solution - Centrifuge @ 12000rpm -Repeat</td>
<td>24°C</td>
<td>1 min</td>
</tr>
<tr>
<td>7</td>
<td>Empty column - Centrifuge @ 12000rpm</td>
<td>24°C</td>
<td>1 min</td>
</tr>
<tr>
<td>8</td>
<td>50µl Elution buffer – incubate – Centrifuge @ 12000rpm</td>
<td>24°C</td>
<td>4 min</td>
</tr>
<tr>
<td>9</td>
<td>Ran a 1% gel at 100 Volts</td>
<td>24°C</td>
<td>2 h</td>
</tr>
<tr>
<td>10</td>
<td>Spectrophotometer - NanoDrop 2000 (Thermo scientific, Fermentas Canada Inc. Canada, Burlington, Ontario)</td>
<td>24°C</td>
<td></td>
</tr>
</tbody>
</table>

2.4.5.3 Sequencing

Sequencing of the plasmid inserts was performed using Big Dye chemistry fluorescence-based cycle sequencing reaction mechanism on an ABI Prism 3130xl Genetic Analyzer (Table 2.4; Applied Biosystems, Foster city, California, USA). In this system double-stranded DNA templates were sequenced from PCR fragments. For each sample, 3 clones were sequenced using with primers Bstq2+ (CCATTCCTCATACATTATTTGTGC), 1556 (CCATAGTGCTTCTGCTGCTAAGAACCCAA) and ES8 (CACTTCTCCATTTGTCCC).
Table 2.4: Procedure for fluorescence-based sequencing reaction.

<table>
<thead>
<tr>
<th>STEPS</th>
<th>METHOD</th>
<th>TEMP</th>
<th>TIME</th>
</tr>
</thead>
</table>
| 1     | Primer (1.6µM) = 2µl  
   Big Dye = 0.4µl  
   buffer = 2µl  
   H2O = 5µl  
   Template (150ng) | 96°C  
   96°C  
   50°C  
   60°C  
   4°C | 1 min  
   10 sec  
   5 sec  
   4 min  
   ∞ |
| 2     | 1µl 125mM EDTA pH8.0 | 24°C | |
| 3     | 26µl (1µl of 3M NaOAc pH5.2 + 25µl 100% ethanol) | 24°C | |
| 4     | Centrifuge at 3000 X g | 24°C | 20 min |
| 5     | Invert to dry plate | 24°C | 5 mins |
| 6     | 35µl cold 70% ethanol | 24°C | 30 sec |
| 7     | Centrifuge at 3000 X g | 24°C | 5 mins |
| 8     | Dry | 50°C | 5 min |
| 9     | 10µl formamide, vortex | 24°C | 15 sec |
| 10    | Denature | 95°C  
   4°C | 3 mins  
   3 mins |

2.4.5.4 Sequence Analysis

Individual contiguous sequences were assembled and edited using the Sequencher 5.0 software program (Gene Codes Corporation, Ann Arbor, Michigan). Multiple sequence alignment were done on the Mafft online server (http://align.bmr.kyushu-u.ac.jp/mafft/online/server/). The pairwise distances of nucleotide alignment was computed by DNADist (University of Washington, USA) with the Kimura two-parameter model. The neighbour-joining tree and bootstrap values were generated using Mega Version 5.05 (Biodesign Institute, Tempe, USA). Highlighter plots were generated by Highlighter at www.hiv.lanl.gov, a visualization tool of aligned nucleotides sequences that highlights nucleotide polymorphisms.
2.5 KIDNEY BIOPSY

Percutaneous renal biopsies were performed by a paediatric nephrologist under ultrasound guidance at IALCH using a trucut biopsy needle. Three biopsy cores were obtained from each patient, divided and distributed as shown in Figure 2.2.

![Figure 2.2: Schematic diagram showing the three biopsy cores, their division and distribution for specialised assessment viz., electron microscopy (EM, Anatomical Pathology); immunofluorescence (IMF, Anatomical Pathology); laser micro-dissection (LMD, National Institutes of Health, US); evaluation of latent viral reservoirs and architecture (EM, Optics & Imaging Centre); immunohistochemistry (IHC, Optics & Imaging Centre) and genetic analysis (PCR and sequencing, Hasso Plattner).](image)

All renal biopsy material were evaluated by a senior pathologist experienced in interpretation of percutaneous renal biopsy at the Department of Anatomical Pathology, National Health Laboratory Service, IALCH. Post biopsy, the patient was followed-up bi-monthly for a period of one year whilst on HAART and ACE-I. At the end of this period a second biopsy was performed. The time frame of 12–14 months follow-up was stringently adhered to and a standard procedure.
2.5.1 Histopathology

2.5.1.1 Fixation and tissue processing

Biopsies were immediately immersed in 5% formal saline (41% formaldehyde / 0.9% NaCl, 1:8 v/v) – dilute formaldehyde (35%, Saarchem, SA) 1:7 in 0.9% NaCl and fixed at RT for 12 h. Samples were orientated and placed in tissue cassettes. These were then dehydrated through a series of ethanol (99% ethanol, Saarchem, SA), cleared with xylene (AR, Saarchem, SA) and infiltrated with paraffin wax (Paraplast Plus, Sherwood Medical, St Louis, USA) in an automatic tissue processor (Excelsior ES, Thermo scientific, Fermentas Canada Inc., Burlington, Ontario). Biopsies were then embedded in cassettes and polymerised at 60°C. The automated schedule of steps outlining this procedure (Table 2.5) was carried out by the Department of Anatomical Pathology, National Health Laboratory Service, IALCH. The processed tissue was then embedded using a Leica EG 1160 embedding station (Leica Biosystems, Newcastle Upon Tyne, UK).

Table 2.5: Fixation, dehydration and embedding schedule for light microscopy.

<table>
<thead>
<tr>
<th>PROCESS</th>
<th>METHOD</th>
<th>TEMP</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixation</td>
<td>10% buffered formal saline</td>
<td>24°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Fixation</td>
<td>10% buffered formal saline</td>
<td>24°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Dehydration</td>
<td>SVR (95% ethanol)</td>
<td>24°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Dehydration</td>
<td>SVR (95% ethanol)</td>
<td>24°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Dehydration</td>
<td>SVR (95% ethanol)</td>
<td>24°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Dehydration</td>
<td>absolute ethanol</td>
<td>24°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Dehydration</td>
<td>absolute ethanol</td>
<td>24°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Dehydration</td>
<td>absolute ethanol</td>
<td>24°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Clearing</td>
<td>xylene</td>
<td>24°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Clearing</td>
<td>xylene</td>
<td>24°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Vacuum infiltration</td>
<td>paraffin wax 1</td>
<td>60°C</td>
<td>2 h</td>
</tr>
<tr>
<td>Vacuum infiltration</td>
<td>paraffin wax 2</td>
<td>60°C</td>
<td>2 h</td>
</tr>
</tbody>
</table>
2.5.1.2 Microtomy

Sections (2µm) were cut on a Leica microtome RM2135 (Leica Biosystems, Newcastle Upon Tyne, UK). They were floated in a water bath and picked onto slides for staining.

2.5.1.3 Haematoxylin & Eosin (H&E); Periodic acid Schiff reaction (PAS), Masson’s trichrome, Miller’s Elastic and Silver Methenamine staining

For each biopsy, one section was cut and stained according to an outlined protocol for H&E (Table 2.6); PAS reaction (Table 2.7); Masson’s Trichrome (Table 2.8) and Miller’s Elastic stain (Table 2.9). In addition, 1 µm sections were cut for Silver Methenamine staining as outlined in Table 2.10.

Table 2.6: Procedure for H&E staining.

<table>
<thead>
<tr>
<th>STEPS</th>
<th>METHOD</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Dewax – xylene</td>
<td>2 x 5 min</td>
</tr>
<tr>
<td>2</td>
<td>Rehydrate – absolute ethanol</td>
<td>2 x 1 min</td>
</tr>
<tr>
<td>3</td>
<td>Rehydrate – 90% ethanol</td>
<td>1 min</td>
</tr>
<tr>
<td>4</td>
<td>Rehydrate – 70% ethanol</td>
<td>1 min</td>
</tr>
<tr>
<td>5</td>
<td>Rehydrate – water</td>
<td>1 min</td>
</tr>
<tr>
<td>6</td>
<td>Mayer’s Haematoxylin (Addendum XI)</td>
<td>5 min</td>
</tr>
<tr>
<td>7</td>
<td>Blue – rinse in running tap water</td>
<td>5 min</td>
</tr>
<tr>
<td>8</td>
<td>0.5% alcoholic eosin (Addendum XI)</td>
<td>2 min</td>
</tr>
<tr>
<td>9</td>
<td>Rinse quickly by immersing slides in 95% ethanol</td>
<td>30 sec</td>
</tr>
<tr>
<td>10</td>
<td>Dehydrate - Absolute Alcohol</td>
<td>2 x 1 min</td>
</tr>
<tr>
<td>11</td>
<td>Dehydrate – Xylene</td>
<td>1 min</td>
</tr>
<tr>
<td>12</td>
<td>Mount in DPX</td>
<td></td>
</tr>
</tbody>
</table>
Table 2.7: Procedure for PAS staining.

<table>
<thead>
<tr>
<th>STEPS</th>
<th>METHOD</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Dewax – xylene</td>
<td>2 x 5 min</td>
</tr>
<tr>
<td>2</td>
<td>Rehydrate – absolute ethanol</td>
<td>2 x 1 min</td>
</tr>
<tr>
<td>3</td>
<td>Rehydrate – 90% ethanol</td>
<td>1 min</td>
</tr>
<tr>
<td>4</td>
<td>Rehydrate – 70% ethanol</td>
<td>1 min</td>
</tr>
<tr>
<td>5</td>
<td>Rehydrate – water</td>
<td>1 min</td>
</tr>
<tr>
<td>6</td>
<td>1% Periodic Acid</td>
<td>10 min</td>
</tr>
<tr>
<td>7</td>
<td>Rinse in running water</td>
<td>30 sec</td>
</tr>
<tr>
<td>8</td>
<td>Schiff reagents (BDH Laboratory Supplies, England)</td>
<td>15 min</td>
</tr>
<tr>
<td>9</td>
<td>Running tap water</td>
<td>5 min</td>
</tr>
<tr>
<td>10</td>
<td>Mayer’s Haematoxylin (Addendum XI)</td>
<td>2 min</td>
</tr>
<tr>
<td>11</td>
<td>Blue in running tap water</td>
<td>2 min</td>
</tr>
<tr>
<td>12</td>
<td>2% Orange-G (KGaA 64271, Merck, Germany) in 5% Phosphotungstic acid</td>
<td>1 dip</td>
</tr>
<tr>
<td>13</td>
<td>Rinse in running tap water</td>
<td>2 min</td>
</tr>
<tr>
<td>14</td>
<td>Dehydrate - Absolute alcohol</td>
<td>2 x 1 min</td>
</tr>
<tr>
<td>15</td>
<td>Dehydrate – Xylene</td>
<td>1 min</td>
</tr>
<tr>
<td>16</td>
<td>Mount in DPX</td>
<td></td>
</tr>
</tbody>
</table>
**Table 2.8:** Procedure for Masson’s Trichome staining.

<table>
<thead>
<tr>
<th>STEPS</th>
<th>METHOD</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Dewax – xylene</td>
<td>2 x 5 min</td>
</tr>
<tr>
<td>2</td>
<td>Rehydrate – absolute ethanol</td>
<td>2 x 1 min</td>
</tr>
<tr>
<td>3</td>
<td>Rehydrate – 90% ethanol</td>
<td>1 min</td>
</tr>
<tr>
<td>4</td>
<td>Rehydrate – 70% ethanol</td>
<td>1 min</td>
</tr>
<tr>
<td>5</td>
<td>Rehydrate – water</td>
<td>1 min</td>
</tr>
<tr>
<td>6</td>
<td>Weigert’s Iron Haematoxylin (Addendum XI)</td>
<td>10 min</td>
</tr>
<tr>
<td>7</td>
<td>Rinse in running tap water</td>
<td>30 sec</td>
</tr>
<tr>
<td>8</td>
<td>1% Acid Alcohol</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Wash in distilled water</td>
<td>1 min</td>
</tr>
<tr>
<td>10</td>
<td>Biebrich scarlet-acid fuchsin (Addendum XI)</td>
<td>3 min</td>
</tr>
<tr>
<td>11</td>
<td>Rinse in distilled water</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>5% Phosphotungstic Acid</td>
<td>10 min</td>
</tr>
<tr>
<td>13</td>
<td>1% Light Green SF yellowish soln (Merck, Germany)</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Rinse in distilled water</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Dehydrate - Absolute alcohol</td>
<td>2 x 1 min</td>
</tr>
<tr>
<td>16</td>
<td>Dehydrate – Xylene</td>
<td>1 min</td>
</tr>
<tr>
<td>17</td>
<td>Mount in DPX</td>
<td></td>
</tr>
</tbody>
</table>
**Table 2.9:** Procedure for Miller’s Elastic staining.

<table>
<thead>
<tr>
<th>STEPS</th>
<th>METHOD</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Dewax – xylene</td>
<td>2 x 5 min</td>
</tr>
<tr>
<td>2</td>
<td>Rehydrate – absolute ethanol</td>
<td>2 x 1 min</td>
</tr>
<tr>
<td>3</td>
<td>Rehydrate – 90% ethanol</td>
<td>1 min</td>
</tr>
<tr>
<td>4</td>
<td>Rehydrate – 70% ethanol</td>
<td>1 min</td>
</tr>
<tr>
<td>5</td>
<td>Rehydrate – water</td>
<td>1 min</td>
</tr>
<tr>
<td>6</td>
<td>0.5% Potassium permanganate (Addendum XI)</td>
<td>5 min</td>
</tr>
<tr>
<td>7</td>
<td>Rinse well</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>1% Oxalic Acid solution</td>
<td>*</td>
</tr>
<tr>
<td>9</td>
<td>Rinse in running water</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Rinse in 70% Alcohol</td>
<td>5 min</td>
</tr>
<tr>
<td>11</td>
<td>Elastic stain (Addendum XI)</td>
<td>1 h</td>
</tr>
<tr>
<td>12</td>
<td>Rinse in 70% Alcohol</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Rinse in running water</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Counterstain with Van Gieson</td>
<td>5 min</td>
</tr>
<tr>
<td>15</td>
<td>Dehydrate through alcohol</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Clear in xylene</td>
<td>2 min</td>
</tr>
<tr>
<td>17</td>
<td>Mount in DPX</td>
<td></td>
</tr>
</tbody>
</table>

* Treat until sections appear white macroscopically
Table 2.10: Procedure for Silver methenamine staining.

<table>
<thead>
<tr>
<th>STEPS</th>
<th>METHOD</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Dewax – xylene</td>
<td>2 x 5 min</td>
</tr>
<tr>
<td>2</td>
<td>Rehydrate – absolute ethanol</td>
<td>2 x 1 min</td>
</tr>
<tr>
<td>3</td>
<td>Rehydrate – 90% ethanol and 70% ethanol</td>
<td>1 min</td>
</tr>
<tr>
<td>4</td>
<td>Rehydrate – water</td>
<td>1 min</td>
</tr>
<tr>
<td>5</td>
<td>Lugol’s iodine (Kanchem cc, Durban, SA)</td>
<td>5 min</td>
</tr>
<tr>
<td>6</td>
<td>Rinse in running water</td>
<td>30 sec</td>
</tr>
<tr>
<td>7</td>
<td>Coplin jar containing ammonia-Alcohol solution</td>
<td>30 min</td>
</tr>
<tr>
<td>8</td>
<td>Rinse in running water</td>
<td>5 min</td>
</tr>
<tr>
<td>9</td>
<td>Distilled water</td>
<td>1 min</td>
</tr>
<tr>
<td>10</td>
<td>1% periodic acid solution</td>
<td>15 min</td>
</tr>
<tr>
<td>11</td>
<td>Rinse in distilled water</td>
<td>30 sec</td>
</tr>
<tr>
<td>12</td>
<td>0.5% thiosemicarbazide</td>
<td>5 min</td>
</tr>
<tr>
<td>13</td>
<td>Rinse in distilled water</td>
<td>3 x 2 min</td>
</tr>
<tr>
<td>14</td>
<td>Pre-heated Methenamine-silver solution (Addendum XI) - 60ºC</td>
<td>60 min</td>
</tr>
<tr>
<td>15</td>
<td>Rinse in distilled water</td>
<td>2 min</td>
</tr>
<tr>
<td>16</td>
<td>0.2% Gold Chloride</td>
<td>2 min</td>
</tr>
<tr>
<td>17</td>
<td>Rinse in distilled water</td>
<td>2 min</td>
</tr>
<tr>
<td>18</td>
<td>5% Sodium thiosulphate</td>
<td>2 min</td>
</tr>
<tr>
<td>19</td>
<td>Rinse in distilled water</td>
<td>2 min</td>
</tr>
<tr>
<td>20</td>
<td>Mayer’s Haematoxylin (Addendum XI)</td>
<td>5 min</td>
</tr>
<tr>
<td>21</td>
<td>Rinse in distilled water</td>
<td>2 min</td>
</tr>
<tr>
<td>22</td>
<td>Lithium carbonate solution</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Rinse in distilled water</td>
<td>2 min</td>
</tr>
<tr>
<td>24</td>
<td>Eosin</td>
<td>3 min</td>
</tr>
<tr>
<td>25</td>
<td>Rinse in distilled water</td>
<td>2 min</td>
</tr>
<tr>
<td>26</td>
<td>Dehydrate - Absolute alcohol</td>
<td>2 x 1 min</td>
</tr>
<tr>
<td>27</td>
<td>Clear in xylene</td>
<td>2 min</td>
</tr>
<tr>
<td>28</td>
<td>Mount in DPX</td>
<td></td>
</tr>
</tbody>
</table>
2.5.1.2 Immunofluorescent staining

The biopsy core in Mitchel’s medium (Vaughn-Jones et al., 1995) was washed with phosphate buffered saline (PBS) (30min). This core was subsequently embedded on a cryostat chuck using Cryo-Optimal Cutting Temperature (OCT) compound. 7µm sections were cut onto poly-l-lysine coated slides. The sections were subsequently washed in PBS for 10mins, prior to incubation in conjugates using a direct immunolabelling technique as follows; FITC-conjugated polyclonal rabbit anti-human Immunoglobulin A (IgA), FITC-conjugated rabbit anti-human Immunoglobulin G (IgG), FITC-conjugated polyclonal rabbit anti-human Immunoglobulin M (IgM), Cytochrome P450 Polyclonal Antibody (MFO), FITC-conjugated polyclonal rabbit anti-human Fibrinogen (1:80) and FITC-conjugated polyclonal rabbit anti-human Complement 1(C1q), 3(C3c), 4(C4c)(4:80) (Dako, Denmark, UK) for 30mins in the dark. Thereafter slides were washed in PBS, and coverslipped with Kaiser’s glycerol jelly as the mountant.

2.5.2 Transmission electron microscopy

2.5.2.1 Fixation and tissue processing

Biopsies were immediately immersed into 4% glutaraldehyde for 24 h at 4°C. The specimen was then diced into 1 mm³ cubes immersed into 0.2M sodium cacodylate, pH 7.2 maintained at 4°C prior to a dehydration protocol. Final dehydration was performed by incubation in propylene oxide with subsequent infiltration, polymerization and embedding in Araldite CY212 epoxy resin embedding kit (Electron Microscopy Services, USA) in polythene capsules (size 00, BEEM) for 48 h at 60°C (Table 2.11).
Table 2.11: Processing schedule for electron microscopy.

<table>
<thead>
<tr>
<th>PROCESS</th>
<th>METHOD</th>
<th>TEMP</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixation</td>
<td>4% glutaraldehyde fixative (Addendum XI)</td>
<td>4°C</td>
<td>24 h</td>
</tr>
<tr>
<td>Wash</td>
<td>0.2 M sodium cacodylate buffer (pH 7.2) (Addendum XI)</td>
<td>20°C</td>
<td>10 min</td>
</tr>
<tr>
<td>Wash</td>
<td>0.2 M sodium cacodylate buffer (pH 7.2)</td>
<td>20°C</td>
<td>10 min</td>
</tr>
<tr>
<td>Fixation/Contrast</td>
<td>1% osmium tetroxide (0.2M NaCacodylate buffer) (Addendum XI)</td>
<td>4°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Wash</td>
<td>0.2 M sodium cacodylate buffer (pH 7.2)</td>
<td>20°C</td>
<td>10 min</td>
</tr>
<tr>
<td>Wash</td>
<td>0.2 M sodium cacodylate buffer (pH 7.2)</td>
<td>20°C</td>
<td>10 min</td>
</tr>
<tr>
<td>Dehydration</td>
<td>70% ethanol</td>
<td>20°C</td>
<td>30 min</td>
</tr>
<tr>
<td>Dehydration</td>
<td>90% ethanol</td>
<td>20°C</td>
<td>30 min</td>
</tr>
<tr>
<td>Dehydration</td>
<td>100% ethanol</td>
<td>20°C</td>
<td>30 min</td>
</tr>
<tr>
<td>Dehydration</td>
<td>100% ethanol</td>
<td>20°C</td>
<td>30 min</td>
</tr>
<tr>
<td>Intermediate</td>
<td>propylene oxide (1,2-epoxypropane)</td>
<td>20°C</td>
<td>30 min</td>
</tr>
<tr>
<td>Infiltration</td>
<td>propylene oxide : Araldite epoxy resin (1:1) (Addendum XI)</td>
<td>20°C</td>
<td>30 min</td>
</tr>
<tr>
<td>Infiltration</td>
<td>Araldite epoxy resin</td>
<td>60°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Infiltration</td>
<td>Araldite epoxy resin</td>
<td>60°C</td>
<td>1 h</td>
</tr>
<tr>
<td>Polymerisation</td>
<td>Araldite epoxy resin</td>
<td>60°C</td>
<td>48 h</td>
</tr>
</tbody>
</table>

2.5.2.2 Ultramicrotomy

Semi-thin (1 µm) sections were cut using glass knives on a Leica R ultramicrotome (Leica Biosystems, Newcastle Upon Tyne, UK). Sections were collected onto glass slides, heat-fixed, stained with 1% toluidine blue (Addendum XI) and examined with a Leica DMLS light microscope (Leica Biosystems, Newcastle Upon Tyne, UK). Fields of interest (always included glomeruli) were selected and located on the block face, and the block trimmed to produce a “mesa” with a trapezoidal shape. Ultrathin sections (50-60 nm) were cut, collected onto uncoated copper 200 mesh grids and stained with potassium permanganate, saturated ethanolic uranyl acetate and Reynold’s lead citrate solution for 3 min (Reynolds, 1963).
2.5.2.3 Transmission electron microscopy evaluation

Diagnosis of the spectrum of pathology in the study cohort was performed at IALCH using the Joel 1010 transmission electron microscope linked to a MegaView III cooled camera. The ultrathin stained sections were evaluated by a pathologist and the results extrapolated to make the final diagnosis.

Thereafter, identification of latent viral reservoirs and assessment of other pathological changes of the biopsy core both pre and post-HAART was performed at the Optic and Imaging Centre. Sections were viewed on the Jeol 1011 transmission electron microscope. Images were digitally archived by a MegaView III camera interfaced to an ITEM Software Imaging System program.

2.5.3 Immunohistochemistry

Two µm paraffin embedded sections were collected on poly-1-lysine coated slides and immunostained using a NovoLink Max Polymer Detection kit (Table 2.12; Leica Biosystems, Newcastle Upon Tyne, United Kingdom).

2.5.3.1 Rabbit Anti-Human Syno Antibody

Anti-Synaptopodin antibody was an affinity isolated antibody produced in rabbit and reactive to human. Specificity was performed by protein array targeting PrEST protein and Western blotting (Horinouchi et al., 2003).
2.5.3.2 Mouse Anti-Human Immunodeficiency Virus Antibody

This was a monoclonal mouse anti-human immunodeficiency virus antibody targeting the band corresponding to the viral core protein p24 and the band corresponding to the precursor protein pr55. Its isotype is IgG1 kappa and clone: Kal-1 (Kaluza et al., 1992).

2.5.3.3 Mouse anti human Ki67 antibody

The monoclonal anti human-Ki67 antibody is a recombinant peptide corresponding to a 1002 bp Ki67 cDNA fragment reacting with a nuclear protein in proliferating cells (Gerdes). The isotype is IgG1 kappa and its clone: MIB-1 (Key et al., 1993).
**Table 2.12: Procedure for immunohistochemical staining.**

<table>
<thead>
<tr>
<th>PROCESS</th>
<th>METHOD</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rehydration</td>
<td>3 x Xylene</td>
<td>3 min</td>
</tr>
<tr>
<td></td>
<td>3 x 100% Ethanol</td>
<td>2 min</td>
</tr>
<tr>
<td></td>
<td>95%, 80%, 70% Ethanol</td>
<td>2 min</td>
</tr>
<tr>
<td></td>
<td>Rehydrate in running tap water</td>
<td>10 min</td>
</tr>
<tr>
<td></td>
<td>Rinse in dH2O</td>
<td>2 min</td>
</tr>
<tr>
<td>Endogenous peroxidase quenching</td>
<td>3% H2O2</td>
<td>15 min</td>
</tr>
<tr>
<td>Wash</td>
<td>Wash in running tap water</td>
<td>10 min</td>
</tr>
<tr>
<td></td>
<td>Rinse in dH2O</td>
<td>2 min</td>
</tr>
<tr>
<td>Antigen retrieval</td>
<td>Microwave on 570W in 0.01M Citric Buffer pH 6</td>
<td>30 min</td>
</tr>
<tr>
<td>Block</td>
<td>Peroxidase Block</td>
<td>5 min</td>
</tr>
<tr>
<td></td>
<td>2 x TBS</td>
<td>5 min</td>
</tr>
<tr>
<td></td>
<td>Protein block</td>
<td>5 min</td>
</tr>
<tr>
<td></td>
<td>2 x TBS</td>
<td>5 min</td>
</tr>
<tr>
<td>Primary antibody</td>
<td>mouse anti-human Ki67 antibody *(1/100)</td>
<td>120 min</td>
</tr>
<tr>
<td></td>
<td>rabbit anti-human synaptopodin antibody *(1/50)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>mouse anti-human immunodeficiency virus p24 antibody *(1/10)</td>
<td></td>
</tr>
<tr>
<td>Wash</td>
<td>2 x TBS</td>
<td>5 min</td>
</tr>
<tr>
<td>Link</td>
<td>NovoLink Polymer</td>
<td>30 min</td>
</tr>
<tr>
<td>Wash</td>
<td>2 x TBS</td>
<td>5 min</td>
</tr>
<tr>
<td>Chromogen</td>
<td>DAB</td>
<td>5 min</td>
</tr>
<tr>
<td>Wash</td>
<td>Rinse slide in water</td>
<td>5 min</td>
</tr>
<tr>
<td>Nuclei stain</td>
<td>Hematoxylin</td>
<td>5 min</td>
</tr>
<tr>
<td>Dehydration</td>
<td>Rinse in dH2O</td>
<td>5 min</td>
</tr>
<tr>
<td></td>
<td>95%, 80%, 70% Ethanol</td>
<td>2 min</td>
</tr>
<tr>
<td></td>
<td>3 x 100% Ethanol</td>
<td>2 min</td>
</tr>
<tr>
<td></td>
<td>3 x Xylene</td>
<td>3 min</td>
</tr>
<tr>
<td>Mountant</td>
<td>DPX</td>
<td></td>
</tr>
</tbody>
</table>

*Ki67 - Monoclonal mouse anti-human, clone MIB-1, Dako, Denmark, UK.
*Synaptopodin - Rabbit anti-Synpo, Sigma-Aldrich Corporation, MO.
*p24 - Monoclonal mouse anti-human immunodeficiency Virus p24, clone Kal-1, Dako, Denmark, UK.
Slides were then viewed on the Zeiss AxioScope A1 and captured on the Zeiss AxioCam ICC3 system image analyses was performed using the AxioVision 4.8.2 software (Carl Zeiss Pty Ltd, Germany).

2.5.4 Laser Microdissection
Laser capture microdissection is a method for isolating specific cells of interest from microscopic regions of tissues. Glomeruli, arteriole and tubules were microdissected using an Arcturus Pixcell II at the NIH Molecular Pathology Laboratory, SAIC-Frederick/NCI-Frederick, USA.

The biopsy tissue was snap frozen in liquid nitrogen. The frozen tissue was then sectioned using a cryostat and collected onto a slide. The area of interest was identified as targets for isolation and subsequently orientated so that it was in the centre of the field of view; it was then microdissected by means of a laser. The dissected sample then via gravity drops into a capture device. The microdissection process did not alter or damage the morphology and chemistry of the sample collected.

2.5.5 Tissue DNA extraction
DNA was extracted from the epithelial cells using the QIAamp DNA mini kit (Qiagen, Chatsworth, CA). Initially, the epithelial cells were placed in an eppendorf tube and ruptured using a hand held rotor-stator homogenizer TissueRuptor (Qiagen, Chatsworth, CA) for approximately 20 sec at maximum speed with plastic disposable probes to ensure sterility of the sample. Similarly, the DNA extraction, HIV proviral DNA quantification and sequence diversity analyses was performed on blood samples as indicated in subheading 2.4.2, 2.4.3 and 2.4.4.
2.6 STATISTICAL ANALYSIS

SPSS version 18 (SPSS Inc., Chicago, Illinois) was used to analyse the data. A statistical
significant level was set at alpha equal 0.05. Descriptive statistics was performed for all
data. Categorical variables were presented in frequency tables (No. and %). Numeric data
were presented by mean, median, standard deviation, minimum, maximum, range, Quartile
1, Quartile 3 and IQR as appropriate.

Inferential statistics regarding categorical data were by means of Pearson Chi-square test
(or Fischer Exact test where appropriate) to determine trends. In the case of comparing
means of numeric continuous data, paired t-tests were performed. An equivalent non-
parametric test was performed where data were not normally distributed.
CHAPTER 3
RESULTS

3.1 PATIENT POPULATION

3.1.1 Pre-HAART Group

A total of 30 HIV infected children presented with persistent proteinuria (pre-HAART). In keeping with the demographic profile of the local HIV epidemic in the Durban Functional Region in South Africa, 28(93.3%) of the children were Black African and 2(6.7%) were of mixed ancestry; 17(56.7%) were males and 13(43.3%) were females. The average age at presentation was 76 months (range: 10 – 159) with 12(40%); younger than 5yrs. All 30 children underwent kidney biopsy and all were commenced on anti-retroviral therapy post kidney biopsy. The demographic profile and source of referral to IALCH is shown in Table 3.1.

3.1.2 Post-HAART Group

Only 20(66.67%) children were followed up for a mean period of 12 months (range: 5 - 17); 7(23.33%) died and 3(10%) were lost to follow-up, post commencement of HAART. The demographic profile for this group was 18(90%) Black African and 2(10%) children of mixed ancestry; 10(50%) were males and 10(50%) females with an average age of 81.3 months (range: 18 - 141). Nine children returned for a repeat biopsy after an average period of 12 months. Seven children demised during the follow up period, 9 were lost to follow-up, and 5 refused a repeat biopsy. Of these 9 children (repeat biopsy), 7(77.8%) were Black African and 2(22.2%) children of mixed ancestry; 5(55.6%) were males and 4(44.4%) females with an average age of 98.7 months (range: 22 - 153).
Table 3.1: Demographics of Referral Source of children with HIV related nephropaty.

<table>
<thead>
<tr>
<th>Population Group:</th>
<th>Pre-HAART</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Percentage</td>
</tr>
<tr>
<td>Black</td>
<td>28</td>
<td>93.3</td>
</tr>
<tr>
<td>Coloured</td>
<td>2</td>
<td>6.7</td>
</tr>
<tr>
<td>Gender:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>13</td>
<td>43.3</td>
</tr>
<tr>
<td>Male</td>
<td>17</td>
<td>56.7</td>
</tr>
<tr>
<td>Mean Age:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Months</td>
<td>30</td>
<td>98.7</td>
</tr>
<tr>
<td>Referral Source:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greys Hospital</td>
<td>7</td>
<td>23.3</td>
</tr>
<tr>
<td>King Edward VIII Hospital</td>
<td>10</td>
<td>33.3</td>
</tr>
<tr>
<td>Mahatma Gandhi Memorial Hospital</td>
<td>2</td>
<td>6.7</td>
</tr>
<tr>
<td>Ngwelezane Hospital</td>
<td>1</td>
<td>3.3</td>
</tr>
<tr>
<td>Prince Mshiyeni Memorial Hospital</td>
<td>8</td>
<td>26.7</td>
</tr>
<tr>
<td>Port Shepstone Hospital</td>
<td>1</td>
<td>3.3</td>
</tr>
<tr>
<td>Stanger Hospital</td>
<td>1</td>
<td>3.3</td>
</tr>
<tr>
<td>Total</td>
<td>30</td>
<td>100.0</td>
</tr>
</tbody>
</table>

3.1.3 Clinical data of Pre-HAART Group

The clinical data for the pre-HAART group is outlined in Table 3.2. Twelve (40%) children had severe range proteinuria, 12(40%) moderate and 6(20%) presented with mild proteinuria. Microscopic haematuria was present in 15(50%) children together with proteinuria. Of the twelve (40%) children presenting with nephrotic syndrome only 2 had anasarca. Five (16.7%) children had hypertension on initial presentation. The mean systolic blood pressure on initial presentation was 108±8 mmHg and diastolic blood pressure of 64±9 mmHg.

All children had growth retardation at initial presentation. Other co-morbidities included 2(6.67%) children with gastroenteritis, 1(3%) bronchopneumonia, 1(3.33%) child had Pneumocystis jiroveci pneumonia, 12(40%) pulmonary Mycobacterium tuberculosis infection and 1(3%) child had chicken pox. None had evidence of urinary tract infection. None of the children had co-existing infections with cytomegalovirus, Epstein Barr virus, parvo virus, herpes simplex virus and hepatitis A, B, and C. Two (6.67%) had generalised
lymphadenopathy, 2(6.67%) chronic lung disease, 2(6.67%) cardiac disease (cardiomyopathy or myocarditis) and 1(3%) child had marasmus.

All patients had haematological abnormalities on initial presentation; 20(66.7%) had anaemia, 12(40%) leucocytosis and 5(16.7%) had thrombocytopenia. Biochemical hepatitis was present in 8(26.7%) children. On initial presentation, 1(3.3%) child had hypocomplementaemia (low C3 and/or C4), 9(30%) hypercholesterolaemia and all had hypergammaglobulinaemia. Biochemical abnormalities present in 22(73.3%) children included: 5(16.7%) children with hyponatraemia, 5(16.7%) hypokalaemia, 2(6.7%) hyperchloraemia, 4(13.3%) hypocalkaemia, and 4(13.3%) having hypophosphataemia. Ten (33.3%) children on initial presentation had systemic acidosis based on a low serum bicarbonate level (<22µmol/L).

Ultrasonography was performed on all children prior to biopsy and showed increased echogencity in 7(23.3%) and an increase in kidney size above the mean corrected for height in 8(26.7%).

Fourteen (46.67%) children had Stage II to V chronic kidney disease on initial presentation: 2(7%) Stage II disease, 3(10%) Stage III disease, 5(17%) Stage IV and 4(13%) children had end stage kidney disease (Stage V).

The mean CD4 count in 19 children done at initial presentation in was 403 cells/µL (range: 28 - 793) and the mean viral load was 232161 copies/µL (range: 19 – 2900000). Seven (23.3%) had a CD4 count less than 350 cells/µL and in 9(30%) children the viral load was greater than 1000 copies/µL.
### 3.1.4 Histopathological spectrum of HIVRN in Pre-HAART

A histopathological spectrum of 30 HIVRN children who underwent kidney biopsy is shown in Figure 3.1. The commonest histopathological form of HIVRN in children in KwaZulu-Natal was classical FSGS present in 13(43.33%) (Figure 3.2 - 3.4); followed by mesangial hypercellularity 10(30%) (Figure 3.5 -3.7); HIVAN 3(11%) (Figure 3.8 -3.12) and MCD 2(6.67%) (Figure 3.13 - 3.14).

![Histopathological spectrum of pre-HAART children with HIV-related nephropathy.](image)

### 3.1.5 Treatment

HIV treatment given was based on the Department of Health guidelines for the Province of KwaZulu-Natal. Additional therapy included angiotensin converting enzyme antagonists, diuretics in those children with oedema and/or persistent hypertension and vitamin supplementation. Child with chronic kidney disease stage III or more had correction of acid base balance, electrolytes and dietary reduction of protein in accordance with K/DOQI guidelines used as anti-renal failure therapy. None of the patients were managed with renal replacement therapy. None of the patients on HAART were resistant to first line anti-retroviral therapy.
Figure 3.2: Light micrograph of Haematoxylin & Eosin stained section showing an increase in mesangial cells (arrows) in a segmental distribution.

Figure 3.3: Light micrograph of Periodic acid-Schiff stain showing segmental mesangial hypercellularity (arrow).
Figure 3.4: Light micrograph of stain Masson’s trichrome illustrating mesangium increase (arrow).

Figure 3.5: Light micrograph of Haematoxylin & Eosin stained section depicting mesangial hypercellularity of glomeruli.
Figure 3.6: Light micrograph of Periodic acid-Schiff stained section depicting segmental mesangial hypercellularity.

Figure 3.7: Light micrograph of Masson’s trichrome stained section illustrating focal mesangial hypercellularity (arrow).
Figure 3.8: Light micrograph of Methenamine stained section illustrating extensive glomerular tuft collapse with pseudocrescent absence.

Figure 3.9: Light micrograph of Haematoxylin & Eosin stained section showing collapse of glomerular capillaries.
Figure 3.10: Light micrograph of Masson’s trichrome stained section showing the collapsing glomerulopathy. Note tubular cast (arrow).

Figure 3.11: Light micrograph of Haematoxylin & Eosin stain showing dilated tubular lumina (L) with eosinophilic casts. Note tubular-interstitial inflammation (arrow).
Figure 3.12: Light micrograph of Haematoxylin & Eosin stained section depicting polymorphonuclear lymphocytes in tubular-interstitium (arrow).

Figure 3.13: Light micrograph of Haematoxylin & Eosin stain normal appearing glomeruli.
Figure 3.14: Light micrograph of Periodic acid-Schiff stained section glomeruli with MCD.
3.1.6 Clinical data of Post-HAART Group

The clinical data for this group is outlined in Table 3.2. None of the children post-HAART presented with persistent hypertension. The mean systolic blood pressure was 114±7 mmHg and diastolic blood pressure was 66±8 mmHg.

At the last hospital visit 13(65%) had total abrogation of proteinuria following treatment, 3(15%) had mild range proteinuria. Four (13.3%) children who failed to respond to treatment had progressive deterioration of renal function despite treatment and at the last hospital visit 1(5%) child was in end stage kidney disease with a blood urea of 33.4 mmol/L and serum creatinine of 694 µmol/L. All 16 children with complete remission, and mild proteinuria on follow-up had preservation of their renal function

Fourteen (70%) patients had haematological abnormalities in the post-HAART group; 4(20%) had anaemia, 9(45%) leucocytosis and 1(5%) had thrombocytopenia. Biochemical hepatitis was present in 1(5%) child. Post-HAART no child had hypocomplementaemia, 2(10%) hypercholesterolaemia and 4(20%) hypergammaglobulinaemia. Electrolyte abnormalities were present in 4(20%) children and included: 2(10%) hyponatraemia, 1(5%) hyperchlorelaemia, 1(5%) hypocalcaemia. Two (10%) had mild persistent systemic acidosis (HCO₃: 18 - 22 mmol/L) despite correction. None of the children had hypophosphataemia or hypokalaemia.

Ultrasonography showed 1(5%) child had increased echogencity in the post-HAART group and 2(10%) children had an increased kidney size above the mean corrected for height.
On last hospital visit 7(35%) children had Stage II to V chronic kidney disease: 3(15%) Stage II disease, 2(10%) Stage III disease, 1(5%) Stage IV and 1(5%) child had end stage kidney disease (Stage V). Of the fourteen children pre-HAART that had chronic kidney disease following HAART 3(21.4%) of the children in the post HAART group had improvement in their kidney function.

On the last recorded follow-up visit the mean CD4 count was 540 cells/µL (range: 181 - 793) and mean viral load 55273 copies/µL (range: 19 - 977011).
Table 3.2: Comparison of children Pre and Post-HAART with HIV related nephropathy.

<table>
<thead>
<tr>
<th>Test</th>
<th>Pre-HAART (N = 30)</th>
<th>Post-HAART (N = 20)</th>
<th>P Value</th>
<th>Post-Biopsy (N = 9)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>Range or %</td>
<td>Std Dev(σ)</td>
<td>Mean</td>
<td>Range or %</td>
</tr>
<tr>
<td>Clinical:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (months)</td>
<td>75</td>
<td>(5 – 158)</td>
<td>49</td>
<td>81.3</td>
<td>(18 – 141)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>19.38</td>
<td>(4.80 – 44.10)</td>
<td>9.50</td>
<td>22</td>
<td>(7 – 50)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>110</td>
<td>(30 – 151)</td>
<td>28</td>
<td>123</td>
<td>(36 – 153)</td>
</tr>
<tr>
<td>Body Surface Area (m²)</td>
<td>0.76</td>
<td>(0.27 – 1.36)</td>
<td>0.28</td>
<td>0.81</td>
<td>(0.33 – 1.46)</td>
</tr>
<tr>
<td>Oedema</td>
<td>2</td>
<td>(1 – 3)</td>
<td>2</td>
<td>2</td>
<td>(1 – 2)</td>
</tr>
<tr>
<td>Stunted</td>
<td>10</td>
<td>33%</td>
<td>-</td>
<td>9</td>
<td>45%</td>
</tr>
<tr>
<td>Wasting</td>
<td>6</td>
<td>20%</td>
<td>-</td>
<td>1</td>
<td>5%</td>
</tr>
<tr>
<td>Blood Pressure:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic (mmHg)</td>
<td>108</td>
<td>(87 – 174)</td>
<td>8</td>
<td>114</td>
<td>(81 – 191)</td>
</tr>
<tr>
<td>Diastolic (mmHg)</td>
<td>64</td>
<td>(41 – 90)</td>
<td>9</td>
<td>66</td>
<td>(32 – 135)</td>
</tr>
<tr>
<td>Urine Dipstick:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>5</td>
<td>(5 – 6)</td>
<td>3</td>
<td>6</td>
<td>(5 – 6)</td>
</tr>
<tr>
<td>SG</td>
<td>1020</td>
<td>(1010 – 1020)</td>
<td>5.2</td>
<td>1015</td>
<td>(1010 – 1020)</td>
</tr>
<tr>
<td>Leucocytes</td>
<td>0</td>
<td>(0 – 0)</td>
<td>0</td>
<td>1</td>
<td>(0 – 3)</td>
</tr>
<tr>
<td>Nitrites</td>
<td>0</td>
<td>(0 – 0)</td>
<td>0</td>
<td>0</td>
<td>(0 – 0)</td>
</tr>
<tr>
<td>Blood</td>
<td>1</td>
<td>(1 – 3)</td>
<td>2</td>
<td>1</td>
<td>(0 – 3)</td>
</tr>
<tr>
<td>Protein</td>
<td>2</td>
<td>(1 – 4)</td>
<td>1</td>
<td>1</td>
<td>(1 – 2)</td>
</tr>
<tr>
<td>Extrarenal opportunistic infections</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute gastroenteritis</td>
<td>2</td>
<td>67%</td>
<td>-</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Chickenpox</td>
<td>1</td>
<td>3%</td>
<td>-</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>2</td>
<td>7%</td>
<td>-</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>bronchopneumonia</td>
<td>1</td>
<td>3%</td>
<td>-</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Pulmonary tuberculosis</td>
<td>12</td>
<td>40%</td>
<td>-</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Haematology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemoglobin (g/dL)</td>
<td>9.5</td>
<td>(4.8 – 14.0)</td>
<td>2.3</td>
<td>11</td>
<td>(7 – 13)</td>
</tr>
<tr>
<td>Platelets (x10⁹/L)</td>
<td>300.60</td>
<td>(105 – 482)</td>
<td>173.91</td>
<td>360</td>
<td>(25 – 714)</td>
</tr>
<tr>
<td>White Cell Count (x10⁹/L)</td>
<td>8</td>
<td>(5.14 – 12.74)</td>
<td>11</td>
<td>8.36</td>
<td>(6.23 – 11.33)</td>
</tr>
</tbody>
</table>
3.1.7 Comparison of children Pre-HAART vs. Post-HAART

Persistent proteinuria significantly decreased in the post-HAART group with only 3(15%) children having mild range proteinuria \( (p = 0.003) \). On initial presentation (pre-HAART) 15(50%) children had microscopic haematuria following treatment and 12 (60%) children did not present with microscopic haematuria. However, 3 children with persistent mild range protein had microscopic haematuria. None of the children post-HAART presented with persistent hypertension \( (p < 0.0001) \). Co-morbid manifestations of HIV-1 present in 5(16.6%) children pre-HAART e.g. (generalised lymphadenopathy, cardiac disease and marasmic) was not present in any of the children in the post-HAART group. Pre-HAART all children had growth retardation at initial presentation and following appropriate treatment 2(10%) children attained linear growth above the 3\(^{rd}\) centile corrected for age and sex after an average of 12 months.

Haematological abnormalities were present in all of the children pre-HAART and in 14(70%) children post-HAART: \([20(66.7\%) \text{ vs. } 4(20\%) \ p < 0.0001]\) had anaemia, \([12(40\%) \text{ vs. } 9(45\%) \ p = 0.0819]\) leucocytosis and \([5(16.7\%) \text{ vs. } 1(5\%) \ p = 0.0161]\) had thrombocytopenia. A biochemical hepatitis was present in 8(26.7%) children pre-HAART and in 1(5%) child post-HAART \( (p = 0.0002) \). One (3.3%) child in the pre-HAART group presented with hypocomplementaemia but this corrected to normal post-HAART.

Hypercholesterolaemia in the pre-HAART vs. post-HAART group significantly decreased \([9(30\%) \text{ vs. } 2(10\%) \ p = 0.0007]\) as did hypergammaglobulinaemia \([30(100\%) \text{ vs. } 4(20\%) \ p < 0.0001]\).

Comparison of electrolyte abnormalities in the pre vs. post-HAART groups showed differences for the following: hyponatraemia \([5(16.7\%) \text{ vs. } 2(10\%) \ p = 0.016]\),
hypokalaemia [5(16.7%) vs. 0(0%) \( p < 0.05 \)] and hypophosphataemia [4(13.3%) vs. 0(0%) \( p < 0.05 \)]. No differences in the groups were noted for hyperchloremia [2(6.7%) vs. 1(5%) \( p = 0.181 \)] and hypocalcaemia [4(13.3%) vs. 1(5%) \( p = 0.057 \)]. Systemic acidosis was present in 10(33.3%) children pre-HAART vs. 2(10%) children post-HAART showing a significant improvement (\( p = 0.0002 \)).

Ultrasonography was performed on all patients prior to biopsy and on comparison there were a significant differences with regard to increased echogenicity pre vs. post-HAART (7 vs. 1; \( p = 0.001 \)) and increase in kidney size above the mean corrected for height (8 vs. 2; \( p = 0.0025 \)). Figure 3.15-3.16 shows the ultrasound of a child pre and post-HAART respectively.

Chronic kidney disease staging for pre vs. post-HAART was as follows: Stage II [2(7%) vs. 3(15%); \( p = 0.422 \)], Stage III [3(10%) vs. 2(10%); \( p = 0.422 \)], Stage IV [5(17%) vs. 1(5%); \( p = 0.016 \)], and [4(13%) vs. 1(5%); \( p = 0.057 \)], children had end stage kidney disease (Stage V).

The mean CD4 count at initial presentation (pre-HAART) was 403 cells/\( \mu \)L (range: 28 - 793) and the mean viral load was 232161 copy/\( \mu \)L (range: 19 – 2900000). In the post-HAART group at last hospital visit the mean CD4 count increased to 540 cells/\( \mu \)L (range: 181 - 793) and mean viral load decreased to 55273 copy/\( \mu \)L (range: 19 - 977011). On comparison of both these parameters at initial presentation and last recorded follow-up visit there were no statistically significant difference (\( p = 0.168 \) and \( p = 0.767 \) respectively).
Figure 3.15: Ultrasound image of the right kidney from a patient with HIV infection pre-HAART; the kidney measured 68.8mm.

Figure 3.16: Ultrasound image of the same kidney (Figure 3.1) one year later i.e., post-HAART; the kidney measured 60.9mm.
3.1.8 Histopathological spectrum of HIVRN in Post-HAART biopsy group

Nine children returned post-HAART and re-consented for repeat biopsy. The histopathological spectrum of post-HAART is illustrated in Figure 3.17 in which the commonest microscopic finding was mesangial hypercellularity present in 55.56% of children; 33.33% having FSGS and 11.11% sclerosing glomerulopathy.

![Figure 3.17: Histopathological spectrum of post-HAART children with HIV-related nephropathy.](image)

3.1.9 Comparison of matched Pre-HAART Biopsy vs. Post-HAART Biopsy

Comparison of the histopathological spectrum of children pre and post-HAART (9 children) showed a difference in histopathology in only two children, one child with tubulointerstitial nephritis on post biopsy was found to have mesangial hypercellularity and another with MCD was found to have mesangial hypercellularity.
3.2 SYNAPTOPODIN, KI67 AND P24 IMMUNOREACTIVITY

3.2.1 Pre-HAART Synaptopodin

Human brain tissue served as the positive control displaying immunoprecipitation within telencephalic dendrites (Figure 3.18). Replacement of anti-synaptopodin antibody with a non-immune sera of the same IgG class produced no immunoreaction (negative control; Figure 3.19). Similarly, replacement of the antibody with Tris buffered saline (TBS) produced no immune reaction. Anti-synaptopodin antibody was immunolocalised within glomerular podocytes in the pre-HAART group (Figure 3.20 - 3.21). Tubular distribution of synaptopodin was absent.

3.2.2 Post-HAART Synaptopodin

The immunolocalisation of synaptopodin was similar to the pre-HAART group. Immunoreactivity was observed within glomerular podocytes (Figure 3.22 - 3.23) but absent in tubules.

3.2.3 Morphometric image analysis of synaptopodin Pre vs. Post-HAART

The immunostaining pattern of synaptopodin within the glomerulus expressed as a mean field area percentage was significantly down-regulated in the pre-HAART compared to the post-HAART group (1.14 vs. 4.47%; p= 0.0068; Figure 3.24). The mean field intensity of the staining reaction within the pre-HAART group compared to the post-HAART group was 1025 (range: 628 - 1221) vs. 685 densitometric unit (range: 167 – 1003; p<0.0001; Figure 3.24).
**Figure 3.18:** Positive control - telencephalic dendrites (arrow). Init Mag X 20.

**Figure 3.19:** Negative control - telencephalic dendrites. Init Mag X 100.

**Figure 3.20:** Pre-HAART - segmental glomerular immunoreactivity of synaptopodin. Init Mag X 40.

**Figure 3.21:** Pre-HAART - Mild to absent immunoreactivity of synaptopodin. Init Mag X 40.

**Figure 3.22:** Post-HAART - globally diffuse immunoreactivity of synaptopodin within podocytes. Init Mag X 40.

**Figure 3.23:** Post-HAART - globally diffuse immunoreactivity of synaptopodin within podocytes. Init Mag X 40.
3.2.4 Pre- HAART Ki67

Ki-67, a nuclear cell cycle protein was expressed within the U87 human glioblastoma cell line and served as the positive control (Figure 3.25). An additional positive control from a patient with a hind gut carcinoma produced positive reactivity within proliferating cells (Figure 3.26). Replacement of the primary antibody with an low immune serum of the same IgG class in the U87 human glioblastoma cell line was non-reactive (negative control; Figure 3.27). In the pre HAART group, Ki67 immunoreactivity was observed within focal and segmental glomerular proliferating visceral epithelial cells/podocytes (Figure 3.28) as well as within parietal epithelial cells (Figure 3.29) and occasionally within tubular epithelial cells (Figure 3.30).

3.2.5 Post-HAART Ki67

There was an absence of Ki-67 immunoreactivity within the glomerular and tubular cells (Figure 3.31 - 3.32).

3.2.6 Morphometric image analysis of Ki67 Pre vs. Post-HAART

The immunoreactivity of Ki-67 within the glomerulus expressed as a mean field area percentage was significantly down-regulated in the post-HAART group (1.01 vs. 4.68; $p < 0.001$; Figure 3.33). The mean field intensity of the staining reaction expressed as a densitometric unit was similar in the pre-HAART group compared to the post-HAART 1162 (range: 657 - 1312) vs. 1116 (range: 1015 - 1229); ($p = 0.1278$; Figure 3.33).
**Figure 3.25:** U87 glioblastoma cell line - positive control (NIH, Washington DC, USA). Init Mag X 10.

**Figure 3.26:** Hind gut carcinoma - positive control. Init Mag X 10.

**Figure 3.27:** U87 human glioblastoma cell line - Negative control. Init Mag X 10.

**Figure 3.28:** Pre-HAART - Ki67 antibody staining the specific tubular epithelial cells (brown). Init Mag X 40.

**Figure 3.29:** Pre-HAART - Ki67 immunoprecipitation within parietal (open arrow) and visceral epithelial cells (arrows). Init Mag X 40.

**Figure 3.30:** Ki67 immunoprecipitation within distal tubular epithelial cells (brown). Init Mag X 20.
Figure 3.31: Post-HAART - Absence of Ki67 immunoreactivity. Init Mag X 40.

Figure 3.32: Post-HAART - Absence of Ki67 immunoreactivity. Init Mag X 40.

Figure 3.33: Histogram illustrating glomerular mean field area and intensity distribution of Ki67.

**3.2.7 Pre-HAART p24**

Sections of HIV infected lymph nodes were used as a positive control (Figure 3.34). Replacement of the primary antibody with non-immune serum of the same IgG class revealed an absence of immunoreactivity (Figure 3.35; negative control). A punctate distribution of the p24 HIV-1 viral core protein was observed within epithelial cells of glomeruli and tubules (Figure 3.36 – 3.37). Additionally, immunoprecipitation was noted within lymphocytes.
3.2.8 Post-HAART p24
Weak to nil immunprecipitation was obscured in podocytes (Figure 3.38 – 3.39).

3.2.9 Morphometric image analysis of p24 Pre vs. Post-HAART
In the post-HAART group, the mean field area percentage of p24 immunoreactivity in the
glomerulus was significantly down regulated compared to the pre-HAART group (1.4 vs.
4.5%; \( p = 0.0035 \); Figure 3.40). The mean intensity of staining expressed as a
densitometric unit was 1116 (range: 847 - 1315) in the pre-HAART group and 854 (range:
854 - 1319) in the post-HAART group (\( p = 0.2473 \); Figure 3.40).
Figure 3.34: Lymph node negative control. Init Mag X 100.

Figure 3.35: Lymph node negative control. Init Mag X 100.

Figure 3.36: Pre-HAART - p24 immunoreactivity within the glomeruli and tubular cells (arrows). Init Mag X 20.

Figure 3.37: Pre-HAART - p24 immunoreactivity within the epithelial cells of glomerulus. Init Mag X 40.

Figure 3.38: Post-HAART - absence of p24 immunoreactivity within renal biopsy. Init Mag X 40.

Figure 3.39: Post-HAART - weak p24 immunoreactivity within renal biopsy. Init Mag X 40.
Figure 3.40: Histogram illustrating glomerular mean field area and intensity distribution of p24.
3.3 ULTRASTRUCTURAL ARCHITECTURAL MORPHOLOGY

3.3.1 Pre-HAART

The ultrastructural assessment of all biopsies conformed to their pathological appraisal. Electron dense deposits consistent with immune complex glomerulonephritis were found within the mesangium or along the peripheral glomerular capillary wall in subendothelial or epimembranous locations. Segmental capillary collapse was also noted.

The GBM was opposed by the foot processes on the urinary aspect and by fenestrated endothelium on the capillary luminal aspect (Figure 3.41). It consisted of an electron dense lamina densa flanked by an electron lucent lamina rara externae and internae on the epithelial and endothelial sides respectively. “Frilling” or irregular contouring of the endothelial aspect of the GBM was frequently observed (Figure 3.42). In addition, double contouring/tramlining of the basement membrane was evident (Figure 3.43). Periodically banded striated electron dense fibrils resembling fibrin and was noted within the lamina densa (Figure 3.44). Immune deposits occurred on the sub epithelial (Figure 3.45) and sub-endothelial aspect (Figure 3.46).

A dysregulated phenotype of visceral epithelial was observed with podocytes effacement varying in severity from focal (Figure 3.47), segmental (Figure 3.48) and diffuse. Subcellularly podocytes displayed pathological features such as mitochondrial stress, swollen/dilated pools of cisternal type endoplasmic reticulum (ER), and cytoplasmic vacuolation. Mitochondrial swelling with peripherally displaced disorientated and disintegrating cristae was frequently observed. Dilatation and vesiculation of the cisternae of rough endoplasmic reticulum was recurrent with the formation of ER pools (Figure 3.49). The contents of these discrete pools contained moderately electron dense secretory
products. Dilated golgi stacks were observed. Centrioles were identified (Figure 3.50). Intra-cytoplasmic fatty degeneration and occurrence of markedly electron dense lipid droplets was observed (Figure 3.51). Nuclear envelope thickening, proliferation and crenation were prominent (Figure 3.52). Vacuolation was noted (Figure 3.53). Subepithelial deposits associated with a basement membrane reaction resulting in a “ball in cup” appearance were observed (Figure 3.54). A relatively undifferentiated podocyte cytoplasm was occasionally observed (Figure 3.55). The plasmalemma of podocytes displayed microvillous extensions (Figure 3.56). Podocytes proliferation and apoptosis were observed.

Mostly, cell bodies of endothelial cells lining capillary loops appeared normal whilst their cytoplasm was fenestrated (Figure 3.57). Intracytoplasmic microtubular reticular structures were frequently observed (Figure 3.58). Due to electron opacity of the microtubules, the microtubular lumen was not discernible and randomly orientated in a reticular fashion. The mesangial extracellular matrix was increased (Figure 3.59). Mesangial cell proliferation varied from focal (Figure 3.60), segmental and diffuse.

Proliferation of parietal epithelial cells with crescent formation was evident (Figure 3.61). Capsular adhesions of parietal epithelial cells to visceral epithelial cells were noted (Figure 3.62). Occasionally, the Bowmans capsule was denuded of parietal epithelial cells (Figure 3.63). Glomerular sclerosis varied in severity from focal (Figure 3.64), segmental and diffuse (Figure 3.65). Proteinaceous casts were observed within proximal (Figure 3.66) and distal tubules (Figure 3.67). Interstitial inflammatory infiltration was noted (Figure 3.68).
Figure 3.41: Electron micrograph illustrating the glomerular filter viz., foot processes (FP) lining the glomerular basement membrane (GBM) and endothelial cell (EC). Note slit diaphragm between foot processes (arrow). Init Mag X 40000.

Figure 3.42: Electron micrograph depicting contouring or frilling (arrow) of the lamina rara interna of the GBM. Note endothelial cell (EC). Init Mag X 25000.
Figure 3.43: Electron micrograph depicting two opposing GBM interfaced with electron dense deposits (open arrow). Cap lumen (L), endothelial cell body (EC) and fenestrations (arrow). Init Mag X 12000.

Figure 3.44: Electron micrograph illustrating GBM with fibrin (arrowed) within the lamina rara densa. Foot processes (FP) and cap lumen (L). Init Mag X 20000.
Figure 3.45: EM graph illustrating focal effacement of foot processes (arrow) with epithelial dense deposits. Init Mag X 20000.

Figure 3.46: EM graph showing sub endothelial immune deposits (arrow). Note also microvillous (MV) transformation of podocytes. Init Mag X 20000.
Figure 3.47: Electron micrograph illustrating glomerular basement membrane (GBM) with focal effacement of the foot process (FP). Note endothelial cell (EC) and fenestrated endothelium (FE). Init Mag X 12000.

Figure 3.48: Electron micrograph illustrating glomerular basement membrane (GBM) with segmental podocytes effacement. Init Mag X 8000.
Figure 3.49: Electron micrograph illustrating cisternal pools of dilated endoplasmic reticulum (arrow). Init Mag X 25000.

Figure 3.50: Electron micrograph showing dilated golgi stacks (arrow) with centrioles (open arrow). Init Mag X 25000.
Figure 3.51: Electron micrograph showing lipid (arrow) distention within podocyte cytoplasm. Note frilling of GBM. Init Mag X 8000.

Figure 3.52: Electron micrograph demonstrating podocyte nucleo lemmal crenation (arrows). Init Mag X 25000.
Figure 3.53: Electron micrograph illustrating vacuolation (V) within a podocyte cell body. Note cap lumen (L). Init Mag X 10000.

Figure 3.54: Electron micrograph showing “ball and cup” (arrow) appearance of immune deposits within the podocyte. Note cap lumen (L). Init Mag X 30000.
Figure 3.55: Electron micrograph showing an undifferentiated podocyte cytoplasm. Init Mag X 10000.

Figure 3.56: Electron micrograph demonstrating podocyte microvillous profusion (arrow). Init Mag X 10000.
Figure 3.57: Electron micrograph illustrating endothelial cell body (EC) and fenestrations (arrow). Inset illustrates cross-cut fenestrations. Init Mag X 10000.

Figure 3.58: Electron micrograph depicting tubular reticular structure (TRS) within an endothelial cell. Note cross-cut endothelial fenestrations (arrow) and cap lumen (L). Init Mag X 25000.
Figure 3.59: Electron micrograph showing mesangial matrix extension (arrow). Init Mag X 10000.

Figure 3.60: Electron micrograph showing focal mesangial cell proliferation (arrow). Init Mag X 2500.
Figure 3.61: Electron micrograph showing crescent formation and occlusion of Bowman’s capsule (BC). Init Mag X 5000.

Figure 3.62: Electron micrograph illustrating visceral and parietal epithelial cell adhesion with occlusion of Bowman’s space. Note Bowman’s capsule (BC). Init Mag X 4000.
Figure 3.63: Electron micrograph illustrating Bowman’s capsule (BC) denuded of parietal epithelial lining (arrow). Init Mag X 10000.

Figure 3.64: Electron micrograph showing incomplete glomerular sclerosis. Init Mag X 6000.
Figure 3.65: Electron micrograph illustrating diffuse glomerular sclerosis. Note capsule (arrow), interstitial inflammatory infiltrate (open arrow) and distal tubular epithelial cells (DT). Init Mag X 2500.

Figure 3.66: Electron micrograph showing normal appearance of proximal tubular cells. Init Mag X 4000.
Figure 3.67: Electron micrograph of distal tubular cells with mild cast inclusion within lumen. Init Mag X 3000.

Figure 3.68: Electron micrograph depicting interstitial inflammatory infiltrate between tubules (T1 and T2). Init Mag X 4000.
3.3.2 Post-HAART

A qualitative ultrastructural assessment of the biopsies conformed to their pathological appraisal.

“Frilling” or irregular contouring of the endothelial aspect of the GBM was noted (Figure 3.69). Immune deposits occurred on the sub epithelial (Figure 3.69) or sub-endothelial aspect.

The phenotype of visceral epithelial cells was improved (Figure 3.70) occurring sometimes with focal (Figure 3.71) and segmental effacement. Subcellularly, podocytes displayed minimal mitochondrial and endoplasmic stress features (Figure 3.72).

Endothelial cells lining capillary loops appeared normal with fenestrations (Figure 3.71).

Mesangial cell proliferation varied from focal (Figure 3.73) and segmental (Figure 3.74) Mesangial matric increase was noted (Figure 3.75).

The parietal epithelial cells lining the Bowmans capsule were occasionally found to adhere to visceral epithelial cells with an occlusion of the Bowmans space (Figure 3.75 - 3.77). Glomerular sclerosis was observed (Figure 3.78).

The proximal (Figure 3.79) and distal tubular lumen were often filled with proteinaceous casts. The renal interstitium displayed inflammatory infiltration of polymorphonuclear lymphocytes cells.
Figure 3.69: Electron micrograph illustrating focal frilling (open arrow) of the GBM. Note foot process effacement and sub epithelial cell deposits (arrow). Init Mag X 12000.

Figure 3.70: Electron micrograph showing normal appearance of podocytes. Note tubule (T), Bowman’s capsule (BC) and interstitium (arrow). Init Mag X 2500.
**Figure 3.71:** Electron micrograph depicting focal effacement of foot processes (arrow). Note cap lumen (L). Init Mag X 12000.

**Figure 3.72:** Electron micrograph showing undilated endoplasmic reticulum (ER) (arrow). Init Mag X 25000.
Figure 3.73: Electron micrograph showing mesangial matrix increase (arrow) and focal mesangial cell increase (open arrow). Init Mag X 4000.

Figure 3.74: Electron micrograph illustrating mesangial cell proliferation (arrow). Init Mag X 3000.
**Figure 3.75:** Electron micrograph illustrating mesangial matrix (open arrow) and adhesion (arrow) of visceral epithelial cells to parietal cell (PC) lining the Bowman’s capsule (BC). Adhesion of BC and podocyte. Init Mag X 6000.

**Figure 3.76:** Electron micrograph depicting occlusion of Bowman’s space. Bowmans capsule (BC). Init Mag X 6000.
Figure 3.77: Electron micrograph illustrating podocyte adherent to parietal cell (arrow). Note Bowman’s space (BS) and capsule (BC). Init Mag X 12000.

Figure 3.78: Electron micrograph showing part of a sclerosed glomeruli. Init Mag X 5000.
Figure 3.79: Electron micrograph showing proximal tubular cells. Init Mag X 8000.
3.4 IDENTIFICATION OF RENAL VIRAL RESERVOIRS

3.4.1 Ultrastructural

3.4.1.1 Pre-HAART

Latent HIV reservoirs were observed within the podocyte cytoplasm. HIV was identified on morphology and size (Figure 3.80 - 3.81). HIV-1 particles were not noted in glomerular mesangial or endothelial cells.

![Figure 3.80: Low power electron micrograph depicting HIV-like particles (arrows) sequestered within an endocytic compartment of a podocyte. Init Mag X 30 000.]

![Figure 3.81: Higher power electron micrograph of 3.80. Init Mag X 60 000.]

3.4.1.2 Post-HAART

Within the post-HAART biopsy core, no latent HIV reservoirs were observed.
3.4.2 HIV proviral DNA quantification

Real-Time polymerase chain reaction assays (RT-PCR) provided evidence of HIV-1 within the kidney. Two standard curves were created using, albumin (to determine the level of input DNA) and gag (HIV copy number).

3.4.2.1 Albumin

A dilution series of albumin amplicon was used as standard template for the amplification using the SYBR Green dye reaction (Figure 3.82). Melting curves for the albumin gene are shown in Figure 3.83.

![Figure 3.82: The standard curve for albumin derived from the crossing points (cycle numbers) of each standard plotted against the logarithmic concentration.](image)
Figure 3.83: (A). Melting curves for albumin amplification products. (B). The melting peaks of the albumin amplification product. The melting temperature (Tm) of the gene product is shown by the arrow.
3.4.2.2 Gag

A stand curve was created utilizing the 8E5 cell line, which contained a single defective genome copy of HIV per cell (Figure 3.84). Melting curves for the \textit{gag} gene are shown in Figure 3.85.

\textbf{Figure 3.84:} The standard curve for \textit{gag} derived from the crossing points (cycle numbers) of each standard plotted against the logarithmic concentration.
Figure 3.85: (A). Melting curves for gag amplification products. (B). The melting peaks of the gag amplification product. The melting temperature (Tm) of the gene product is shown by the arrow.
3.4.2.3 Verification of PCR specificity

Real time PCR products of a positive and negative control as well as samples were verified using by a 1% agarose gel which was run for 1h30 at 100 Volts. Specific amplification of proviral DNA viz., gag was indicated by the presence of a 95 bp band (Figure 3.86).

![Image](image_url)

**Figure 3.86:** Validation of PCR specificity on a 1% (w/v) agarose gel. Amplified products of gag are shown by the presence of a 95bp product.

3.4.2.4 Calculated expression levels of proviral DNA

HIV-1 proviral load levels was dissimilar amongst the different areas of the kidney that were laser micro-dissected viz., glomeruli (2.14), tubules (1.95), arterioles (2.86) and whole biopsy core (-0.38) (Figure 3.87). The proviral load differed significantly between the glomerulus, tubules and arterioles vs. the whole biopsy \(p < 0.0001\). The proviral load expression was the highest within the arterioles followed by the glomeruli. There was no significant difference of the proviral load between tubules and arterioles \(p < 0.05\).
Our results revealed a statistically significant elevated level of proviral DNA in whole kidney biopsy compared to PBMCs (0.53 vs. -0.92; p < 0.0005; Figure 3.88). The proviral load of the post-HAART patients (n = 9) that were biopsied was significantly lower when compared to their matched pre-HAART sample (-1.34 vs. 0.73; p < 0.02; Figure 3.89). A few of the follow up patients real time assay were below the detectable levels of the real time machine. Using the standard curve created the threshold was shown to be 0.2ng/ml.

The proviral DNA level of the biopsy was significantly different to the blood of the pre-HAART (n = 30; p < 0.0001) unlike the biopsy vs. the blood levels in the post-HAART group (n = 9; p < 0.05; Figure 3.90).

Furthermore, we compared proviral DNA load pre and post-HAART in the 9 children undergoing repeat biopsy groups; biopsy (0.53 vs. -1.34) and blood (-0.92 vs. 0.53; Figure 3.90). Finally, we compared the pre vs. post-proviral DNA level (-0.08 vs. 0.67) to the pre vs. post-CD4 count (2.58 vs. 2.67) and pre vs. post-Viral load (3.87 vs. 3.45; Figure 3.91). The correlation graph (D) showed the relationship between Viral load and proviral DNA to CD4 count. The pre viral load and post viral load showed a positive and negative correlation to CD4 respectively.
Figure 3.87: Scatterplot of proviral DNA of the whole tissue, and the laser micro-dissected glomeruli, tubules and arterioles within the pre-HAART group.

Figure 3.88: Scatterplot of proviral DNA in the biopsy vs. blood within the pre-HAART group.
Figure 3.89: A line plot of proviral DNA from blood obtained for patients that were biopsied in the post-HAART group and matched with their pre-HAART counterpart.

Figure 3.90: A scatterplot of proviral DNA of biopsy and blood compared between pre-HAART and post-HAART.
Figure 3.91: (A). Scatterplot comparing the square root of CD4 T cells between the pre vs. post-HAART groups. (B). Scattergram comparing the log transformation of the HIV proviral DNA between the pre vs. post-HAART groups. (C). Scatterplot of the log transformation of viral load between the pre-HAART and post-HAART groups. (D). A correlation graph showing the relationship between A, B and C.
3.5 SEQUENCE DIVERSITY ANALYSES

3.5.1 Confirmation of Envelope PCR

Extracted DNA was subjected to nested PCR of C2-C5 fragment of the *env* gene reaction and analysed on a 1% (w/v) agarose gel to verify successful amplification. A representative agarose gel pattern of C2-C5 fragment DNA sample is shown in Figure 3.92. Successfully nested PCR from HIVRN samples was confirmed by the presence of 957Kb DNA bands.

![Micrograph of an agarose gel illustrating amplification of C2-C5 fragment of the *env* gene as shown by the presence of a 957 bp product.](image)

**Figure 3.92:** Micrograph of an agarose gel illustrating amplification of C2-C5 fragment of the *env* gene as shown by the presence of a 957 bp product.

Ligation of the amplified product into a topo 2.1 vector (Invitrogen) resulted in clonal constructs. The presence of the insert in white colonies was determined by performing colony PCR using specific primers and restriction analysis. Colonies containing inserts were utilized for sequencing. The schematic diagram below shows the actual arrangement of the inserted PCR product within the plasmid (Figure 3.93).
3.5.2 Phylogenetic analysis biopsy vs. blood

The representative Highlighter plots for the envelope region shown in Figure 3.94, comparing the mutations acquired and lost between biopsy vs. blood. A phylogenetic tree generated showed the distinguishing differences between the HIV-1 env DNA extracted from blood vs. biopsy (Figure 3.95).
Figure 3.94: Highlighter plot depicting mutations found in env region of blood vs. biopsy.
Figure 3.95: Phylogenetic analysis of HIV-1 env sequences C2-C5 region comparing blood (Bld) vs. biopsy (Bio). Sequences were rooted using representative South African HIV-1 subtype C sequence from Los Alamos database accession number HQ615983.

3.5.3 Phylogenetic analysis Pre vs. Post-HAART

The Highlighter Plots showed that before and after treatment mutations are gained and lost with an equal frequency (Figure 3.96). Furthermore, our results showed silent and non-silent mutations within env comparing pre vs. post-HAART (Figure 3.97). Finally a representative tree comparing pre to post-HAART (Figure 3.98).
Figure 3.96: Highlighter plot depicting the positions and identities of nucleotide polymorphism insertions and deletions across the env region from blood (Bld) samples for pre vs. post-HAART analysis.
Figure 3.97: Highlighter plot depicting silent and non-silent mutations within the env gene from blood (Bld) for pre vs. post-HAART.
Figure 3.98: Phylogenetic analysis of HIV-1 env sequences C2-C5 region comparing pre vs. post-HAART blood (Bld). Sequences were rooted using representative South African HIV-1 subtype C sequence from Los Alamos database accession number HQ615983.
CHAPTER 4
DISCUSSION

Sub-Saharan Africa has just over 10% of the world’s population, yet it bears 70% of the burden of the HIV epidemic with approximately 25.4 million people being infected by the virus. KwaZulu-Natal is the epicenter of this pandemic. Renal disease has become an increasingly prevalent entity in HIV-infected patients; therefore KwaZulu-Natal is faced with a challenge that is approaching epidemic proportions with HIV related renal disease being a major cause of morbidity and mortality. Nonetheless, a general lack of surveillance and reporting for renal disease in HIV-positive patients exists in this geographical region.

Rao et al., (1987) divided the HIV-1-associated renal parenchymal diseases into four groups: (1) acute tubular dysfunction with electrolyte fluid abnormalities and/or renal failure caused by infections and nephrotoxic drugs; (2) HIV glomerulopathies related to immunological abnormalities (IgA nephropathy, lupus-like syndromes, and HIV-associated immune complex renal disease); (3) HIV-associated thrombotic microangiopathies, including atypical forms of the hemolytic uremic syndrome; and (4) HIV-1-associated nephropathy (HIVAN) (Connor et al., 1988; Strauss et al., 1989; Turner et al., 1997).

In the early 1980s, soon after the onset of the HIV/AIDS epidemic, nephropathy was increasingly recognized to be associated with HIV infection. HIVAN is characterized by a collapsing glomerulopathy with collapse of glomerular capillary structures and a hyperplasia of podocytes, microcystic transformation of renal tubules, and concomitant interstitial inflammation and fibrosis. To-date it is estimated that about 10% of HIV-
infected patients develop HIVAN worldwide (Han et al., 2006a; Valeri and Neusy, 1991). However, it appears that this prevalence is influenced by the type of study (whether autopsy or biopsy based) and the demographics of the HIV-infected population.

A study by Lascure et al., (2011) showed HIVAN decreased over time, while FSGS emerged as the most common cause of glomerular diseases (46.9%) in HIV-infected individuals in the period 2004 - 2007. This study showed that HIV related nephropathy exceeds any other cause of kidney disease responsible for end stage renal disease, and has been increasingly recognized as a significant cause of morbidity and mortality (Lescure et al., 2011).

Unfortunately there is also a paucity of data of HIVRN from Africa. The true prevalence of childhood HIVRN is also unknown for Africa. Consequentially, this alarming reality emphasis the importance of outlining the spectrum of HIV related nephropathies within this geographical epicenter of the global HIV pandemic as well as evaluating the efficacy of HAART in combination with ACE-I in our population. Moreover, from a pathology standpoint, it is important to address whether HIV related nephropathy is a direct consequence of viral infection of the renal parenchyma or is it a secondary consequence of systemic infection.

It is interesting to note that Black patients have a relative risk of 51.1% compared to White patients for developing end-stage renal disease from AIDS or an AIDS-defining diagnosis (Bhimma, 2007; Kimmel et al., 2003). This increased burden of chronic kidney disease, particularly end-stage kidney diseases in populations of African ancestry has been largely unexplained. A review of over 200 patients with HIV-associated nephropathy in the USA
found that 90% were Black and 70% male (Bourgoignie, 1990; D'Agati and Appel, 1997). This predominance among Black African Americans and males is striking if one considers that in the United States, HIV infection is three times more common among Whites than Blacks with a preponderance of males being infected (Bourgoignie, 1990). Also, it is important to remember the low incidence of HIVAN in Europe presumably reflects the region’s small Black population (Barbian di Belgiojoso et al., 1990; Baumelou et al., 1989; Burger et al., 1989).

Using the United States Renal Data System, Ahuja et al., (2004) report that of 7732 patients with HIVAN only 60 were classified as children, of which 88% were Black and there was an equal distribution in terms of gender. Other studies have reported a male gender preponderance in HIV related nephropathy (Anochie et al., 2008), a finding supported in this study in which 56.7% were males.

Strauss et al., (1993) and others have reported a prevalence of 10-15% HIVAN of approximately in HIV infected children of which 95% were African American (Connor et al., 1988; Ingulli et al., 1991; Ray et al., 1998; Ray et al., 2004; Strauss et al., 1989). There is a high prevalence of the duffy antigen chemokine receptor (DARC) promoter polymorphism in the Black race (Hadley and Peiper, 1997; Ray et al., 2004), and previous studies have shown that HIV-1 binds to DARC (Lachgar et al., 1998). Additionally, genetic variation at the MYH9 locus substantially explains the increased burden of FSGS and hypertensive end-stage kidney disease among African Americans (Kopp et al., 2008). In a recent study a major source of genetic risk for African American patients with end stage kidney disease and FSGS was localized to apolipoprotein L1 (ApoL1), 14kb from MYH9. This study also showed the effect of carrying two APOL1 risk alleles accounted
for 18% of FSGS and 35% of HIVAN which implies that eliminating this genetic variation will reduce FSGS and HIVAN by 67% (Kopp et al., 2011).

In contrast to most studies that believe HIVAN is a late manifestation of HIV infection (Ahuja et al., 2004; Anochie et al., 2008; Ray et al., 1998; Ross et al., 2000; Winston et al., 1999), recent studies have reported HIVAN as an early manifestation of HIV infection (Anochie et al., 2008; Burns et al., 1997; Ramsuran et al., 2011a). It is plausible to assume HIVRN is a early manifestation of HIV infection from our study since the occurrence of HIV infection in the youngest patient recruited in our cohort was 10 months, and 12(40%) were younger then 5yrs, supporting this hypothesis.

This study is part of the largest paediatric cohort in Africa that followed-up HIV-infected children for 1 year (pre and post-HAART). It outlines the spectrum of paediatric nephropathy in treatment-naïve children in KwaZulu-Natal as being FSGS (43.3%), mesangial hypercellularity (30%), HIVAN (10%), tubulointerstitial nephritis (6.67%), minimal change (6.67%) and sclerosing glomerulopathy (3.3%). This spectrum contrasts to the adult chronic kidney disease population in which HIVAN was shown to be the most common form of chronic kidney disease. In a previous South African study performed on adult patients from the same centre, HIVAN was also found to occur in 83.3% of all patients who were biopsied (Han et al., 2006a).

Whereas collapsing FSGS (HIVAN) is the predominant lesion in adult HIV-infected patients undergoing renal biopsy, this is not the case in children in the United States (Bourgoignie, 1990). Data from diverse geographic regions of the United States suggest that lesions other than FSGS, such as mild mesangial proliferative forms of
glomerulopathy and immune-mediated glomerulonephritis, are more frequent in children than adult patients with HIV infection (D'Agati and Appel, 1997; Strauss et al., 1993). However, in one of the largest reported series of children with HIVRN in Africa to-date, the most frequent histological form of the disease in Black children was the classic form of FSGS accounting for 37.3% of all cases of children who underwent kidney biopsy (Ramsuran et al., 2011a). This study, a sub-group of the latter study cohort, also reports a predominance of FSGS (43%).

The absence of HIVICK in our study may be due to the fact that most of the children recruited in this study were of African origin. According to previous studies, HIVICK has a racial distribution occurring predominantly (80%) in patients of Caucasian origin, particularly drug abusers (Lescure et al., 2011). Although HIVICK a 'lupus-like' picture is absent in our cohort of children, it accounts for approximately a quarter of HIV-related kidney diseases in Black adults from Johannesburg, South Africa (Gerntholz et al., 2006). The explanation provided by Gerntholz et al., for this high incidence of HIVICK as in HIV-infected patients there are often large amounts of circulating antigen associated with a polyclonal antibody response. This could lead to the formation of immune complexes, either in the circulation or in situ in the kidney itself. The concomitant activation of inflammatory mediators would then result in secondary renal damage in a manner analogous to lupus nephritis (Gerntholz et al., 2006). However the low incidence of HIVICK in children in our cohort of patients did not support this hypothesis.

In a Miami-based caucasian population of HIV-infected adults with glomerular disease, 17% had a mild forms of focal glomerulosclerosis, 75% had diffuse mesangial hyperplasia, and none had severe FSGS (Bourgoignie, 1990). Whilst the latter study fails to supports
our histopathological finding, the spectrum of HIVAN seen in Caribbean and American Blacks, in which 55% had severe focal sclerosis, 9% had mild focal sclerosis, and only 27% had diffuse mesangial hyperplasia (Cohen, 1990).

Other histological forms of HIVRN, such as membranous nephropathy and IgA nephropathy were absent in children in our study. This could be due to IgA nephropathy being a rare disease in people of Black African origin (Gerntholz et al., 2006; Kimmel et al., 1992) and the small sample size in this study. However in a study in adults from South Africa 13% had membranous nephropathy and 5% IgA nephropathy (Gerntholz et al., 2006)

In this study we found that oedema and hypertension occurred at a lower incidence in children post-HAART which is in accordance with reports from adult patients (Cochat et al., 2009; Herman and Klotman, 2003). The low incidence of these clinical findings on initial presentation may hide the presence of nephropathy. The possible explanation for the absence of these two clinical findings is that these patients have salt-losing nephropathy, which accounts for the normal blood pressure, and the high oncotic pressure contributed by the marked hypergammaglobulinaemia that prevents the development of oedema (Klotman, 1999; Ramsuran et al., 2011a). Also, the lack of oedema and hypertension in these children despite the presence of heavy proteinuria may mask the presence of nephropathy (Klotman, 1999; Ramsuran et al., 2011a).

Electrolyte disorders in patients with AIDS can have multiple and variable causes. Other studies have reported hyponatremia as the most common electrolyte abnormality in majority of their patients (Bourgoignie, 1990; Cusano et al., 1989; Seney et al., 1989;
In this study hyponatremia was noted in 5(16.7%) patients at initial visit, on follow-up only 2(10%) patients remained hyponatremic following treatment.

Hyperkalemia has been reported in 16% of patients with AIDS (Seney et al., 1989). This increased serum potassium may be the consequence of Addison's disease, or it can result from hyperreninemia (Bourgoignie, 1990). In our study 5(16.7%) patients presented with hyperkalemia, but reverted to normal at follow-up showing significant difference between pre and post-HAART groups. All five children had chronic kidney disease stage II-V, with one child having ESRD.

Mild to moderate hypocalcemia, generally associated with hypoalbuminemia affects the majority of AIDS infected patients (Seney et al., 1989; Vaziri et al., 1985). The hypoalbuminemia however does not always fully account for the hypocalcemia (Seney et al., 1989; Vaziri et al., 1985). Four (13.3%) presented with hypocalcemia at initial presentation, but only three resolved on follow-up. This child’s eGFR decreased to 27(m/s/m^2/min) on follow-up and the child developed hypocalcemia following correction of metabolic acidosis.

The largest reported series of imaging findings in HIV nephropathy identified new sonographic findings of advanced HIV-associated nephropathy involving decreased corticomedullary definition, decreased renal sinus fat, parenchymal heterogeneity and cortical echogenic bands and a globular appearance (Bourgoignie, 1989). In our study, ultrasonographic examination of the kidneys revealed enlarged kidneys in only 40% of the pre-HAART group compared to 10% of the post-HAART group. Kidneys in patients with HIVRN have being reported to be either normal-sized or enlarged and size does not
correlate with the degree of proteinuria (Bourgoignie, 1989). Thus enlarged kidney size is not a sensitive marker of HIVRN in our children. However, Post-HAART there was a statistically significant decrease in kidney size and echogenicity, which is in accordance with reports from adult patients.

Renal dysfunction is an important complication of advanced HIV infection in Africa. In our study we showed that in 12 children the eGFR were stabilized, 3 deteriorated and 5 improved post-HAART. Thus HAART in combination with ACEI treatment has been shown to ameliorate renal function in children with HIVRN. However, studies carried out amongst adults with advanced HIV disease in rural Uganda showed improved renal function over 2 years on HAART (Peters et al., 2008). Given a longer period of follow-up it is possible that a larger proportion of children may show improvement in their renal function in our study.

The combination of collapsing FSGS and extensive renal tubular injury is thought to be specific to HIVAN although previous studies have shown both adults and children not infected with HIV-1 can develop similar lesions (Ray et al., 2004; Singh et al., 2000; Vivette, 2003). Thus, it is tempting to speculate that infectious agents other than HIV-1 may be involved in the pathogenesis of collapsing FSGS. Several studies have investigated the role of *Mycoplasma fermentans*, the polyomavirus simian virus 40, and parvovirus B19 with inconclusive results (Kimmel et al., 2003; Moudgil et al., 2001; Ray et al., 2004). In our study we had very low incidence of opportunistic infections.

The survival of HIV-infected children after the development of clinical nephropathy is reported to be dismal (Ingulli et al., 1991; Rajpoot et al., 1996; Ray et al., 1998; Strauss et
Some studies noted that HIVAN progresses to ESRD at a very rapid rate, varying from weeks to months (Ahuja et al., 2004; Pardo et al., 1984; Rao et al., 1984). However, Strauss et al. (1993) and Ray et al. (2004) noted a less fulminant course in children compared with adults. In this study, overall patient survival at 1 year follow-up (post-HAART) was 76%. Laradi et al. (1998) demonstrated lower patient survival at 0.5, 1 and 3 yr to be 73 ± 5, 55 ± 6, and 38 ± 7%, respectively. The 7 patients that demised in our study were predominantly non-renal related causes, suggesting that in this new era of HIV therapy survival rates have considerably improved. Laradi et al. (1998) suggests that the only reliable predictor of patient survival is the intensity of immunodeficiency.

Our study has shown the beneficial effects of HAART in combination with ACE-I in managing patients with HIVRN. All patients recruited pre-HAART presented with varying degrees of proteinuria, with 40% in the nephrotic range. Post-HAART only 15% of patient’s had mild degrees of proteinuria and it is possible that with a longer follow-up period this 15% may also attain remission.

Whilst the ultrastructural examination of human biopsies are of great value in general pathology, they are essential to the interpretation of renal biopsies. This is the first study to perform a comprehensive evaluation of the ultrastructural pathology of children with HIV related glomerulo-nephropathy in Africa. Additionally, electron microscopy may add to and confirm molecular analyses.

Consistent with FSGS, the incidence of tubular reticular structures were frequently noted within endothelial cells lining glomerulo-capillary loops. Tubuloreticular inclusions have
previously been noted within the cytoplasm of glomerular and other vascular endothelial cell of HIV-associated FSGS (Cohen and Nast, 1988; D'Agati and Appel, 1997).

Cellular immune factors have been implicated in renal pathology. Interstitial inflammatory infiltration was frequently observed in our study. HIV-associated FSGS and immune complex disease, is also characterised with a dense interstitial inflammatory infiltrate (Cohen and Nast, 1988; D'Agati and Appel, 1997; Rao et al., 1984). Since different immune cell populations characterize the latter conditions, a cellular influence on phenotypic expression may be involved. Furthermore, this rich inflammatory cell milieu supports direct viral entry into renal epithelial cells via trans-infection by phagocytosis of released virus or perhaps during direct leucocyte-to-renal cell contact (Bruggeman and Nelson, 2009; Wu and Kewalramani, 2006).

Podocytes, the specialized epithelial cells that form the final filtration barrier of the glomerulus, are one of the primary cell types infected by HIV-1 (Barisoni et al., 1999; Winston et al., 2001). HIVAN is associated with podocyte effacement and loss of cytoskeletal structure on electron microscopy (Barisoni et al., 1999). Accumulating evidence indicates that podocyte damage triggers progression of glomerular deterioration that leads to glomerular sclerosis (Zuo et al., 2006).

Moreover, podocytes are terminally differentiated cells that normally cannot proliferate. They do not change their phenotype in response to injury, however, there are experimental data showing that podocyte can change their phenotype and proliferate in experimental crescentic glomerulonephritis and HIV nephropathy.
Podocyte hyperplasia (pseudocrescent formation) as typically observed in adults with collapsing glomerulopathies was also noted in our pediatric cohort. Thorner et al., (2008) have indicated that proliferating podocytes may initiate the formation of and populate true glomerular crescents (Bruggeman and Nelson, 2009). In our pre-HAART group proliferation of parietal epithelial cells with adhesions to visceral epithelium and crescent formation was evident.

In this study, the podocyte cytopathic features noted included ER stress, lipid distention and mitochondrial oedema which are direct causes of viral insult. It may be plausible to hypothesize that the observation of dilated pools of cisternal type ER in the podocyte cytoplasm may be attributed to ER stress. An increasing amount of literature supports the hypothesis that viruses like other ER stress signals may induce membrane proliferation through the activation of specific components of the Unfolded Protein Response (Kaufman, 2002; Umareddy et al., 2007). This response alleviates stress by stimulating protein folding and degradation in the ER and down-regulating overall protein synthesis, finally decreasing viral replication. Additionally, the Unfolded Protein Response may account for the mitochondrial oedema and nucleolemmal crenation observed in this study.

Furthermore, HIV-1 infection has been shown to induce alteration of cellular lipids (Raulin, 2002). The observation of distention/accumulation of lipid droplets within podocytes in the pre-HAART group may hence be viral induced.

Moreover, the occurrence of podocyte vacuolation in this study may also be attributed to viral presence (Henics and Wheatley, 1999). Induction of cytoplasmic vacuoles by viruses have been described previously (Henics and Wheatley, 1999). This finding lends credence to the assumption that the HIV-1 presence induces cellular vacuolation.
Mesangial proliferation was prominent. Mesangial cells have been shown to express HIV-1 receptor and co-receptors (Bruggeman and Nelson, 2009). However, in our study, HIV-1 was not observed in glomerulo-mesangial and endothelial cells. These findings are supported by (Cohen et al., 1989; Kimmel et al., 1993a; Marras et al., 2002). Additionally, reports on the infection of mesangial cells in vitro are inconclusive whilst endothelial cells are CD4 and co-receptor negative (Bruggeman and Nelson, 2009). This study does not report transcytosis or evidence of direct replication within endothelial and mesangial cells.

Subepithelial deposits in relation to the GBM, resulting in a “ball-in-cup” reaction pattern was noted. This form of immune-complex-mediated glomerulopathy is thought to represent a distinctive form of HIV associated glomerulo-nephropathy (Naicker et al., 2007). The irregular contouring of the GBM as frequently observed within both pre and post-HAART group is a frequent pathological observation associated with nephropathy.

Fibrin is an important mediator of glomerular injury and is pivotal in crescent formation in glomerulonephritis (Holdsworth et al., 1979; Thomson et al., 1975). The ability of macrophages to initiate intraglomerular fibrin deposition in association with augmented levels of glomerular procoagulant activity has recently been demonstrated in a passively induced model of experimental glomerulonephritis (Tipping and Holdsworth, 1986). The occurrence of fibrin deposition within the GBM as noted in this study may be linked to a temporal relationship between macrophage accumulation and glomerular fibrin deposition (Holdsworth and Tipping, 1985).
Podocytes have several functions; the slit diaphragm complements the glomerular filtration barrier by limiting molecules based on their size, charge and shape (Naicker et al., 1997). Additionally they lay down and remodel the GBM with structural functions maintaining capillary loop structure against the ballooning force of hydrostatic pressure and contractile force of mesangial cells (Kimmel et al., 2003). FSGS is a disorder of podocyte depletion (Barisoni et al., 1999). In contrast, HIVAN is manifested by abnormal extensive proliferation of podocytes, cells that are normally terminally differentiated. Recent results showed that HIV can directly infect the podocyte, and a series of interrelated pathways leads to loss of the differentiated phenotype with extensive proliferation and resultant glomerular collapse (Bostrom and Freedman, 2010; Papeta et al., 2009).

In this study, we evaluated renal epithelial proliferation and dedifferentiation using immunohistochemistry analysis performed on specific cell type markers; Ki67 and synaptopodin which was evaluated pre and post-HAART. Additionally, we demonstrated viral core protein, p24 in renal biopsies pre and post-HAART.

Classically, HIV entry is into cells are receptor mediated epithelial cells are CD4 negative, hence an unrecognized site of HIV-1 infection. However it has been shown that other epithelial cells such as cervical epithelial cells may harbor HIV-1 (Barisoni et al., 2000b). Additionally, murine models support the latter findings (Salifu. M, 2010). This study conclusively demonstrates HIV-1 viral core proteins within glomerular and tubular epithelial cells. The mean field area percentages of these proteins were statistically significant in the pre-HAART group compared to the post-HAART group. A direct translation implies efficacy of HAART over a 1 year period in reducing viral reservoirs.
Our results show weak immunoreactivity of synaptopodin, an actin based cytoskeleton podocyte protein in pre-HAART group. Following a year of HAART the mean field area percentage of synaptopodin was upregulated indicating reconstitution of the initial podocyte effacement. Previous studies have implicated HIV-1 proteins such as Tat, Nef and Vpr in podocyte dysfunction and phenotype change. The latter finding is supported by our p24 immunolabelling and evidence of viral reservoirs by electron microscopy. The introduction of HAART and ACE-I as the combination prophylaxis in this study, proved to be immensely efficient in glomerular structural and functional reconstitution.

In this study, the cell cycle protein, Ki67 was statistically, higher in the pre-HAART group compared to the post-HAART group (1.01 vs. 4.68; \( p < 0.001 \)). This epithelial proliferation in the pre-HAART group was expected as the spectrum consisted of majority (84%) of proliferative glomerular disorders viz., HIVAN, FSGS and mesangial hypercellularity. The down regulation of this antibody in the post-HAART group is indicative of the efficiency of the combination therapy of HAART and ACE-I.

In (1989), Cohen et al., reported the presence of HIV RNA in podocytes by in situ hybridization. These findings were corroborated by the microdissection studies of Kimmel et al., (1993a). However, a failure to replicate these studies using in situ hybridization, the inability to demonstrate the presence of viral peptides in renal parenchymal cells by immunohistochemistry, and the inability to demonstrate appropriate receptors for viral entry on renal parenchymal cells was reported (Cohen et al., 1989). This study provides evidence for localized replication of HIV-1 in the kidney and the existence of a renal viral reservoir using polymerase chain reaction assays and transmission electron microscopy.
Proviral integrated HIV-1 DNA genomes induce productive replication via the transcription of viral RNA genome defining the spread of HIV-1 virions (Skalka, 1999). Both HIV-1 proviral DNA and plasma RNA detection denotes two basic targets to monitor the viral reservoir and viral replication respectively (Clementi et al., 1996; Yilmaz, 2001). It is important to note that the detection of HIV-1 proviral DNA in PBMCs is an important diagnostic marker in the evaluation of HIV-1 of newborns of HIV-1 seropositive women (Yilmaz, 2001).

Proviral HIV-1 DNA is also a useful indicator for detecting viral reservoirs. Our results demonstrate proviral quantification of HIV-1 DNA in PBMCs and biopsy tissue using simple SYBR green based real time assay. This assay successfully amplified/detected proviral DNA from different laser micro-dissected epithelial cells within the kidney and from PBMCs. HIV-1 proviral DNA were elevated in biopsy tissue as compared to PBMCs. Likewise, Gibellini et al., (2004) and Popper et al., (2000), report a higher proviral load in tissue compared to blood. Additionally, in our study HIV-1 proviral DNA expression within glomeruli were higher than tubules and whole biopsy tissue. It is possible that the low proviral DNA yield within whole biopsy tissue is due to dilution attributed to an admixture of cell types.

Additionally, this study shows a decrease of HIV-1 DNA content post-HAART compared to pre-HAART. Gibellini et al (2004) report analogous data. Thus, despite the major effect HAART has in decreasing proviral DNA (as observed in this study), it was not successful in eradicating the total proviral load. Hence the SYBR green PCR technique is useful for monitoring HIV-1 DNA contaminated cells in infected patients receiving
HAART, since HIV-1 reservoir infection formed during the primary infection and highly resistant to therapy is one of the major obstacles to eradication of infection.

Since proviral DNA has been simultaneously amplified and quantified in patients that had an absence of detectable plasma viremia, HIV-1 proviral DNA count may be a potential biomarker identifying latent viral reservoirs and determining the impact/efficacy of HAART. In contrast to a report by Gibellini et al., (2004), there was no correlation between proviral DNA vs. viral load. However, there was a statistically significant correlation between the CD4+ T cell count (post-HAART) vs. proviral DNA (post-HAART).

We showed the ubiquitous presence of HIV DNA in renal tissue of HIV-infected patients whilst other studies are limited to the localization of HIV-1 messenger RNA in renal tissue, specifically glomerular and tubular epithelial cells (Bruggeman et al., 2000; Kimmel et al., 2003; Ross and Klotman, 2002; Winston et al., 2001). From these results one can conclude that HIV-1 proviral DNA load represents the infection reservoir in epithelial cells within the kidney and plays a pivotal role in immune surveillance escape. Winston et al., (2001) demonstrated viral transcripts in renal epithelial cells in patients on HAART that is similar to a report of the persistence of spliced and unspliced HIV-1 mRNA in PBMCs in such patients. These results suggest that renal epithelial cells may be a persistent reservoir of HIV-1 RNA transcription and that any interruption in therapy could lead to the rapid formation of infectious virions (Ho and Zhang, 2000).

In this study, RT-PCR provided evidence of HIV-1 within the kidney, specifically by amplification of proviral DNA *viz.*, *gag*. Since renal epithelial cells lack CD4, HIV-1 has
exploited receptor mediated entry thereby utilising unconventional mechanisms to cross the epithelium. The ultrastructural and genetic evidence provided in this study supports the theory of a non-receptor mediated HIV-1 trafficking across renal epithelial cells. It is important to note that no replication occurs within the epithelial cell however, endocytic trafficking of the virus from apical to basal pole of the cell occur. Previous studies have shown that non-lymphoid cells may be exploited as a means of virus trafficking rather than a means of replication (Bruggeman and Nelson, 2009).

The lipid composition of the apical epithelial membrane exhibits unique features. It contains Gal Cer, a monohexosylceramide which is markedly enriched at the apical surface of epithelial cells (Alfsen et al., 2001; Simons and van Meer, 1988). Transient lateral assemblies of these glycosphingolipids are stabilized by cholesterol and they participate in the establishment of microdomains referred to as rafts, which act as platforms for endocytosis (Brown and London, 1998; Rietveld and Simons, 1998) and transcytosis (Hansen et al., 1999; Verkade et al., 2000). Gal Cer is thought to act as gp120 epithelial cell receptor thereby facilitating movement of HIV-1 across the epithelium (Bhat et al., 1993; Yahi et al., 1992).

The subunit of beta-integrins of intercellular adhesion molecule-grabbing non-integrin, expressed by cervical epithelium binds to gp120 on fibronectin coated virions thereby facilitating viral entry (Hladik and McElrath, 2008). A direct extrapolation of these findings to our study may be linked to the glomerular fibrin deposition and to the fibronectin content of the GBM, all of which probably enable gp120 binding.
The GBM consists of type IV collagen, structural glycoproteins and proteoglycans rich in heparin sulphate proteoglycans. Interactions of HIV-1 gp120 with transmembrane heparin sulphate proteoglycans (especially syndecan-1 and syndecan-2) expressed by epithelial cells can also contribute to HIV-1 attachment and entry (Bobardt et al., 2007). Given that Arg298 is critical for HIV-1 binding to syndecans (de Parseval et al., 2005), HIV-1 exploits syndecans (syndecan-1 and syndecan-2) to facilitate its adsorption onto the epithelium (Bobardt et al., 2007).

HIV infection of the kidney has been etiologically related to the development of nephropathy (Bruggeman et al., 1997; Winston et al., 2001). The expression of viral genes alone, may induce HIVAN, whereas virus production or immune responses to viral proteins viz., Nef, Vpr and Tat might be required to induce HIVICK (Bruggeman and Nelson, 2009; Dickie et al., 1991). HIVAN is mostly owing to direct viral infiltration of renal cells (Bruggeman et al., 1997; Kimmel et al., 1993b; Marras et al., 2002). This study shows direct evidence of HIV-1 sequestration within endocytic compartments of glomerular visceral epithelial cells supporting the hypothesis that the kidney could serve as a latent viral reservoir for HIV-1. HIV-1 nucleic acids have been shown to be present in both the non-lymphoid and lymphoid renal compartments of patients diagnosed with HIVAN (Bruggeman et al., 2000; Cohen et al., 1989; Kimmel et al., 1993a). Renal epithelial cells, however, do not normally express T cell surface glycoprotein CD4, CCR5, or CXCR-4 hence the route by which HIV-1 enters these cells is poorly understood (Eitner et al., 1998; Eitner et al., 2000; Grone et al., 2002; Segerer et al., 1999). Non receptor mediated entry of HIV-1 is facilitated via interaction of epithelial cells with the HIV-1 surface envelope glycoprotein subunit gp120 which foster transcytosis (Bomsel, 1997).
Raft microdomains are involved in endocytosis via caveolae like structures and subsequent transcytosis of HIV-1 across epithelial cells (Kaushic, 2011; Nazli et al., 2010).

Many of the previously reported studies focusing on plasma and PBMC sequences derived from HIV-1 do not accurately describe the full scope of HIV infection within the tissue compartments (Lerner et al., 2011). As viral persistence is attributed to viral latency in cellular reservoirs, ongoing replication or poor drug penetration, leads to viral sanctuaries, despite the major benefits of HAART in the eradication of HIV-1 (Bull et al., 2009; Chun et al., 1997; Finzi et al., 1999; Lerner et al., 2011; Zhang et al., 2000).

Central to current theories regarding viral pathogenesis and the immune response to infection, is understanding the nature of sequence change (or viral diversity), dynamics and spread within the HIV-1 genome. Previous studies comparing published sequences have shown that the gag and pol genes are more highly conserved than env (Simmonds et al., 1990).

The hypervariable regions of env not only are polymorphic in sequence but in many cases also differ in length (Alizon et al., 1986; Hahn et al., 1986; Simmonds et al., 1990; Starcich et al., 1986). This study compared viral sequences of the C2-C5 region of HIV-1 env from epithelial cells to those of PBMC pre and post-HAART. We found that the sequence diversity of env varied in our study cohort. However, there has been no satisfactory explanation of the high rates of mutation in localized regions of the env gene. It could be argued that the cause is simply a lack of functional constraints which might limit the amount of variation in regions such as the CD4 binding site (Cordonnier et al., 1989; Lasky et al., 1987).
As expected no HIV-1 quasispecies were found as this study was performed in children. Analysis of env sequences derived from both blood and biopsy tissue were found to yield relatively homogeneous populations respectively. However, there were two different sequences for circulating virus (blood) and latent virus (biopsy) signifying compartmentalization. In recent studies, compartmentalization of genital tract compared to blood of HIV-1 sequences has been observed in 50 to 75% patients (Bull et al., 2009; Coombs et al., 1998; Delwart et al., 1998; Ellerbrock et al., 2001; Gupta et al., 2000).

HAART inhibits HIV-1 replication to the extent that plasma viremia levels fall below the detectable amounts of HIV-1 RNA copies (<50 copies/ml). Desire et al., (2001) showed a decline in viral load to undetectable levels with the use of HAART, but later the same patients with a “clean” behavior progress to a high viral load, as if re-infected. A study by Lerner et al., (2011) reported that HIV infected patients that strictly adhere to HAART have uniformly low genomic diversity within the early established and persistence viral reservoirs. These findings are in agreement with our results of a low diversity viral population post-HAART. Highlighter plot analysis indicated that the few mutations observed within the post-HAART group were found to be synonymous mutations. Additionally, there were no significant HIV sequence diversity between glomeruli, arterioles and tubules.

A plausible hypothesis for this occurrence is that the latent virus has undergone mutations hence has a different sequence, thereby escaping HAART and later re-infecting the patient. Therefore this study demonstrates the potential significance of early initiation of HAART.
in controlling viral diversification. The viral mutation may arise from immune suppression pressures exacerbated by the immature immune system of the child.

Proviral sequence diversity is important in determining whether unique viruses evolve within the epithelial cells is particularly relevant to developing an effective vaccine and interventions to reduce HIV-1 transmission. In addition, further studies are warranted to investigate mechanisms producing monotypic viral reservoirs that have been established early in infection within epithelial cells, and more importantly to determine whether the proliferation of cells with provirus sustain HIV-1 persistence despite the effect of HAART and incomplete immune restoration (Bull et al., 2009).

In conclusion, this study classified the spectrum of paediatric nephropathy in treatment-naïve children within KwaZulu-Natal (in descending rank) as being FSGS, mesangial hypercellularity, HIVAN, tubulointerstitial nephritis, minimal change and sclerosing glomerulopathy. Notably, in the HAART era this spectrum was marginally altered. Additionally, our study demonstrates podocyte phenotype dysregulation pre-HAART with loss of differentiation markers and increased proliferation and reconstitution post antiretroviral and angiotensin converting enzyme inhibiting therapy. Evidence of ultrastructural viral reservoirs within epithelial cells is supported by a genetic appraisal confirming the ubiquitous presence of HIV DNA in renal tissue. Moreover, sequence analysis showed viral evolution and compartmentalization between renal viral reservoirs to PBMCs. Finally, the interplay of viral genes and host response, influenced by genetic background, may contribute to the variable manifestations of HIV-1 infection in the kidney in our paediatric population.
REFERENCES


Gupta, P., Leroux, C., Patterson, B. K., Kingsley, L., Rinaldo, C., Ding, M., Chen, Y., Kulka, K., Buchanan, W., McKeon, B. et al. (2000). Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral Quasi species between blood and semen. *J Infect Dis* 182, 79-87.


ADDENDUM I

THE SPECTRUM OF HIV-RELATED NEPHROPATHY IN CHILDREN
ADDENDUM II

THE ROLE OF PODOCYTES IN THE EARLY DETECTION OF PRE-ECLAMPSIA
ADDENDUM III

PODOCYTURIA IN THE EARLY DETECTION OF PRE-ECLAMPSIA-A PILOT STUDY
ADDENDUM IV

STAGING OF HIV RELATED NEPHROPATHY PATIENTS
ADDENDUM IV

STAGING OF HIV RELATED NEPHROPATHY PATIENTS

Stage I  
Lymphadenopaty
Asymptomatic

Stage II  
Hepatosplenomegaly
Papular Pruritic eruptions
Seborrhoeic dermatitis
Extensive human papilloma virus infection
Extensive molluscum contagiosum
Fungal nail infections
Recurrent oral ulceration
Linear gingival erythema
Angular Chellitis
Parotid enlargement
Herpes zoster
Recurrences or chronic RTIs (otitis media, otorrhoea, sinusitis)

Stage III  
Moderate unexplained malnutrition
Unexplained persistent diarrhea
Unexplained persistent fever
Oral Candidiasis
Oral hairy leukoplakia
Acute necrotizing ulcerative gingivitis / periodontitis
Pulmonary TB
Tuberculous lymphadenopathy (axillary, cervical or inguinal)
Severe recurrent presumed bacterial pneumonia
Unexplained anaemia (<8gm/dl), and/or thrombocytopenia (<50,000/mm³) for more than one month
Chronic HIV-associated lung disease including bronchiectasis
Symptomatic Lymphoid interstitial pneumonitis (LIP)

Stage IV  
Unexplained sever wasting or sever malnutrition not adequately
Pneumocystis Pneumonia
Recurrent sever presumed bacterial infection
Chronic herpes simplex infection (orolabial or cutaneous of more than one months duration)
Extrapulmonary TB
Kaposi’s sarcoma
Oesophageal candidiasis
CNS toxoplasmosis (outside the neonatal period)
HIV encephalopathy
CMV infection
Extrapulmonary cryptococcosis including meningitis
Any disseminated endemic mycosis (e.g. Extrapulmonary histoplasmosis, coccidiomycosis, penicilliosis)
Cryptosporidiosis
Isosporiasis
Disseminated non-tuberculous mycobacterial infection
Candida of trachea, bronchi or lungs
Visceral herpes simplex infection
Cerebral or B cell non-Hodgkin’s lymphoma
Progressive multifocal leukoencephalopathy
HIV-associated cardiomyopathy or HIV-associated nephropathy
ADDENDUM V

POST-GRADUATE APPROVAL
ADDENDUM VI

ETHICS APPROVAL
19 March 2008

Mr D Ramsuran
Optics & Imaging Centre
DDMRI
Nelson R Mandela School of Medicine
University of KwaZulu-Natal

Dear Mr Ramsuran

PROTOCOL: The Spectrum of HIV related nephropathy in KwaZulu-Natal: A pathogenetic appraisal and impact of HAART. Optics & Imaging Centre. Mr. Duram Ramsuran. RE:Bf149/07

The Biomedical Research Ethics Committee considered the abovementioned application and the protocol was approved by a full sitting of the committee at a meeting held on 11 December 2007 pending appropriate responses to queries raised. Your responses received on 12 March 2008 to queries raised on 07 February 2008 have been noted by a sub-committee of the Biomedical Research Ethics Committee. The conditions have now been met and the study is given full ethics approval and may begin as at 19 March 2008.

This approval is valid for one year from 19 March 2008. To ensure continuous approval, an application for recertification should be submitted a couple of months before the expiry date. In addition, when consent is a requirement, the consent process will need to be repeated annually.

I take this opportunity to wish you everything of the best with your study. Please send the Biomedical Research Ethics Committee a copy of your report once completed.

Yours sincerely

PROFESSOR D WASSENAAR
Chair: Biomedical Research Ethics Committee
ADDENDUM VII

IALCH MANAGERS APPROVAL
PERMISSION TO CONDUCT A RESEARCH STUDY/TRIAL

This must be completed and submitted to the Medical Superintendent/s / Hospital Manager/s for signature.

For King Edward VIII Hospital (KEH) and Inkosi Albert Luthuli Central Hospital (ALCH) studies please submit the document together with the following:

1. Research proposal and protocol.
2. Letter stating ethical committee approval.
3. Details of other research presently being performed by yourself if in the employ of KEH (individually or as a collaborator).
4. Details of any financial or human resource implications to KEH, including all laboratory test, EEGs, X-rays, use of nurses, etc. (See Schedule 1).
5. Declaration of all funding applications / grants, please supply substantiating documentation.
6. Complete the attached KEH Form - "Research Details".

Once the document has been signed it should be returned to Mrs S Du Plessis: Biomedical Research Ethic Committee, Room 110, Graham Smith Building, Westville Campus, University of KwaZulu-Natal.

To: Chief Medical Superintendent / Hospital Manager

Permission is requested to conduct the above research study at the hospital/s indicated below.

Site 1 Address: J.A.H.C.H. Investigator/s: [Signature]
[Signature]
Co-Investigator:
[Signature]

Signature of Chief Medical Superintendent / Hospital Manager:

Date: 07/03/08

Site 2 Address: ____________________________
Investigator/s: ____________________________
Co-Investigator: ____________________________

Signature of Chief Medical Superintendent / Hospital Manager:

Date: ____________________________

NB: Medical Superintendent/s / Hospital Manager/s to send a copy of this document to Natalia
ADDENDUM VIII

KEH VIII MANAGERS APPROVAL
PERMISSION TO CONDUCT A RESEARCH STUDY/TRIAL

This must be completed and submitted to the Medical Superintendent/s / Hospital Manager/s for signature.

For King Edward VIII Hospital (KEH) and Inkosi Albert Luthuli Central Hospital (IALCH) studies please submit the document together with the following:

1. Research proposal and protocol.
2. Letter giving provisional ethical approval.
3. Details of other research presently being performed by yourself if in the employ of KEH, (individually or as a collaborator).
4. Details of any financial or human resource implications to KEH, including all laboratory tests, EEGs, X-rays, use of nurses, etc. (See Addendum 1)
5. Declaration of all funding applications / grants, please supply substantiating documentation.
6. Complete the attached KEH Form “Research Details”

Once the document has been signed it should be returned to Mrs S Buccas: Biomedical Research Ethics Administrator, Room 449, Gortan Medical Building, Westville Campus, University of KwaZulu-Natal.

To: Chief Medical Superintendent / Hospital Manager

Permission is requested to conduct the above research study at the hospitals indicated below:

Site 1 address: ____________________________

Investigator/s:

Principal: __________
Co-investigator: __________

Site 2 address: ____________________________

Investigator/s:

Principal: __________
Co-investigator: __________

Signature of Medical Superintendent / Hospital Manager:

Date: __________

Signature of Chief Medical Superintendent / Hospital Manager:

Date: __________

NB: Medical Superintendent/s / Hospital Manager/s to send a copy of this document to Natalia.
ADDENDUM IX

EXAMPLE OF INFORMED CONSENT
**SECTION 4: INFORMATION GIVEN TO PARTICIPANTS** (an example follows):

**INFORMATION DOCUMENT**

**Study title:** The spectrum of HIV related nephropathy in KwaZulu-Natal: A pathogenetic appraisal and impact of HAART.

Good day Miss/Mrs ________________. My name is Duran Ramsuran. Thank you for giving me the time to speak to you.

We, R Bhimma, T Naicker, and D Ramsuran from the Department of Paediatrics and Child Health, University of KwaZulu-Natal., are carrying out research on kidney diseases in children, from which one of the investigators will obtain an academic degree. As you know HIV may affect the kidney, if we can pick up kidney involvement early and treat, the child may do much better. Kidney biopsies are standard of care in patients presenting with persistent proteinuria. This study will determine the effect of highly active anti-retroviral therapy. It will also help us to study the mechanism of injury by the HIV virus on the kidney and the way this is altered by treatment.

We are asking for your permission to include you or your child in our research study. We require your permission to take a sample of blood, urine and a kidney biopsy so that we may study it. There will be a repeat biopsy after a year to assess the how good the treatment was.

The general purpose of the study is to learn more about how genes influence kidney disease, particularly nephrotic syndrome. Genes are the parts of the body’s cells that carry the coded information (DNA) that determine how all the body parts function. To date there have been few studies have been carried out in Africa which address how genes influence kidney disease. The specific purpose of the study is to determine how genes influence kidney disease.

When your child undergoes the kidney biopsy mentioned above, we request your permission to take a small portion of the kidney biopsy sample for research studies. We will study which genes are expressed (active) in the kidney. In patients who show persistent proteinuria and/or deterioration in renal function this second biopsy is clinically indicated to evaluate progression or regression of disease following HAART and ACEI therapy. As your child will undergo a kidney biopsy that is part of routine medical care, this study also requires a small sample for research purposes post highly active anti-retroviral therapy.

We plan to recruit 30 subjects to participate in the present study all of whom must be South African citizens. We will be collecting blood, urine and kidney biopsies from 30 patients who are HIV positive and have renal disease. You will be followed-up for life or until you are cured following diagnosis and appropriate treatment to assess kidney function. All these samples are being collected and will be studied at the Nelson Mandela Medical School. We treat the specimens chemically, and store them at the Medical School so we can analyse them over the next three years. We will require your permission prior to specimen collection to do this.

Blood letting may result in mild pain and discomfort. A single tube of blood is required, for research studies to learn whether your child’s genes are slightly different from those...
individuals who do not have kidney disease. All preventions will be taken to ensure this will be done under sterile conditions to prevent infection. You will not have any immediate benefit from participating in this study. Participation in this study will not alter the management of your disease. However, if we show that the treatment works many children in the future will benefit.

You will be given pertinent information on the study while involved in the project and after the results are available.

Alternatives: Your participation is voluntary/optional. Refusal to participate will involve no penalty or loss of benefits to you. You may discontinue participation at any time without penalty/loss of benefits to which you are otherwise entitled. You will not be given any reimbursement for participating in the study.

Personal information will be kept confidential. Personal information may only be disclosed if required by law. Records of your child’s information will not be added in, have your child’s name recorded but only a number. Organizations that may inspect and/or copy your research records for quality assurance and data analysis include groups such as the Research Ethics Committee and the Medicines Control Council (where appropriate).

You may contact the researchers at any time. Their contact details are as follows:
Prof R Bhimma - Tel.: 031-2604351 or 031-2604345
Duran Ramsuran- 031-2604274 0735821636
Prof T Naicker- 031-2604435 or 031-2604746

Contact details of BREC Administrator – for reporting of complaints/ problems:
MRS S BUCCAS, Nelson R Mandela School of Medicine, Private Bag 7, Congella 4013
Telephone: +27 (0) 31 260 4769
Fax: +27 (0) 31 260 4609 email: buccas@ukzn.ac.za
ISAHLUKO 4: ULWAZI OLUNIKEZWA ABATHATHA INXEXHEBA

INCWADI YESAZISO

Isihloko socwaningo: Isandulela ngculazi esinobudlelwano nezifo zezinso kwisiFundazwe saKwaZulu-Natal; Ucwangingo nobungozi besifo iHAART.


Isicelo sokuzimbandakanya: Sisiza imvume yakho yokuba wena nama ingane yakho nibe yingxenye yalulcwaninga uluzokwenzi. Sisiza imvume yakho yokuba sitathethe igazi, umchamo kanye nokuhloluza kwezimo zekwazi ukukucwaninga. Lulcwaninga luyophinda esikhathini esingangonyaka ukuze kutholakala ukuthi ezowethleza zibe nemphumelelo kawebambele.

Inhloso yalesisifundo: Inhloso yalesisifundo nokwazi kabanzi ukuthi ama Genes athintana kanjani nesifundo zezinso, kahle kahle kwathi Nephrotic Syndrome. Ama Genes ayenye yezicubu zomzimba esitholo kwona ulwazi oluphathelene nama DNA okuyiwoza asthengisayo ukuthi nokuhloluza zomzimba zisebenza kahle na. Kuse kube inamhlanlele kunezifundo ezizondlandzana ezilokhu zenziwa lafaro eAfrica ezichaza kahle ukuthi ama Genes athintana kanjani nesifundo zezinso. Inhloso ukwazi kabanzi nokuningi ngokuthi ama Genes athintana kanjani nesifundo zezinso.

Uma umntwana wakho eba ingxenye ekwenzeni I Biopsy njengoba kuchaziwe ngenhla, siyaye sicele imvume yakho njengombali ukuba sitathethe isicubu esinca nje esizobu isibonelo kulesisifundo. Siyobeke sesibheka ukuthi iyiphi I Genes esibhemsisa kahle nenzo yakhe. Umntwana wakho uma ethathethe ingxenye kukhona nokunakekekeleka okuthile akutholayo, abukho ubungozi nomzimba ukungaphathheki kahle angase abe nacho ngokuthi kusethenziswa isicubu sakhe.

ubudokotela esaziwa ngokuthi iNelson R Mandela School of Medicine. Konke okuyobe kuthathwe kwwe kuyolahla ngamakhemikhali bese kugcinwa kuso lesisikhungo ukuze bakwazi ukukekubungula esikhathini esingangeminyaka emithathu esizayo. Siyodinga imvume yakho ngaphambi kokuba sithele konke lokhu.

Ukuthathwa kwegazi kungaholela ebuhlungwini obuncane nje nokungakhululeki. Ibhodlela elincane nje legazi elidingekayo eliqondene nalesisifundo sezophenyo ukuze sazi ukuthi amaGenes omntwana wakho ahlukile yini nawalabo abangenayo inkinga yesifo yezinso.

**Ingozi engabakhona:** Ukuthathwa kwegazi kungaholela ezinhlwini ezincane ngokunjalo nokungaphatheki kahle. Sidinga ishubhana elilodwa legazi. Konke lokhu kuyokwentsiwa ngokuba kuqinisekiswe ukuthi akukho magciwane angenayo.


**Imfihlo:** Imininingwane yakho izohlala iyimfihlo. Abantu abangafunyana lolulwazi yilabo abasemakomitini nezinyunyana zocwangingako.

**Imibuzo:** Kungabe unayo yini imibuzo?

**Imininingwane yocwangingako:** Uma udinga olunye ulwazi noma kukhona ongagculisekile ngakho, mayelana nocwangingako, ungaxhumana nalaba abalandelayo:

<table>
<thead>
<tr>
<th></th>
<th>Telephone 1</th>
<th>Telephone 2</th>
<th></th>
<th>Telephone 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prof R Bhimma</strong></td>
<td>031-260 4351</td>
<td>031-260 4345</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prof T Naicker</strong></td>
<td>031-260 4435</td>
<td>031-260 4746</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Duran Ramsuran</strong></td>
<td>031-260 4274</td>
<td>031-260 4746</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SECTION 5: INFORMED CONSENT (an example follows)

This document must be written in language understandable to the subject

CONSENT DOCUMENT

Study Title:

The spectrum of HIV related nephropathy in KwaZulu-Natal: A pathogenetic appraisal and impact of HAART.

Consent to Participate in Research

You have been asked to grant permission for your child/yoursel
__________________________ to participate in a research study.

You have been informed about the study by ______________________

You may contact R Bhimma / D Ramsuran at 2604351/4274 (cell- 0735821636) any time if you have questions about the research or if you are injured as a result of the research.

You may contact the Biomedical Research Office at the Nelson R Mandela School of Medicine at 031-260 4769 if you have questions about your rights as a research subject.

Your participation in this research is voluntary, and you will not be penalized or lose benefits if you refuse to participate or decide to stop.

If you agree to participate, you will be given a signed copy of this document and the participant information sheet which is a written summary of the research.

The research study, including the above information, has been described to me orally. I understand what my involvement in the study means and I voluntarily agree to participate.

____________________      ____________________
Signature of Participant                            Date

____________________   _____________________
Signature of Witness                                Date
(Where applicable)

____________________   _____________________
Signature of Translator                            Date
(Where applicable)
ISAHLUKO 5: ULWAZI OLUNIKEZWA ABATHATHA INXEXHEBA INCWADI YOLWAZI

Isihloko socwaningo:
Isandulela ngculazi esinobudlelwano nezifo zezinso kwisFundazwe saKwaZulu-Natal;
Ucwaningo lwesibalo nobungozi besifo iHAART

Imvume yokuzimbakanya nocwaningo
Uyacelwa ukuba unikeze imvume yengane yakho noma wena uqobo ________________________________ ukuba uzimbandakanye ocwaningweni olwenziwayo.

Ulwazi ngocwaningo uluthole ngo ________________________________

Ungathintana no R Bhimma / D Ramsuran kwinombolo yocingo u031-260 4351/4274 (umakhalekhukhwini – 073 582 1636) ngazozonke izikhathi uma unemibuzo mayelana nocwaningo noma uthole ukulimala ngezizathu zoqhutshwa kocwanking.

Ungathintana nehovisi leBiomedical Research Office esikoleni sokufundela ubudokotela iNelson R Mandela kulenombolo yocingo 031-260 4769 uma unemibuzo ngamalungela akho maqondana nocwango.

Uba yingxenye yocwango ngokusothandweni lakho futhi uma ungenaso isifiso sokuba yingxenye kumbe unesifiso sokuyeka phakathi nocwango ukukho nhlawulo oyoyikhokha kumbe nzuzo eyokulahlekela.

Uma uvuma ukuba yingxenye yocwango, uyonikezwa ikhophi esayiniwe yalencwadi kanye nepheshana lemininingwane yozinikele okuyincwadi yocwango ebekwe ngamafuphi.

Ucwaningo kanye nolwazi olungenhla, luchaziwe kimina ngomlomo. Ngiyaqonda ukuthi ukuba yingxenye yalolucwango kusho ukuthini futhi ngiyavuma ukuzinikela ukuthi ngibe yingxenye.

_________________________  ______________________
Isishicilelo Sozinikele    Usuku

_________________________  ______________________
Isishicilelo Sofakazi    Usuku
(Uma kunesidingo)

_________________________  ______________________
Isishicilelo Sikatolika    Usuku
(Uma kunesidingo)
ADDENDUM X

ETHICS APPROVAL FOR CONTROL SAMPLE
ADDENDUM XI

SOLUTION PREPARATION
ADDENDUM XI
SOLUTION PREPARATION

Mayer’s Haematoxylin
- 4g Haematoxylin
- 4g Citric acid
- 1g Sodium Iodate
- 200g Chloral Hydate
- 200g Aluminium Ammonium Sulphate
- 4000ml distilled water

0.5% Alcoholic Eosin
- 20g Eosin
-4000ml Absolute Alcohol
- 20ml Acetic Acid

Weigert’s Iron Haematoxylin
Working Solution: (1:1) Weigerts Solution A: Weigerts Solution B
Weigerts Solution A:
- 1g Haematoxylin
- 100ml 95% alcohol
Weigerts Solution B:
- 4ml 29% Ferric Chloride
- 100ml Distilled water
- 1ml concentrated hydrochloric Acid
**Biebrich Scarlet-Acid Fuchsin Solution**

- 90ml 1% Aqueous Biebrich Scarlet
- 10ml 1% Aqueous Acid Fuchsin
- 1ml Acetic Acid, glacial

**0.5% Potassium Permanganate**

- 10g Potassium Permanganate
- 2000ml distilled water
- 3m Sulphuric Acid

**Elastic Stain**

- 1g Victoria Blue 4R
- 1g Basic Fuchsin
- 1g Crystal Violet
- Dissolved in 200ml distilled water (warm)
- 4g Resorcin
- 1g Dextrin
- 50ml 30% Aqueous ferric Chloride
- Filter
- 200ml 95% Alcohol
- Filter
- Make up to 200ml with 95% Alcohol
- 2ml concentrated Hydrochloric Acid
Methenamine Silver Solution

- 50ml 3% Hexamine solution
- 2.5ml 5% Silver Nitrate solution
- Filter 40ml of solution
- 5ml 5% Borax

4% Glutaraldehyde

- 25ml 0.2M Cacodylate buffer
- 8ml 25% Glutaraldehyde

Cacodylate buffer (0.2M)

- 21.4g Sodium Cacodylate in 250ml distilled water
- 40ml 0.2M Hydrochloric Acid
- Make up to 500ml with distilled water

Palades Fixative (Osmium tetroxide)

- 2ml Osmium tetroxide
- 3ml Cacodylate buffer
- 2.8ml distilled water

Araldite

- 10g Epoxy resin
- 10g DDSA
- 1g Dibutylphthalate
- 0.5g DMP 30

1% Toluidine blue

- 1% Sodium Bicarbonate

- 1g Toluidine blue

- filter

- 40ml Glycerine to 60ml of above solution